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Background:  Preterm birth (PTB) is a major cause of infant morbidity and mortality, and 
accurate assessment of women in threatened preterm labour (TPTL) is vital for identifying 
need for appropriate intervention.  Risk assessment in TPTL is challenging, however, due to 
its complex and multifactoral nature.  In many women, TPTL symptoms do not progress to 
spontaneous PTB (sPTB) so assessment that reassures quickly, often through use of tests, 
e.g. fetal fibronectin (fFN) and cervical length (CL), may reduce unnecessary intervention 
and decrease anxiety.  Aims:  This PhD project had two main objectives: first to improve 
TPTL risk assessment by further developing the clinical decision support tool, the “QUIPP” 
mobile phone application, which simplifies risk assessment by calculating individual % risk 
of sPTB based on risk status, fFN and CL results.  The second objective was to understand 
TPTL from the women’s perspective in order to inform future improvements in care.  
Method: The study comprised three components: 1) a prospective cohort study, collecting 
data on risk factors, test results and interventions.  Predictive utility of fFN and CL were 
investigated, as well as generation and validation of risk prediction algorithms for the 
second version of QUIPP; 2) a qualitative study of women’s experience of TPTL through 
one-to-one semi-structured interviews; 3) a qualitative study of clinicians using the first 
version of QUIPP.   Results:  Cohort study: 1186 women were recruited at 11 UK hospitals 
between March 2015 and October 2017, with data available for analysis on 1037.  
Prevalence of sPTB was 3.9% (40/1037) and 12.1% (125/1037) at <34 and <37 weeks’ 
gestation, respectively.  Validation of QUIPP algorithms, using risk factors and fFN results 
alone, demonstrated good prediction of sPTB <30 weeks’ gestation (AUC 0.96, 95% CI 
0.94-0.99) and at <1 week of testing (AUC 0.91, 95% CI 0.87-0.96).  Qualitative study:  Four 
themes emerged following interviews with 19 women: i) coping with uncertainty; ii) 
dealing with conflicts; iii) aspects of care and iv) interactions with professionals.  QUIPP 
users’ study: 10 clinicians expressed predominantly positive views and suggested 
improvements.  Conclusion:  All components of this project informed development of 
QUIPP v.2 (algorithms and design), which appears superior in predicting sPTB compared to 
previously reported predictive utility of fFN, CL and QUIPP v.1 algorithms. The qualitative 
study was the first exploring women’s experience of TPTL in a UK hospital with a specialist 
preterm service, and findings further support the need for women of all risk groups to 
have timely access to advice and information, and continuity of care. 
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This PhD project focusses on threatened preterm labour (TPTL) risk assessment and 
management, and the experience of women with symptoms.  The project has two 
major elements, the first being the development of a clinical decision support tool that 
predicts risk of preterm birth for individual women based on their background risk 
factors and test results. The second element is a qualitative study exploring women’s 
experience of TPTL and identification of aspects of care that could be improved.  Both 
elements together were designed to inform future changes to TPTL management that 
could result in a more positive experience for women.  This chapter outlines current 
assessment and treatment options for women with symptoms of TPTL, and then 
moves on to discuss the broad concept of risk assessment in maternity care along with 
some of its challenges.  It provides insights into how decision aids can be utilized to 
support both the communication of risk and decision making.  The chapter concludes 
with the argument that this area of maternity care has potential for improvement.   
 
 
1.1. What is preterm birth and threatened preterm labour? 
 
Preterm birth (PTB), defined as birth before 37 weeks' gestation, is a major cause of 
infant death, as well as physical, developmental, emotional and financial problems for 
families, and health and social care systems (Marlow et al., 2014). The incidence of 
preterm birth appears to be increasing globally (Blencowe et al., 2013), currently 
affects around 7% of births in the UK (Office for National Statistics, 2015; Information 
Services Division, 2017) and it has been estimated to cost the NHS £2.9 billion every 
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year (Mangham et al., 2009).  Efforts to reduce the incidence and consequences of 
preterm birth are therefore of paramount importance. 
 
Approximately two thirds of preterm births are associated with preterm labour and/or 
prelabour preterm ruptured membranes (PPROM) (Blencowe et al., 2013); the rest 
being medically indicated, or iatrogenic PTB.  Preterm labour is the initiation of regular 
and painful contractions with dilatation of the cervix, before 37 weeks’ gestation.  If 
pregnant women present with symptoms of abdominal pain and/or uterine 
tightenings, but established labour is not diagnosed on speculum or digital 
examination, it is unknown whether, or not, they are indeed in the early stages of 
“true” labour, and they are described as having symptoms of threatened preterm 
labour (TPTL) (McPheeters et al., 2005).   
 
1.2. What are the causes of threatened preterm labour? 
 
The physiological mechanisms driving the onset of preterm labour remain unclear, but 
evidence suggests that it can be caused by inflammation or infection, uterine ischemia 
or haemorrhage, uterine over distension, cervical insufficiency and stress, by way of 
activation of the maternal/fetal hypothalamic-pituitary-adrenal axis (Goldenberg et al., 
2008; Romero et al., 2006; Duthie and Reynolds, 2013) (Figure 1).   
 




Figure 1. Causes of preterm labour.  HPA=hypothalamic pituitary adrenal; 
CRH=Corticotropin-releasing hormone; ACTH= adrenocorticotropic hormone; 
MMPs=matrix metalloproteinases (Tribe, unpublished). 
 
 
Abdominal pain associated with TPTL may not, however, be the onset of “true labour” 
as it may have other causes, such as urinary tract infection (UTI), fibroid and ligament 
distention. 
   
1.3. Who is at risk of threatened preterm labour? 
 
Many factors affect a woman’s risk of preterm labour and birth.  These include 
demographic factors, including age, ethnicity, weight and socioeconomic status (Di 
Renzo et al., 2011a; Ferrero et al., 2016).  Lifestyle factors such as smoking, 
recreational drugs and environmental factors such as air pollution have also been 
associated with increased risk (Dew et al., 2007; Bertin et al., 2015). A woman’s risk is 
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also influenced by previous medical and obstetric history, e.g. cervical surgery, uterine 
anomaly, previous preterm birth or late miscarriages, previous full dilatation caesarean 
section and factors specific to this pregnancy, for example multiple pregnancy, or 
conditions such as polyhydramnios or obstetric cholestasis (Berretta et al., 2013; 
Epstein et al., 1998; Fisk and Storey, 1988; Goldenberg et al., 2008; Grimbizis et al., 
2001; Watson et al., 2017a).  However, many women who have no known risk factors, 
particularly those experiencing their first pregnancy, will have preterm labour and/or 
birth (Mercer et al., 1996). 
 
The implications of preterm birth are widely known, so the development of symptoms 
or problems that may indicate premature birth can cause considerable stress and 
anxiety.  This state is not only unpleasant, but may even increase the risk of preterm 
birth.  A large body of literature suggests an association between stress and preterm 
birth and plausible aetiologies, such as the interaction between stress hormones and 
the inflammatory response, have been suggested (Christian, 2012; Latendresse, 2009; 
Rich-Edwards and Grizzard, 2005; Ruiz et al., 2003; Wadhwa et al., 2001).   The form of 
stress may also be important. Lobel et al., (2008) in their study of state anxiety, 
perceived stress, life events, pregnancy-specific stress, and health behaviours in 279 
pregnant women, found that pregnancy-specific stress, i.e. stress resulting from 
factors relating directly to their pregnancy, which includes concerns about the baby’s 
health, may be an even more important contributor to adverse birth outcomes than 
general stress.   
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1.4. Current methods of TPTL assessment 
 
When a woman first presents with symptoms of threatened preterm labour, her 
clinician will review her maternity notes and take a history.  This is in order to establish 
the woman’s current condition and assess her risk of delivering early.  Clinical signs and 
symptoms are noted, and a speculum examination is carried out in order to visually 
assess whether the cervix is dilating.  If still unclear, the clinician may undertake a 
digital vaginal examination (NICE, 2015).  If the diagnosis of preterm labour is 
uncertain, which is often the case in early labour, other tests may be performed.  
Methods of assessment vary around the UK but can also include transvaginal 
ultrasound scan measurement of cervical length (TVS CL) and various biochemical 
vaginal swab tests (Stock et al., 2015). The first NICE guideline related to preterm birth 
was published in 2015 (NICE, 2015).  A summary of the recommendations for care of 
women with symptoms suggestive of preterm labour with intact membranes are 
shown in Figure 2.  It is not currently known how many hospitals are strictly using the 
guideline in practice, however, findings from a Delphi consensus of preterm specialists 
in the UK, undertaken separately from this PhD, indicated that they were not fully 
supportive of implementation, and they were particularly concerned about the 
recommended “treat-all” strategy for women at less than 30 weeks’ gestation (Carter 











Figure 2. Summary of NICE (2015) Preterm Labour and Birth Guideline (NG25) 
recommendations for women with intact membranes with definitions and guideline 
section numbers. TPTL=threatened preterm labour; PTL=preterm labour; 











1.4.1. Transvaginal ultrasound scan measurement of cervical length 
 
Transvaginal ultrasound scan measurement of cervical length (TVS CL) has been shown 
to be useful in the risk assessment of women with symptoms of TPTL (Fuchs et al., 
2004; Iams et al., 1996; Leitich et al., 1999a; Owen et al., 2003, Sotiriadis et al., 2010).  
It is more accurate than digital examination because measurement can be made of the 
full length of the cervical canal including the internal os, and the presence or absence 
of cervical “funneling”, where the cervix begins to open from the inside, can be 
determined (Crane et al., 1997). A cervical measurement of 25 mm or less is generally 
considered short (Lim et al., 2011).  Risk of PTB is increased if cervical length is 
between 15 and 25 mm, and is significantly increased if less than 15 mm (Heath et al., 
1998; Tsoi et al., 2005; Berghella et al., 2009).  Although recognised as a useful 
predictor of preterm birth in women with symptoms of TPTL, it is not currently widely 
performed in the UK, possibly due to a paucity of staff adequately trained in 
ultrasound scanning, and the availability of suitable equipment in relevant clinical 
areas.  This was recognised by the National Institute for Health and Care Excellence 
(NICE) who proposed that the Royal College of Obstetricians and Gynaecologists 
(RCOG) should extend their obstetric trainees ultrasound module to include TVS CL 
(NICE, 2015).   
 
In addition to its role in risk assessment, clinician knowledge of cervical length also 
might even prevent preterm birth.  Berghella and colleagues’ (2017) systematic review 
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and meta-analysis identified three trials, where a total of 287 participants with TPTL 
symptoms were randomised to CL screening with knowledge of the cervical length 
(n=145) or no knowledge (n=142).   The known CL group had a significantly lower rate 
of preterm birth at less than 37 weeks than the control group (22.1% vs 34.5%; RR, 
0.64 (95% CI 0.44-0.94)) and a later gestational age at delivery (mean difference 0.64 
(95% CI 0.03-1.24)).  The biological impact of TVS CL on PTB is unknown, however the 
authors suggest that knowledge of the result may reduce the need for repeated digital 
vaginal examinations.  
 
1.4.2. Fetal fibronectin 
 
Fetal Fibronectin (fFN) is an extracellular glycoprotein found in amniotic fluid, placenta 
tissue and in the decidua basilis.  It is believed to be released following mechanical or 
inflammatory damage to the membranes and its potential as a predictive marker for 
preterm birth, particularly its high negative predictive value, has been established for 
several years (Abbott et al., 2013; Honest et al., 2002; Leitich et al., 1999b; Lockwood 
et al., 1991; Matsuura et al., 1988; Peaceman et al., 1997).  Originally, analysis was 
carried out by ELISA laboratory test.  More recently bedside test analysers have been 
manufactured and are marketed by a US company, Hologic Inc. (Massachusetts, USA). 
 
In the UK, test results for fFN were, until relatively recently, presented as dichotomous 
(i.e. positive or negative), based on a threshold of 50 ng/ml.  Newer analysers can now 
provide results as concentrations in ng/ml, and it has been suggested that using 
alternative thresholds, i.e. <10 ng/ml and >200 ng/ml, rather than a cut off of 50 
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ng/ml, may improve positive prediction of the test and further aid clinical management 
(Abbott et al., 2013; Foster and Shennan, 2014).   
 
How beneficial fFN testing is in directing management or reducing negative outcomes 
remains unclear, however, as studies evaluating such effects report varying findings.  A 
systematic review and health economic analysis, undertaken on behalf of the NIHR 
Health Technology Assessment (Deshpande et al., 2013) concluded that use of fFN in 
the assessment of women with symptoms of TPTL is likely to reduce health care costs 
without adversely effecting outcomes, providing women with negative results are 
managed appropriately.  Basak and Babbur (2012) undertook an audit of in utero 
transfers (IUT) over three years in their UK district general hospital, and found that the 
introduction of fFN testing reduced the proportion of IUTs for TPTL from 60% to 26.7%.   
More recently, however, a systematic review and meta-analysis of randomised 
controlled trials found no difference in the incidence of preterm birth at any gestation, 
in the management of women with TPTL or in neonatal outcomes, although they did 
find a slight increase in healthcare cost (Berghella and Saccone, 2016).  As 
management, which included interventions such as the administration of tocolysis or 
steroids for fetal lung maturation, was similar in both groups, it is not surprising that 
there was no difference in rate of preterm birth or neonatal outcomes.  The authors 
suggest that, based on their findings, routine use of fFN in women with TPTL is not 
justified.  However, this conclusion must be viewed with caution.  Four of the six 
included trials were published in or before 2004, one was available only in abstract 
form, and in two of the four where time frame was indicated, data were collected 
between the years 2000 and 2002.  At this time, fFN was a relatively new test, 
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providing only dichotomous results, and it is possible that clinicians may not have been 
so confident in allowing the results to influence their management.  
   
1.4.3. Other biomarkers 
 
Since the establishment of fFN as a recognised predictor of preterm birth the detection 
of other proteins, such as insulin-like growth factor binding protein-1 (ILGF-1) and 
placental alpha microglobulin-1 (PAMG-1) have been the basis of newer bedside 
prediction tests.   Although findings of some small studies suggest they may have a role 
in TPTL assessment (Ehsanipoor et al., 2016; Nikolova et al., 2014; Wing et al., 2017) 
the body of evidence supporting their efficacy is currently substantially smaller than 
that relating to fFN (Di Renzo et al., 2011b).  
 
Other potentially useful biomarkers for the prediction of preterm birth have been 
suggested, and these include albumin and vitamin D-binding protein in cervico-vaginal 
fluid (Liong et al., 2014) and cell-free RNA (cfRNA) transcripts in maternal blood 
samples (Ngo et al., 2018).  Lucaroni and colleagues (2018) undertook a review of 14 
systematic reviews of biomarkers for predicting spontaneous PTB (sPTB) and 
concluded that, after fFN, which had the strongest association with sPTB, maternal 
serum alpha fetoprotein (AFP), C-reactive protein (CRP) and the cytokine, interleukin-6 
also had potential roles in prediction of sPTB. AFP was associated with an OR of 4 and 3 
for sPTB <34 and < 37 weeks, respectively; CRP had odds ratios for sPTB of 2 (95% CI 1–
2) and 8 (95% CI 4–16) in maternal plasma and amniotic fluid, respectively, and 
interleukin-6, had an odds ratio of 2 and a positive likelihood ratio of 12. 
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1.4.4. Combining biomarkers 
 
Whether combining biomarkers can increase accuracy of prediction is contentious 
issue.  Some commentators suggest that taking the two most strongly established 
predictors of preterm birth, combining fFN and TVS CL is likely to lead to better risk 
assessment (Bolt et al., 2011; Bruijn et al., 2016; DeFranco et al., 2013; Gomez et al., 
2005; Ness et al., 2007) and significant reduction in healthcare costs (van Baaren et al., 
2013).  Others, however, disagree.  Levine and colleagues (2018) found that combining 
fFN and CL did not improve prediction over using either test alone in a cohort of 537 
USA women with symptoms of TPTL.  In another prospective cohort study, carried out 
in four UK and two South African hospitals, where test results were blinded to 
attending clinicians (n=195), Tsoi and colleagues (2006) concluded that the addition of 
fFN result to TVS CL did not improve prediction of preterm birth within seven days.   
 
1.5. Interventions to reduce risks associated with TPTL  
 
Following examination and assessment, if a woman is considered to be at risk of 
delivering prematurely, she may be offered a number of interventions that have been 
shown to reduce the risks of neonatal morbidity and mortality associated with preterm 
birth.  These include administration of antenatal corticosteroids for fetal lung 
maturation, drugs to reduce or stop uterine contractions (tocolytics), magnesium 
sulphate for fetal neuroprotection, and hospital admission with IUT, if necessary, to 
ensure the availability of appropriate neonatal intensive care.  As with all 
interventions, however, the risks must be considered alongside the benefits.  
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Administration of steroids, usually in the form of dexamethasone or betamethasone, 
substantially improves outcomes in babies born preterm (Royal College of 
Obstetricians and Gynaecologists, 2010), and is recommended for all women at 
significant risk of delivery between 24 weeks’ (or earlier, if the fetus is considered 
viable) and 34 weeks’ gestation. A full course consists of two doses 24 hours apart, and 
the optimal clinical effect is seen between 24 hours and seven days (Norberg et al., 
2017).  This can, of course, be difficult to judge and evidence suggests that many 
women may be receiving them at inappropriate times.  In a retrospective cohort study 
of 630 women who had had preterm birth between 24 and 34 weeks, Levin and 
colleagues (2016) found that although 93% (589/630) had received steroids, only 40% 
(238/589) received them between 24 hours and 7 days.  If the birth does not take 
place within the optimal window and the women has a further episode of TPTL, 
repeated administration of steroids may occur.  There is evidence, however, that 
multiple courses of steroids may be harmful and lead to growth restriction and 
possible longer term cardiovascular effects in the baby (Asztalos et al., 2014; Murphy 
et al., 2008; Norberg et al., 2013).  Although the balance of risk indicates 
administration of steroids should be repeated if preterm birth remains likely after the 
time of maximum effect (McKinlay et al., 2012), this should be avoided if possible, and 
so appropriate timing of the first course is of great importance.  Additionally, although 
not appearing to have lasting adverse effects on the woman, the administration of 
steroids can substantially affect blood sugar levels and those with impaired glucose 
tolerance or diabetes require extra monitoring (Royal College of Obstetricians and 
Gynaecologists, 2010).   
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Tocolytic drugs are designed to stop uterine contractions. A range of drugs have be 
used for this purpose and these include ritodrine, terbutaline, indomethacin, 
nifedipine, atosiban and magnesium sulphate (Gyetvai et al., 1999).  Evidence suggests 
that they can delay delivery for up to seven days, but with no proven reduction in 
neonatal morbidity (Gyetvai et al., 1999; Haas et al., 2009; Smith et al., 2009).  
Currently, the main rationale for tocolytic use is to delay the birth for at least 48 hours 
to allow completing of a course of steroids, and for IUT, if necessary, to a hospital with 
an appropriate level of specialist neonatal care (Haram et al., 2015). Many tocolytics 
have unpleasant and potentially dangerous side effects, including nausea, vomiting, 
palpitations and hypotension, and if offered, must be used with caution (NICE, 2015).  
Tocolytics most offered in UK currently include nifedipine and atosiban. 
 
Evidence suggests that administration of antenatal magnesium sulphate substantially 
reduces the risk of cerebral palsy in children of women at risk of preterm birth 
(Constantine et al., 2009; Crowther et al., 2014). However, magnesium sulphate 
overdose can lead to loss of deep tendon reflexes and respiratory depression and both 
the woman and fetus require careful monitoring. 
 
Women may be admitted to hospital for observation and to ensure neonatal facilities 
are available should their symptoms progress quickly to established labour, as this can 
substantially improve the outcomes of preterm babies (Marlow et al., 2014).   They 
may also be advised to stay in for “bed rest”.  There is, however, no evidence to 
support the use of bed rest for women at risk of PTB (Sosa et al., 2015) and there may 
be other potential adverse effects such as weight gain and risk of deep vein thrombosis 
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due to lack of mobility.  Despite the lack of evidence bed rest is still frequently advised 
(Sciscione, 2010).   Hospitalisation is costly, both for the NHS, and for the woman, and 
can mean loss of income, difficulties with childcare and work, as well as isolation and 
increased anxiety (Lowenkron, 1999; Mackinnon, 2006).  In contrast, for women with a 
history of preterm birth, hospital admission may be reassuring.   Although the 
mechanism is unclear, as discussed in more detail in Section 11.2.2, anxiety and 
depression are known to increase the risk of spontaneous preterm birth (Dole et al., 
2003) and a reduction in anxiety may help these high risk women (O’Brien et al., 2010).  
The very process of being monitored carefully, or perceptions of additional support, 
may have a protective effect.  Indeed, Sandall and colleagues’ systematic review found 
a reduction of preterm birth in women who had received midwifery-led continuity 
models of care compared to those with “shared-care” models (Sandall et al., 2016). 
The biological pathways for this effect remain to be clarified. 
 
If a woman in TPTL is admitted to a hospital that does not have adequate neonatal 
facilities for her gestation, she may be transferred to another, which could be located 
at a significant distance from home.  As well as practical and financial difficulties, the 
emotional impact on women is likely to be significant, with increased anxiety as a 
result of being in an unfamiliar environment and feelings of isolation and separation 
anxiety (Porcellato et al., 2015).  IUT can be a complicated and costly procedure for the 
doctors organising the transfer (Gale et al., 2012), and if the woman does not 
subsequently deliver preterm, it could result in an antenatal bed and neonatal cot 
being unnecessarily “blocked”, potentially leaving a woman living closer to the 
receiving hospital requiring IUT elsewhere, or her baby being transferred postnatally, 
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which is more dangerous (Watson et al., 2017b).    Currently, there are no data 
available to estimate the number of seemingly unnecessary transfers in the UK, but 
Badgery-Parker and colleague’s (2012) large Australian retrospective cohort study of 
women admitted to hospital at 20 to 36 weeks’ between 2001 and 2008 (n=110,439) 
found that of women transferred for suspected TPTL only 38% delivered prematurely.   
 
 
1.6. Challenges in providing appropriate care in TPTL 
 
Although advances in care have led to more, and earlier, babies surviving preterm 
birth, it remains hard to accurately predict, even when a women presents with 
symptoms of threatened preterm labour (TPTL).  If cervical dilation is not evident on 
speculum or digital examination it is difficult to know whether labour has indeed 
started and will progress to preterm birth, and whether the woman should be 
admitted and receive clinical care, or be discharged.    
 
Symptoms of TPTL (e.g. abdominal pain and/or uterine contractions) are not accurate 
predictors of preterm birth (Copper et al., 1990, Iams et al., 2002) but because the 
consequences of not treating women in “true” preterm labour could be devastating, 
many receive unnecessary interventions.  Overtreatment of women with symptoms of 
TPTL is a problem because of the danger of adverse effects of the interventions, as 
detailed in Section 1.5, as well as significant, and potentially unnecessary, healthcare 
expenditure (Lucovnik et al., 2013; Mozurkewich et al., 2000;  van Baaren et al., 2013).   
 
The extent of this problem is significant. At least half of women with symptoms of TPTL 
will deliver at term (Kiefer and Vintzileos, 2008; McPheeters et al., 2005).  One study 
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reported as many as 82% of women with preterm labour symptoms eventually being 
discharged home with a diagnosis of false preterm labour (Chao et al., 2011), while in 
Iams and colleagues’ (1995) study of the utility of fFN in TPTL, using a threshold of 50 
ng/ml, only 32% of women delivered preterm. Boesveld et al., (2014) found that in 
their retrospective cohort study of 984 women receiving antenatal corticosteroids for 
fetal lung maturation, only 40.1% of those with suspected preterm labour delivered 
within 7 days, the time within which the drug has its optimum effect.  
 
1.7. Risk assessment in maternity care 
 
The purpose of antenatal care is to prevent and/or treat conditions that threaten the 
life or health of pregnant women and their babies, as well as to help women to 
“approach pregnancy and birth as positive experiences” (Banta, 2003, p.4).    A 
fundamental element of maternity care is risk assessment which aims to identify those 
in need of extra surveillance or intervention.  This is important because, while 
healthcare interventions are designed to prevent or mitigate poor outcomes they need 
to be appropriately targeted, both to avoid iatrogenic adverse effects and to protect 
finite health resources (Hoffman and Cooper, 2012; Pathirana et al., 2017).    Risk 
assessment in healthcare involves clinicians taking note of the patient’s history and 
current symptoms, and applying their knowledge and experience of previous cases 
with known outcome.   This assessment is then used as a basis for shared decision 
making, when the clinician and patient come to a conclusion on the best course of 
action (Godolphin, 2009).     
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1.7.1. Uncertainty in risk assessment  
 
Whilst it is a fundamental part of healthcare, the process of risk assessment is not 
always straightforward.  An individual’s risk is often calculated based on a statistical 
probability that an event, or hazard, will occur.  These probabilities are based on 
frequencies observed in past studies of heterogeneous populations.  So, whilst they 
can provide some assistance in approximating the risk and informing decision making, 
they cannot eliminate the inherent uncertainty of future events (Dhawale et al., 2017).  
Although maternal and neonatal mortality rates have decreased dramatically in high 
income countries since the first half of the 20th century, pregnancy outcomes for 
individual women remain impossible to predict with certainty.  
 
The issue of uncertainty resonates in all areas of healthcare, where the best course of 
action is often unclear and there has to be a trade-off between potential benefits and 
possible harms (Politi, 2015).    The communication of uncertainty can also be very 
challenging.  Han (2013) describes a number of difficulties that include the reliability of 
the probability information it is based upon, the lack of evidence on the best methods 
for communicating it and the ethical issue of whether the communication of 
uncertainty can affect patient autonomy to the extent that it does more harm than 
good.  Politi and colleagues (2011) found that the communication of uncertainty can 
lead to lower patient satisfaction, although the authors argue that this is a necessary 
part of shared decision making.    A later review of the literature concluded that 
uncertainty must at least be acknowledged and that clinicians should aim to help 
patients through “the emotionally laden process of grappling with unknowns.” (Politi 
2015, p.4):    
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“Acknowledging uncertainty and collaborating with patients through the 
unknowns of medical care is not easy, but can have long-lasting benefits 
for both patient care and the patient-clinician relationship.” (p.4). 
 
Although now recognised as an important element of informed decision making (David 
and Akintomide, 2016), evidence remains lacking on the most effective methods of 
communicating uncertainty (Ahmed et al., 2012; Politi et al., 2007; Royal College of 
Obstetricians and Gynaecologists, 2008).  In the absence of this evidence, the Royal 
College of Obstetricians and Gynaecologists has published guidelines and general 
principles, which advise the clinician to:  
“accept and involve patients as a partner by informing them of the risk; 
plan what you will say and be appropriately informed about the patient’s 
medical, social and educational circumstances; ensure that your advice is 
up to date and in line with your departmental practice; evaluate the 
patient’s understanding of what you have discussed; listen to their 
concerns; maintain trust and credibility by being honest, frank and open.” 
(Royal College of Obstetricians and Gynaecologists, 2008, p.5).    
 
 
Another issue with communication of uncertainty and risk probabilities is a lack of 
numerical understanding in both patients and clinicians (Lipkus et al., 2001; Lloyd et 
al., 2001).  Recognising a particular need to address the lack of numerical literacy of 
patients which results in difficulties in understanding probability statistics, Fagerlin and 
colleagues (2011) made 10 recommendations on how best to communicate complex 








1 Use plain language to make written and verbal materials more 
understandable.  
2 Present data using absolute risks.  
3 Present information in pictographs if you are going to include graphs.  
4 Present data using frequencies.  
5 Use an incremental risk format to highlight how treatment changes risks from 
pre-existing baseline levels.  
6 Be aware that the order in which risks and benefits are presented can affect 
risk perceptions.  
7 Consider using summary tables that include all of the risks and benefits for 
each treatment option.  
8 Recognize that comparative risk information (e.g., what the average person’s 
risk is) is persuasive and not just informative.  
9 Consider presenting only the information that is most critical to the patients’ 
decision making, even at the expense of completeness.  
10 Repeatedly draw patients’ attention to the time interval over which a risk 
occurs. 
Figure 3. Summary of recommendations for risk communication to 
patients, adapted from Fagerlin et al., 2011, (p.1437). 
 
 
Even when an individual’s probability of risk has been reliably calculated, how that risk 
is perceived, what it means to the patient as an individual and how it influences their 
decision can be very varied, and not necessarily in line with that of their clinician 
(Brewer et al., 2007; Herxheimer, 2005; Lee et al., 2012).  This risk perception can be 
influenced by the way the risk is communicated.  Simply the way the risk is framed, 
that is, whether it is presented as a gain or a loss, e.g.: “you have a 5% chance of your 
baby being born early” as opposed to “you have a 95% chance of your baby being born 
at term”, can have a profound effect on an individual’s perception of risk (Paling, 
2003).   Gigerenzer and Edwards (2003) warn that care should be taken that risk is not 
presented in such a way as to serve the best interests of the institution, rather than 
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1.7.2. Decision support tools 
 
Decision support tools, or decision aids, can help both patients and clinicians to 
evaluate the often vast and complex information required before they can come to an 
informed decision.  These tools come in various forms, including booklets, 
questionnaires that help a patient to consider what is most important to them, videos, 
or interactive computerised tools.   Use of decision aids in clinical practice has grown 
substantially over the last two decades, but recognition of the important influence 
they can have on patient decisions, and the variability of their quality, inspired the 
establishment of the International Patient Decision Aids Standards (IPDAS) 
Collaboration (Elwyn et al., 2006).  This collaboration developed a set of internationally 
recognised standards that could be used as a checklist by developers and evaluators 
for improving the quality of decision aids and the reporting of their evaluations. 
 
Despite publication of these standards, and while the quantity of available patient 
decision aids increased, quality was not always assured.  A systematic review of 
papers, published in 2013, describing development and evaluation of patient decision 
aids using an adapted framework based on an earlier set of criteria, the Ottawa Patient 
Decision Aids Framework (O’Connor et al., 1999), and IPDAS criteria found that: “Only 
about half [patient decision aids] appear to have been field tested with patients, and 
even fewer had been reviewed or tested by clinicians not involved in the development 
process” (Coulter et al., 2013, p.4). 
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More recent evidence appears to support the use of patient decision aids.  A  Cochrane 
Systematic Review (Stacey et al., 2017) found good quality evidence that using decision 
aids can improve accuracy of risk perceptions (accuracy of risk perceptions (relative 
risk 2.10; 95% CI 1.66 to 2.66)) and reduce decisional conflict (mean difference in 
decisional conflict score (DCS) −9.28/100; 95% CI −12.20 to −6.36).  Nilsson et al., 
(2015), in their systematic review, also found a decrease in decisional conflict in 
women using decision aids when considering vaginal birth after caesarean section.    
 
The popularity and acceptance of decision aids in healthcare appears to now be well 
embedded in the UK.  The NHS Rightcare initiative makes available a number of 
evidence-based patient decision aids through their website.  However, the number of 
aids is currently limited, with only one related to maternity care: “Birth options after 
previous caesarean section decision aid” (NHS England, 2018). 
 
1.7.3. Improving the presentation of risk information  
 
The way the information is presented in a decision support tool can have a major 
influence on decision making.  This is particularly important with the presentation of 
risk information (Ahmed et al., 2012).  As described earlier, numerical literacy can 
affect the ways people interpret risk, so ratios and percentages may be more helpfully 
reported as frequencies, e.g. 1 in 100 people (David and Akintomide, 2016).  
 
Personalised risk estimates have also been shown to increase informed choice.   Of the 
three good quality studies included in Edward et al.,’s (2013) Cochrane Systematic 
Review, 45.2% (592/1309) of participants receiving personalised risk information made 
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informed choices, compared to 20.2% (229/1135) who received generic risk 
information.  
 
In an attempt to identify best practice in risk communication used in decision aids, 
Trevana et al., (2013) developed an evidence summary by expert consensus and 
proposed a set of guiding principles that should be considered when including 
numerical estimates in decision aids.  These are shown in Figure 4. 
1 The inclusion of numeric estimates with PtDAs [patient decision aids) 
improves patient’s accuracy of risk comprehension. 
2 Consider the cognitive tasks required of DA [decision aid] users and choose 
the appropriate format for presenting the information (e.g. comparing the 
chance of two independent events at a defined point in time). 
3 Define a relevant reference class (i.e. denominator) for your target audience 
and try to keep this consistent throughout the DA.  In defining the reference 
class, take time into consideration.  
4 Try to use a consistent format throughout the DA. 
5 Avoid using 1 in x formats with variable denominators.  
6 Consider your target group’s graph literacy and numeracy and include 
appropriate formats.  
7 Consider the magnitude of the numbers you are presenting and the possibility 
of format bias.  This may be reduced through concurrent use of appropriate 
visual formats.  
 
Figure 4. Guiding principles for including numeric estimates in decision aids. Adapted 
from Trevana et al., 2013. 
 
Graphical representations, such as icon arrays, can be used to illustrate risk visually, 
and may even save time during consultations (Edwards et al., 1999).  Galesic and 
colleagues’ (2009) study of older adults and university students found using icon arrays 
increased accuracy in understanding risk reduction in both groups. Icon arrays display 
a number of dots, or other figures representing people, and highlighting is used to 
depict those affected by the risk within the context of the population.   
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A relatively recent example of an icon array can be found in a decision aid for women 
choosing place of birth (Coxon, 2014, Figure 5).  This visually demonstrates the 
differences in neonatal outcome - as defined in the Birthplace Study (Hollowell et al., 
2011) – by planned place of birth, and is designed to help women compare these risks 
as they make this important decision.  Although the use of these icon arrays in this 
decision aid booklet aims at simplifying risk in different scenarios, some women, 
particularly those with limited literacy, may need assistance in interpretation. 
 
 
Figure 5. Icon array displaying risk of poor neonatal outcome by planned place of birth. 
From Coxon (2014). 
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1.7.4. Mobile technology in healthcare 
 
 
The use of digital technology in healthcare has been recent and rapid and the 
advantages of mHealth, i.e. digital health technologies that utilize mobile phones, is 
seen as a natural progression (Perera, 2012).   Mobile technology has been found to be 
useful for data collection, provision of health information and communications, 
particularly in lower and middle income countries, where mobile phones are very 
common (Amoakoh-Coleman et al., 2016; Kay et al., 2011; Sondaal et al., 2016).  An 
increasing body of evidence suggests mHealth interventions can improve outcomes 
and health service utilization (Bush et al., 2017; Chen et al., 2018; Sondaal et al., 2016).  
One of the particular advantages of mobile phone applications is that they can be 
updated regularly, ensuring information is based on current evidence, and they are so 
readily accessible (Arbour and Stec, 2018).   Clinical decision support tools that 
incorporate an element of personalised risk calculation may be most suited to a 
computer-based programme which calculates an individual’s risk based on inputted 
risk factors and variables such as age.  Complex tools such as these are sometimes 
referred to as Computerized Decision Support Systems (CDSSs) (Liberati et al., 2017).   
 
Mobile phone health applications are widely used by clinicians as well as patients.  A 
survey of UK medical students (n=257) and junior doctors (n=131) carried out in 2011 
found a high level of smart phone ownership (79%, 203/257 and 75%, 98/131, 
respectively) and mobile application usage (76%, 155/203 and 72%, 71/98, 
respectively) with both groups expressing an interest in the development of additional 
apps to enhance their education and professional practice (Payne et al., 2012).  As 
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technology has moved on in recent years, this is likely to have increased.  A more 
recent survey of 197 Californian obstetrics and gynaecology doctors found that 95% 
used mobile apps in the clinical setting (Perry et al., 2017). 
 
There are concerns, however, that without official validation and regulation some 
medical apps may produce erroneous results and lead to incorrect, inappropriate or 
even dangerous decisions (Bierbrier et al., 2014).   In 2015, in recognition of the 
growing number of medical apps in use, the USA’s regulatory body the Food and Drugs 
Administration (FDA) issued guidance (FDA, 2015).  This guidance stipulates that if a 
mobile app is defined as a medical device it will be regulated in the same way as other 
medical devices.   In the UK, the Medicines and Healthcare products Regulatory Agency 
(MHRA) also considers and regulates medical mobile apps providing they meet the 
regulatory body’s definition of a medical device (MHRA, 2018). 
 
1.8. Relationship of this PhD project with the QUIPP app. 
 
One of the objectives of this PhD project, as explained in detail in Chapter 4, was to 
inform development of a risk assessment tool that had already been created by the 
King’s College, London (KCL) Department of Women and Children’s Health Preterm 
Birth Group (Abbott et al., 2011; Kurht et al., 2016a, 2016b).  This section explains the 
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1.8.1. Creation of the preterm birth risk assessment tool 
 
The risk assessment tool was first manifest as a Microsoft Excel spreadsheet (Figure 6), 
where risk factors, gestation and test results were entered in defined cells (highlighted 
in mauve in Figure 6) and a probability of preterm delivery was generated and shown 
in other cells (highlighted in green, Figure 6).  The algorithms used in generating the 
risk prediction scores were developed using data collected during the EQUIPP study 
(REC Ref. 10/H0806/68) and are reported in Kuhrt et al., (2016a) and Kuhrt et al., 
(2016b).   
 
 
Figure 6. Excel spreadsheet showing first version of the KCL Department of Women 
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1.8.2. First version of the risk assessment tool as an iPhone App.   
 
Before commencement of the recruitment phase of this PhD project, an independent 
mobile phone app designer (James Appatta) was engaged to develop the risk 
assessment tool into an iPhone app, QUIPP version 1 (Figure 7). This app utilized the 
same prediction algorithms into a more user-friendly format, which was then used in 
the Preterm Surveillance Clinic at Guy’s and St Thomas’ NHS Foundation Trust (GSTfT) 
and by other members of the UK Preterm Clinical Network (UKPCN), a body of 
clinicians running specialist clinics for women at high risk of preterm birth.   
 
Figure 7. Risk assessment tool for high risk asymptomatic women – QUIPP App version 
1. 
 
1.8.3. Developments occurring during PhD project 
 
The next phase of development was planned to commence after the completion of this 
PhD project.  However, before the participant recruitment phase was complete, a 
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funding application to evaluate the QUIPP app in practice was successful (EQUIPTT, 
REC Ref. 17/LO/1802, funded by Guy’s and St Thomas’ Charity, Registered Charity No. 
1160316; ISRCTN trial registry number ISRCTN17846337).  The opportunity was taken 
to proceed with developing the second version of the app and to ensure the prediction 
algorithms were as up-to-date as possible before commencement of that study.  A 
decision was taken by the Preterm Birth Research group, of which I am a member, to 
update the predictive algorithms prior to completion of PETRA using data already 
gathered (as at the end of May 2017) along with relevant participant data from earlier 
studies that I had been closely involved in (EQUIPP REC Ref. 10/H0806/68 and POPPY 
REC Ref. 09/H0802/97).   My involvement at that stage had been to prepare the data 
set used in creation of the new algorithms. These were tested by calibration before 
being applied in the new version of the QUIPP app.  Formal validation was carried out, 
by myself and the department statistician, Mr Paul Seed, after completion of the 
PETRA study and is presented in Section 8.7 as part of the final results of this thesis.   
 
Data obtained from the qualitative components of the PhD project were also used to 
inform developments in usability and visual illustration of risk.  These will be explained 
in more detail in later relevant chapters. 
 
 
1.9. Summary and justification for thesis 
 
In summary, for those women whose symptoms develop into preterm labour and 
birth, accurate risk assessment and diagnosis is vital so interventions that minimize the 
associated risks can be instigated quickly.  What is also very important, however, is the 
fact that many women who experience symptoms of TPTL will not subsequently 
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deliver early, so clinical assessment and test results that can reassure as quickly as 
possible are likely to be beneficial by both reducing unnecessary intervention and 
decreasing anxiety. 
 
Risk assessment in TPTL remains complex, partly because clinicians need to make 
judgements based on the woman’s history as well as at least three other continuous 
variables, i.e. pregnancy gestation, fFN result and cervical length.  A simple-to-use, 
accurate tool, which combines risk factors and test results into one % risk score, was 
proposed to improve the process of decision making (Abbott et al., 2011; Kuhrt et al., 
2015). Because data from symptomatic women was limited, in the first version of 
QUIPP, prediction algorithms for use in TPTL were limited to singleton pregnancies and 
qfFN test results.  This study would address this by gathering data, including TVS CL, 
from a large prospective cohort. 
 
Other aspects of a woman’s clinical care may also affect her experience of TPTL in 
positive and negative ways.  Levels of anxiety, as discussed earlier in Section 1.3 may 
also independently influence risk of preterm birth.  A deeper understanding of the 
experience from the woman’s perspective may highlight areas for potential 
improvement in TPTL care that could be subsequently incorporated into clinical 
guidelines.  
 
This PhD project sought to address these two issues: i) the need for improved risk 
assessment and ii) the identification of how TPTL care could be improved.  This was 
achieved through developing a clinical decision support tool that predicts individual 
risk of preterm delivery and undertaking a qualitative study exploring women’s 
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experience.  Prior to addressing these questions experimentally, two literature reviews 
were undertaken to determine the current knowledge pertaining to the use of mobile 
apps in pregnancy and to establish what is currently known about women’s experience 
of TPTL.   








2.1. Introduction to literature review 
Despite the apparent extensive use of medical mobile phone applications (apps) by 
both clinicians and patients, there appears to be a paucity of peer-reviewed 
professional journal publications, particularly in relation to preterm birth.  A review of 
the Cochrane Pregnancy and Childbirth Group’s Trials Register (Davey et al., 2015), 
found no trials of risk-scoring systems, of any kind, for predicting preterm birth with 
the aim of reducing associated adverse outcomes.   
 
As development of a TPTL risk assessment tool was a core element of this PhD project, 
the main purpose of this literature review was to explore use of mobile phone apps for 
clinical decision support or risk assessment, and to identify papers that could provide 
insights that could be used to inform further development of the QUIPP app.   An initial 
scoping exercise undertaken for this thesis identified only one paper reporting any sort 
of evaluation of a mobile app for decision support specifically related to preterm birth 
(Watson et al., 2017b).  This paper, in fact, relates to the first version QUIPP app 
developed by our research team, as outlined in section 1.8, and it reports results of a 
study using retrospectively collected data on 355 women with symptoms of 
threatened preterm labour to evaluate the predictive accuracy of the app.  Watson et 
al., (2017b) modelled the effect of a “treat all” strategy for 188 women presenting in 
TPTL under 30 weeks’ gestation, as per the contemporary NICE Preterm guideline 
(NICE, 2015). The findings of this exercise suggested that 89% (n=169) of hospital 
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admissions could have been safely avoided if a threshold of 5% risk of delivery within 
the next seven days had been used to guide clinical practice.  However, whilst the 
paper reports an evaluation of reliability of the statistical algorithms used in the risk 
prediction calculations, no other aspects of the QUIPP app, such as usability or 
acceptability by clinicians or women are reported.   
 
In view of the paucity of relevant literature relating to preterm birth, the scope of the 
review was expanded to include evaluations of any mobile phone applications used by 
clinicians for decision support or risk assessment in any area of pregnancy care.  
Specific objectives were to: 
1. Determine the current landscape of mobile phone apps use for decision 
support or risk assessment by clinicians in pregnancy care. 
2. Identify perceived benefits and potential hazards of use in clinical practice. 
3. Identify facilitators and barriers to implementation of these apps into clinical 
practice. 
 
2.2. Search Strategy 
Inclusion and exclusion criteria for the review were decided upon prior to initiating a 
database search and are listed in Table 1.  
 
Table 1. Inclusion and exclusion criteria for the literature review “Mobile apps for 
clinical decision support in pregnancy”. 
 
Inclusion  Exclusion 
Mobile phone applications (apps) for 
decision support or risk assessment in 
pregnancy 
Decision aids not utilizing mobile app technology, e.g. 
clinical guidelines/models/decision trees 
Apps for data collection or delivery of 
information/health promotion 
Statistical prediction models 
Primary research or report of app 
development and evaluation published 
in peer reviewed journals 
Literature review 
Study protocols 
Commentaries or editorials 
App for use by clinicians or both 
clinicians and pregnant women 
App for use by pregnant women only 




The research databases used in the search included: Medline, Embase, PsychoInfo and 
the Cochrane Database of Systematic Review, with search terms and limits used for 
each database listed in Table 2.  Reference lists and citing articles were also reviewed 
for other potentially relevant papers.   In addition to these research databases, the 
online journals JMIR MHealth and UHealth, which have a specific focus on digital 
health, were also searched for papers reporting on pregnancy, labour or birth. 
 
Table 2. Search terms and limits for the literature review "Mobile apps for clinical 
decision support in pregnancy". 
 Search term  Search term Limit 
Medline 
(n=598) 
Pregnancy OR Exp Labour, 
Obstetric OR  
Labour OR 
Premature Birth OR 
Obstetric Labor, 







mHealth.mp OR mobile 
application.mp OR 
Exp Mobile Applications 
OR smart phone.mp 
OR Exp Smartphone 
OR Decision aid$.mp 
OR Risk assessment tool$.mp OR 
Predictive model.mp OR App.mp 
Papers published 
since 2007 (when 
the iPhone and 





Pregnancy OR Exp Labour, 
Obstetric OR  
Labour OR 
Premature Birth OR 
Obstetric Labor, 






mHealth.mp OR mobile 
application.mp OR 
Exp Mobile Applications 
OR smart phone.mp 
OR Exp Smartphone 
OR Decision aid$.mp 
OR Risk assessment tool$.mp OR 
Predictive model.mp OR App.mp 
Papers published 
since 2007 (when 
the iPhone and 
first mobile apps 
were available); 
Humans; Full text 
(as large number, 





Pregnancy OR Exp Labour, 
Obstetric OR  
Labour OR 
Premature Birth OR 
Obstetric Labor, 




mHealth.mp OR mobile 
application.mp OR 
Exp Mobile Applications 
OR smart phone.mp 
OR Exp Smartphone 
OR Decision aid$.mp 
OR Risk assessment tool$.mp OR 
Predictive model.mp OR App.mp 
Papers published 
since 2007 (when 
the iPhone and 













mHealth OR decision aid OR risk 
assessment tool OR smart phone 






Pregnancy OR Labour OR 
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2.3. Results of search strategy 
After removal of duplicates, the database and JMIR journals search produced a total of 
909 articles for screening.  Review of the titles and abstracts identified 774 of these to 
be ineligible based on the inclusion criteria, leaving 135 papers for full text review.  Of 
these, only 13 were eligible for inclusion, with 122 being excluded for the reasons 
shown in the PRISMA flow diagram (Figure 8). 





Figure 8. PRISMA 2009 Flow Diagram of results of literature search for “Mobile apps 
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2.4. Characteristics of the papers included in the review 
 
Details of the 13 included papers are shown in Table 3.  A formal review of quality was 
not undertaken because this was not a rigorous attempt at establishing the efficacy of 
an intervention.  Instead, the aim was a broad exploration of the use of mobile apps, 
with the added objective of gaining helpful insights into the development process 
gleaned from reports published by their developers.  Of the included papers, the 
majority (n=10) described early development of the mobile application with results of 
feasibility, usability studies and/or satisfaction studies (Dunsmuir et al., 2014; Jeon et 
al., 2016; Jonas et al., 2016; Lim et al., 2015; Mackillop et al., 2014; Marko et al., 2016; 
Peleg et al., 2017; Stroux et al., 2016; Tsai et al., 2014; von Dadelszen et al., 2015). Two 
reported results of studies evaluating maternity care projects in which the app was a 
central component of care delivery (Battle et al., 2015; Vélez et al., 2014) and one 
(Watson et al., 2017b) reported a study testing the reliability of the risk prediction 
scores created by the QUIPP app, as noted above.  
 
Seven papers reported on studies or projects based in low and middle income 
countries, including Africa and Guatemala (Battle et al., 2015; Dunsmuir et al., 2014; 
Lim et al., 2015; Stroux et al., 2016; Tsai et al., 2014; Vélez et al., 2014; von Dadelszen 
et al., 2015).  Two were based in the UK (Mackillop et al., 2014; Watson et al., 2017b), 
one in Spain and Italy (Peleg et al., 2017) and one in USA (Marko et al., 2016).  In two 
papers the location of the project was unclear, however one of the corresponding 
authors was based in Korea (Jeon et al., 2016) and the other in Germany (Jonas et al., 
2016).  All were published between 2014 and 2017: four in 2014; three in 2015; four in 
2016 and two in 2017.   
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Four papers reported on apps focusing on preeclampsia (Dunsmuir et al., 2014; Jonas 
et al., 2016; Lim et al., 2015; von Dadelszen et al., 2015). Three of these, however, all 
referred to the same project, Pre-eclampsia Integrated Estimate of Risk (PIERS) 
(Dunsmuir et al., 2014; Lim et al., 2015; von Dadelszen et al., 2015).  Gestational 
diabetes was the focus for two papers (Mackillop et al., 2014; Peleg et al., 2017).  The 
aims of the maternity care projects were to increase the number of births in a health 
facility in Zanzibar (Battle et al., 2015) and to improve access to maternity care for 
women in Ghana (Vélez et al., 2014).  The pregnancy focus of each of the remaining 
five papers were: metabolic syndrome (Jeon et al., 2016); weight and blood pressure 
monitoring (Marko et al., 2016); identification of fetal compromise (Stroux et al., 
2016); antenatal depression (Tsai et al., 2014) and preterm birth (Watson et al., 
2017b). 
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Table 3. Characteristics of papers included in literature review "Mobile apps for clinical decision support in pregnancy". 
 
Description of paper and study 
design 


















Mixed methods evaluation of 
program using app. 
 
Report of findings from a mixed 
methods study qualitative and  
quantitative data evaluation the 
“mHealth for Safer Deliveries” 
program - an integrated mobile 
health intervention on maternal 
care utilization. 
 
The program was designed to 
address each of the “three 
delays” to receiving skilled care 
at delivery: (1) the decision to 
seek care; (2) reaching skilled 
care; and (3) the provision of 








were conducted during 
September-October 
2014 in all districts using 
semi-structured 
interviews (women, 
n=27; CHWs, n=25; 
health facility workers, 
n=12) 
 
Quantitative data were 
collected as part of the 
intervention between 





YES YES YES  “The program supported 
community health workers 
(CHWs) who were trained to 
use a phone with a user-
friendly decision-support 
application.  This enabled the 
CHWs to:  
 
1. Counsel the mother and 
family on healthy behaviours 
and recognizing danger signs. 
2. Record permissions from 
husband and family members 
agreeing to a facility-based 
delivery. 
3. Screen women (and their 
babies) for complications from 
pregnancy up to a week after 
delivery and refer them as 
needed to the health facility. 
4. Use mobile banking to pay 
for transportation to the 
health facility when the 
woman is referred, paying for 
transport without ever 
touching cash. 
5. Use text or voice 
communication to notify a 
health facility that a woman is 
in transit.” 
“The qualitative interviews identiﬁed perceptions of the program, 
including both reasons for success and barriers to facility delivery.  
One of the themes that emerged from many of the CHW participants 
was the positive effect of the phone in increasing their conﬁdence in 
referring women to the health facility. CHWs felt a greater sense of self-
efﬁcacy due to a broadening of their knowledge.  
CHWs and mothers cited the portability of the phone (with client 
record) and the ability to send and receive calls and SMS messages 
critical for their communication with clients, health facilities, and drivers 
at all times of the day.  
For mothers, the ability to easily reach their designated CHW also 
created a sense of security and trust between them.  Overall the sense 
of feeling safe, supported, and secure was a strong theme and a 
primary reason for women getting to the facilities. 
The ease of arranging and paying for transport in case of a 
complication or for labour was cited as critical in all three informant 
groups.  Transport was cited by most health worker informants from 
delivery facilities as a reason for the increase in facility delivery. 
The actual decision to seek care was often attributed to CHWs' 
counselling messages and the general support they provided during 
the mother's pregnancy, delivery, and the postnatal period, even over 
the availability of free transport. 
Many health workers stated that a CHW present at the point of referral 
was a positive impact on the health worker preparedness.   
Health workers from delivery centres almost universally attributed the 
increase in deliveries at their facilities to the program. 
Some women reported concerns about facility care and costs. 
Of the 13,231 women who delivered in the program, 75% did so at a 
facility and 78% under skilled care compared to a baseline of 35%. 
The majority of CHWs discussed the positive relationships that emerged 
between themselves and the facility worker due to their frequent 
communication. 
Some mothers also mentioned the cost associated facility deliveries 
being a deterrent to themselves or their husbands/families, despite 
national policy declaring services to be free.” 




Description of paper and study 
design 














2. Dunsmuir et 
al., (2014)  
 
 
Describes development of app 
and results of usability study. 
 
This paper describes the 
development process, including 
challenges and solutions, of the 
PIERS on the Move (POTM) is a 
low cost, easy-to-use, mobile 
health (mHealth) application for 
accurately predicting the risk of 
adverse outcomes associated 




Cape Town, South Africa.    
 
November 2011 to 
January 2013 
 
At the time of 
publication, 202 women 
had been assessed with 
the POTM application. 
 
A total of 37 nurses and 
midwives evaluated the 
user interface through 





YES YES   “The clinical data collected in 
women with pre-eclampsia are 
used as the inputs to a 
predictive model providing a 
risk score for the development 
of adverse outcomes. 
 
App calculates a risk score 
using clinical findings 
(including measurements by 
pulse oximeter connected to a 
smartphone). Based on the 
risk score, the application 
provides recommendations on 




“Smartphones are rapidly becoming available in many low resource 
settings and their small size and weight facilitate their use during 
home visits.  
The developed Phone Oximeter applications can run on existing 
smartphones, already owned or used by health care providers.   
Smartphones can also serve as communication devices to facilitate 
escalation of care.  
GPS functionality can also be used to track data collection locations. 
Mobile devices can be used to perform data validation and inform 
the user of any errors.  
The application selectively requires the performance of additional 
investigations.  E.g. if the woman is hypertensive, the application will 
suggest the need for a dipstick proteinuria measurement and ask 
about the symptoms the woman is experiencing.  
Multiple language support was required. Translations in the 
necessary languages are stored. 
The ﬁrst usability study revealed that entering patient contact details 
was the most time-consuming task due to user inexperience with a 
small onscreen keypad. The keypad size was expanded for the next 
usability study.  
Many potential users had not had prior experience with smartphones.  
To address this problem, the amount of information on one screen 
was kept to a minimum and if scrolling is necessary, the application 
auto-advances the scrolling as the user enters data. The interface 
now avoids the use of dropdown lists, and instead shows all options 
simultaneously with checkboxes or radio buttons.  
Security is a challenge when data are collected on mobile devices 
during home visits.  Therefore, the data stored are encrypted.  
Additionally, to deter the theft of devices, all devices are marked as 
being used for medical research purposes.  
The app uses GPS-based location information and includes an audit 
trail of each user’s modiﬁcations to the data on the device.   
The task of user control is delegated to local data managers.  
Datasets are stored on Research Electronic Data Capture (REDCap) 
and synchronised with mobile devices of the care team.   
Cultural differences were identified and led to modiﬁed application 
versions for each country. In addition to different pictograms and 
languages, some of the data ﬁelds and recommendations for 
treatment were speciﬁc to users and locations.   
 
Achieving the acceptance of the mobile application by investigators 
in the countries involved in the trial has been an ongoing process.  
The effort involves introducing new processes and new technology to 
users with very little relevant technology experience. The users 
required signiﬁcant amounts of training, but they also provided 
valuable feedback that led to new ideas on how to simplify the 
information presented in the application.  Above all, the application 
must be developed with input from users. This is necessary to design 
a ﬂexible application that considers the users training and limitations 
and anticipates possible scenarios that will be encountered.” 




Description of paper and study 
design 


















Describes development of app 
and results of evaluation study. 
 
Paper reporting the development 
and evaluation of four mobile 
applications that provide tailored 
nursing recommendations for 
metabolic syndrome 
management in pregnancy.  
Evaluation included the 
algorithm proficiency and 
efficiency, user interface, 
usability, and effectiveness. 
Usability evaluated using 




based in Korea).    
 
Paper reports 
“evaluations by experts 
and users.” But does not 
specify any detail or 



















management, e.g. “when a 
patient intakes more calories 
than needed, the alert 
function can alert the patient 
by sending a message based 
on the daily calorie intake that 
the diary function has helped 
the patient to track.”p.512” 
No further detail or examples 
reported. 
 
“Proficiency of the algorithms ranged from 88.2 to 100.0 and their 
efficiency ranged from 69.0 to 100.0.  
The obesity app had the lowest proficiency and efficiency.  
For the GDM and hypertension apps, all recommendations made by the 
evaluators concurred with recommendations derived from the apps.  
In the heuristics evaluations, 13 and 10 problems were flagged for the 
obesity and hypertension apps, respectively. All of these heuristics 
problems were resolved before the apps were used. 
Usability scored 3.5 out of 5 for the obesity app and 3.5 out of 5 for the 
GDM app. User satisfaction scored 3.6 out of 5 for the hypertension 
app.  
The hypertension app increased medication adherence from 4.2 to 5.2 
out of 6 (p=0.001) for the hypertensive patients.” 
 
Paper reports only results of usability scores but no detail on specific 
areas for improvement. 




Describes development of app 
and results of evaluation study. 
 
Paper describes the development 
and evaluation of a smartphone-
based imaging and automated 
analytical tool which 
incorporates the Congo Red Dot 
(CRD) test.  This test assesses the 
presence of misfolded proteins 
in urine, and shows promise as a 
diagnostic and prognostic tool 
for preeclampsia.  
Stage 1: evaluation of a 
preliminary version of image 
processing software tool using 
stored images. 
Stage 2: testing improvements in 
real-time on newly prepared 
standardized CRD arrays and 
analysed the results for 
agreement. 
Stage 3: Analysis of test results 
across four operators, including 
untrained personnel (n=1) who 
did not receive any instruction or 
prior knowledge of the system. 
Setting and time period 
not explicit. 
Corresponding author 
based in Germany.  
 





YES   YES “Smartphone application 
guides the user through seven 
easy steps, and that can be 
used successfully by non-
specialized personnel, through 
test image acquisition to 
interpretation of result. 
 
This approach provides an 
inexpensive molecular test 
and automated smart phone 
based readout that can be 
performed as a batched 
laboratory test by modestly 
trained personnel in almost 
any environment, from an 
urban medical centre to a 
lightly staffed field clinic.” 
 
“Eliminates the need for a separate handheld imaging device or other 
hardware. 
Smartphone-based diagnostic tool that is independent of 
communication data rate, quality of service, and data transfer security.   
An objective element to the clinical work-up for preeclampsia which 
especially in low resource settings relies heavily on subjective 
interpretation of signs and symptoms by healthcare providers.  
Due to its simplicity and the low cost of required materials, the CRD test 
has the potential to fill this gap for diagnosing preeclampsia in 
resource-poor settings.” 
 




Description of paper and study 
design 


















Describes development of app 
and results of 2 usability and 
feasibility studies. 
 
Paper reports findings of study 
assessing the usability and 
feasibility of PIERS on the Move, 
an mHealth App for pre-
eclampsia triage, with mid-level 
health workers, for iteratively 
refining the system.   
 
Two usability studies were 
performed with the potential 
end-users. Each step in the 
development process used the 
findings of the previous, thus 
iteratively improving on the 
design and features available in 
the app:  
Usability study 1: 
evaluation by advanced 
midwifery students at 
Tygerberg Hospital 
(Cape Town, South 
Africa), (n=15). 
 
Usability study 2: 
evaluation of the next 
iteration by maternal 
nursing staff at Frere 
Maternity Hospital (East 
London, South Africa), 
(n=22). 
 
Nov 2012 to Dec 2013. 
Pre-
eclampsia 
YES YES  YES “Pre-eclampsia Integrated 
Estimate of RiSk (PIERS) on the 
Move (PotM) is a low cost, 
easy-to-use, mobile health 
(mHealth) platform that has 
been created to aid health 
workers in making decisions 
around the management of 
hypertensive pregnant 
women.  The app combines 
two previously successful 
innovations into a mHealth 
app: the miniPIERS risk 
assessment model and the 
Phone Oximeter.” 
“Study 1: major issues in the functionality of the touch-screen keyboard 
and date scroll wheels were identified (total errors n=212).  
Study 2: major improvements in navigation of the app were suggested 
(total errors n=144).  
Overall, users felt the app was usable using the Computer Systems 
Usability Questionnaire; median (range) values for Study 1 = 2 (1-6) and 
Study 2 = 1 (1-7).  
Usability problems were often related to mobile phone features (e.g., 
scroll wheels, touch screen use). 
To demonstrate feasibility, PotM was used by one research nurse for the 
pilot clinical study. In total, more than 500 evaluations were performed 
on more than 200 patients. The median (interquartile range) time to 
complete an evaluation was 4 min 55 sec (3 min 25 sec to 6 min 56 
sec).” 
 
Authors emphasise the importance of using target end-users in the 
design and evaluation and that is will result in easier integration into 
health care settings.  
 
6. Mackillop et 
al., (2014)  
 
 
Describes development of app 
and results of evaluation study. 
 
Paper describes development of 
a prototype software application 
for the management of women 
with or at high risk of Gestational 
Diabetes. 
 
A custom website was built for 
clinician review of the data 
transmitted by the smartphone. 
After system refinement, further 
evaluation was undertaken for 
usability and reliability in a 48-





participated in the beta 
testing phase and 50 of 
the 104 women 
approached volunteered 





YES YES YES YES “Functional objectives 
included the ability to: 
1. Allow women to accurately 
and easily record blood 
glucose measurements, which 
are then automatically 
uploaded to a website.  
2. Allow health care 
professionals to access these 
measurements remotely and 
respond quickly to them, thus 
potentially improving 
glycaemic control without the 
need for more intensive face-
to-face contact. 
3. Allow 2-way communication 
between women and health 
care professionals.  
4. Promote user participation 
(empowerment) of pregnant 




“The interactivity of the application has been extended with patients 
being able to add a comment to each reading-often using this to 
explain a high reading or to record what they have just eaten.  
To remind patients to perform a BG reading after their meal, an optional 
alert was implemented.  
The displays were changed to show BG readings in both graphical and 
tabular formats. 
To make the application more intuitive to navigate, illustrations have 
been added to on-screen buttons to illustrate key functions. User 
instructions are embedded in the application in the form of videos that 
automatically run to illustrate specific actions.  
Members of the clinical team were given the facility to add a note on 
the website, for example, to record a medication change or dietary 
advice intervention, when the management of patients is shared 
between several members of the clinical team.  
Alerts were added to help prioritize and highlight patients who required 
an intervention.  
A “strip” counter was added to help the midwife know when more 
blood glucose measurement strips needed to be sent to a patient. 
Patients are also able to place a request for strips from the midwife 
using either the free-text comment or phone-request functionalities. 
Findings demonstrate high usage and excellent compliance with the 
system, with 85% of women recording the minimum required number 
of BG readings each week.” 




Description of paper and study 
design 


















Prospective observational study 
assessing feasibility, efficacy and 
satisfaction. 
 
Paper reports findings of a 
prospective observational pilot 
study to determine the feasibility 
of monitoring patients remotely 
in prenatal care using a mobile 
phone app and connected digital 
devices. 
 
As measures of the feasibility of 
the system, participants were 
studied for engagement with the 
app, accuracy of remote data, 
efficacy of alert system, and 
patient satisfaction. 
 
Patient satisfaction was 
measured using a 12-question 
survey that was completed by 
participants after 20 weeks of 
platform usage. 
Department of Obstetrics 
& Gynecology at the 
George Washington 
University Hospital, USA.   
 
July 2014 to January 
2015. 
 
n=8 women with low risk 








YES YES YES YES Mobile phone app with a 
connected digital weight scale 
and blood pressure cuff for at-
home data collection for the 
duration of pregnancy.  At-
home data was assessed for 
abnormal values of blood 
pressure or weight to 
generate clinical alerts to the 
patient and provider. 
 
 
“Patient engagement with the mobile app averaged 5.5 times per week 
over the 6-month study period. Weight data collection and blood 
pressure data collection averaged 1.5 times and 1.1 times per week, 
respectively.  
At-home measurements of weight and blood pressure were highly 
accurate compared to in-office measurements.  
Automatic clinical alerts identified two episodes of abnormal weight 
gain with no false triggers.  
After reviewing data sets of all clinical variables and all organized alerts, 
no incidences of inappropriate alerts or unaddressed alerts were 
discovered. 
All 6 participants who completed the survey felt comfortable with the 
concept and technical aspects of remote monitoring, were able to easily 
access provider resources.  
Most (83%, 5/6) of the participants felt that the app assisted with 
healthy pregnancy-related behaviours, were satisfied with prenatal care, 
felt more connected with their provider, and felt more knowledgeable 
about their pregnancy.  
Patients demonstrated high satisfaction with the system.  
 
The described monitoring system has the ability to collect data more 
frequently than office visits alone, allowing for the potential to develop 
predictive models to screen normal pregnancies and identify pregnancy 
risk earlier. “ 
 




Description of paper and study 
design 


















Mixed methods study of 
compliance, satisfaction and 
quality of life. 
 
The MobiGuide project aimed to 
establish a user-friendly, patient-
centred mobile decision-support 
system for patients and for their 
care providers, based on the 
continuous application of clinical 
guidelines and on semantically 
integrated electronic health 
records.  
 
The objective of this paper was 
to evaluate whether the initial 
deployment of the MobiGuide 
system, for two different clinical 
domains - atrial fibrillation (AF) 
and gestational diabetes (GDM) - 
had achieved three main 
outcomes: (a) high patients’ and 
care providers’ compliance to 
clinical-guideline based 
monitoring reminders and 
recommendations, (b) high 
patients and care providers’ 
satisfaction, and (c) increased 
patients’ quality of life. 
Italy and Spain 
 
April to December 2015. 
 
The study involved ten 
AF patients from IRCCS 
Foundation “Sal-  
vatore Maugeri”, Pavia, 
Italy and twenty 
gestational GDM 
patients from Parc Tauli 
Sabadell University 
Hospital, Sabadell, Spain. 
 
As a control group for 
GDM, researchers 
referred to data from a 
historical group of 247 
patients, similar in 
characteristics, who had 
been followed up during 




YES YES YES YES “MobiGuide is a remote 
chronic-patient management 
system that has ﬁve main 
objectives:  
(1) Increasing patient safety 
and quality of care through 
provision of personalized 
ubiquitous decision-support 
to the patients. (2) Semantic 
data integration into a 
personal health records. (3) 
Creation of a generic 
architecture that supports 
interoperation with a variety 
of portable sensors, and 
different hospital electronic 
health records. (4) Distribution 
of the decision support system 
(DSS), between a mobile DSS 
that runs on the patient’s 
smart phone and a backend 
DSS that is accessible via the 
Internet by the patients’ care 
providers. (5) Performance of 
intelligent data analysis, to 
discover clinical data patterns 




In the GDM domain, blood 
glucose monitor and 
sphygmomanometer were 
connected to the patient’s 
smart phone by Bluetooth.   
“Continuous monitoring of the most important health parameters 
(glycaemia, ketonuria and BP for GDM patients) was performed at 
encouragingly high compliance rates by GDM patients. The compliance 
of the MobiGuide cohort was signiﬁcantly higher than that of the 
historical cohort (1.01 vs. 0.87, with p-value of 0.0312). 
The fact that the measurement data were available to the physicians via 
the system without needing to rely on the patients bringing in their 
monitoring devices and paper diaries had a great beneﬁt. Since the 
clinicians knew the real data values, they felt that the decisions were 
made faster and were better; as they could review the results before the 
visits, the time spent reviewing the data was shorter.  
They stated that they liked very much the system’s ability to adapt to 
context.  
All AF and GDM clinicians agreed (i.e., provided ratings of 4 or 5) that 
MobiGuide helps them in identifying priorities and increases patient 
safety via its data quality awareness (which prompts patients to re-enter 
data, repeat measurements, thus improving the recommendations 
delivered by the system that depend on data quality).  
Overall, the sense of safety that the system has provided to the patients 
was its greatest asset.” 
 




Description of paper and study 
design 


















Mixed methods study of 
feasibility and acceptability. 
 
Paper describes findings of a 
mixed methods feasibility study 
to evaluate a smart phone based 
system designed to identify fetal 
compromise.  
 
The feasibility assessment was 
designed to evaluate whether 
frontline healthcare workers 
could operate the study 
equipment (1D foetal Doppler, 
pulse oximeter and recording 
application) and record signals 
successfully using a smart phone. 
 
The study also set out to gauge 
user need and to assess the 
acceptability by both healthcare 








n=22 pregnant women. 
 
Written feedback was 




YES YES YES YES “A smartphone-based system 
including peripheral sensors, 
pulse oximeter and handheld 
Doppler for the identification 
of foetal compromise.  
Designed for use by illiterate 
birth attendants, the system 
uses pictograms, audio 
guidance, local and cloud 
processing, SMS alerts and 
voice calling.” 
 
“The six staff who provided written feedback found all system 
components easy to operate and independently agreed on the potential 
benefit of such system.  
Three key areas for successful foetal cardiac signal recording have 
emerged, the ability to operate the equipment provided, the clinical 
knowledge to identify and to target the best possible signal, and the 
degree of willingness to employ such technology.  
The technology-related difficulties experienced by the participants were 
largely related to the participants’ educational level (including a very 
high illiteracy rate amongst traditional birth attendants) and experience 
in handling similar equipment.  
Several of the observed challenges could to some extent be attributed 
to a lack of appropriate training and guidance material.  
Several areas for improvement were identified during the feasibility 
testing. The familiarity with the technology and the clinical 
understanding of the physiological signals and their characteristics, the 
system’s usability and ultimately signal quality, could all be improved by 
a combination of educational measures such as training and training 
manuals, an appropriate application interface and built-in guidance on 
the phone with real time quality feedback.  
The implementation of signal analysis capabilities, such as the 
discrimination of maternal from foetal cardiac signal by comparing the 
pulse oximeter to the ultrasound measure, would provide real-time 
quality improvement and reduce false readings.  
To be maximally inclusive the application interface was therefore 
adapted using a combination of audio and visual instructions only, 
replacing any written content. Likewise, the mechanism to record 
patient information manually was changed to voice and image capture, 
eliminating the need for written input. As a result, each screen presents 
an illustration serving as a visual clue to prompt a certain action. 
 
The findings of this study have informed for the next stage of 
development: 
 
1. Mobile application ~ Continuum of care: Extension of the application 
from prenatal assessment only, to the inclusion of intrapartum and 
postnatal health checks: a) Comprehensive health checks: Inclusion of 
maternal blood pressure measurements and checks for pregnancy-
related complications into the application work flow; b) User interface 
(UI): The design of a user-centred mobile application interface, to be 
inclusive of an illiterate user group; c) Signal analysis: Implementation of 
heart rate analysis including discrimination between the maternal and 
foetal rhythm; d) Emergency response: Implementation of logic to 
trigger calls to higher level care staff in case of detected emergencies. 
 
2. Integration into medical records ~ Data consolidation: Automated 
upload of recorded signals, patient and health information to the 
medical record system, openMRS, a globally adopted open source 
electronic medical record (EMR) system. 
 
3. User training and education ~ User manuals: The development of on-
phone user manuals, inclusive of an illiterate user group. User training: 
The development of training sessions, which will teach participants in the 
application of all devices and the appropriate clinical knowledge to 
enable the recording of good quality physiological signals and the 
assessment of complications.” 
 




Description of paper and study 
design 


















Paper describes findings of a 
feasibility study aimed at 
determining the extent to which 
community health workers could 
be trained to conduct case 
finding using short and 
ultrashort screening instruments 
programmed into mobile 
phones. 
 
Pregnant women were recruited 
independently in two cross-
sectional studies and assessed 
for antenatal depression. 
Khayelitsha, South Africa,  
 
May 2009 to September 
2010 (n=1,144) 
 
May 2010 to February 
2011  (n=361) 
Antenatal 
depression 
YES YES   “In both studies, the Xhosa 
version of the EPDS-10 was 
administered using survey 
software programmed into a 
mobile phone.” 
“The estimated operating characteristics based on data collected by 
community health workers using mobile phones during routine 
antenatal wellness care were comparable to those based on data 
collected by trained research assistants.  
Irrespective of whether the data were collected by research assistants or 
by community health workers, the socio-demographic profiles and 
estimates of reliability and validity were qualitatively similar across the 
two studies.  
The findings demonstrated the feasibility of using community health 
workers, who had no previous research training, to conduct case finding 
for antenatal depression using short and ultrashort screening 
instruments programmed into mobile phones.  
The findings have important programmatic implications for mHealth 
interventions and leveraging existing human resources to improve 
maternal mental health and child health in resource-limited settings.” 
 




Mixed methods study evaluating 
a program using app. 
 
The Millennium Villages Project 
(MVP) was an integrated rural 
development program to achieve 
the Millennium Development 
Goals (MDGs) in low-income 
rural Africa by 2015.  The 
Millennium Village Health 
System (MVHS) is a major 
component of the project, whose 
core strategy is to ensure 
universal access to services free 
of charge at the point of care, 
with a continuum of services 
from the household to the clinic 
and the referral hospital.  This 
paper describes a descriptive 
usability study composed of 3 
phases to evaluate an mClinic 
prototype: 1) hybrid lab-live 
software evaluation of mClinic to 
identify usability issues; 2) 
completion of a usability 
questionnaire; and 3) interviews 
that included low-fidelity 
prototyping of new functionality 





All midwives working in 





YES YES YES  “A mobile health (mHealth) 
application, known as mClinic, 
captures data for managing 
patient care, program 
evaluation and monitoring, 
decision making, and 
management, and allows 
midwives to access the MVG-
Net.” 
“Good ergonomics and minimalist design applied primarily to the 
QWERTY (keyboard) phone selected for testing. The keyboard was small 
and the midwives had difficulty pressing one button at a time, reading 
the keyboard, and using the function key to select numbers. There was 
greater success with the touch-screen phone.  
In respect of privacy, and social conventions, interviews revealed the 
necessity of application-level password protection because it is 
common for cellular phones to be shared among staff and family 
members, and therefore phone level locking would be inadequate.  
Midwives strongly agreed that mClinic was useful and were in 
agreement to neutral about ease of use and user control.  
In the interviews, some midwives indicated that they believed that 
mClinic will be helpful to them and reduce the time they spend creating 
monthly reports.  
After being shown the low-fidelity prototypes, several midwives 
expressed concern that the prototype maternal health form set would 
be too time intensive and cumbersome to use.  
All the midwives were dismissive of designs that included extensive 
free-text fields. More positive interest was generated for expanding the 
register-type forms and expanding them to capture monthly reporting 
data. 
Other potential benefits include lower start up and maintenance costs 
and improved accuracy and timeliness of data collection.  
As is consistent with the literature, the midwives preferred when the 
screen contained less data and did not require scrolling. 
A key factor to the success of eHealth implementation in developing 
countries is user acceptance.  Methods for increasing user acceptance 
include providing adequate support and training for learning the new 
system, encouraging local ownership and data use, cultivating local 
leadership and project champions, and being sensitive to local culture.  
Additional studies have shown that alignment of the eHealth 
intervention with user needs and provider technical self-efficacy is also a 
significant factor in technology acceptance.” 
 




Description of paper and study 
design 



















Paper describing observations 
noted during development of 
app. 
 
This paper describes 
observations noted during 
development of the PIERS (Pre-
eclampsia Integrated Estimate of 
RiSk) models that identify 
pregnant women with pre-
eclampsia who are most likely to 
develop life-threatening 
complications, and suggests 
recommendations for 
development of mHealth in 
perinatal care. 
 
The authors had developed and 
validated two outcome 
prediction models, the PIERS (full 
and mini). Both models have 
accurate ability to identify 
women at low risk of developing 
imminent complications. 
For use in low and 














YES YES YES YES “The PIERS on the Move 
(POM) smart phone app 
integrates miniPIERS and 
clinical decision algorithms to 
support community health 
care professionals (cHCPs) as 
they provide prenatal care, 
diagnose pre-eclampsia, and 
initiate lifesaving therapies in 
the woman’s home prior to 
urgent transfer to an effective 
facility. 
 
The researchers have also 
developed a modiﬁed blood 
pressure device (Microlife 
3AS1-2; Microlife, Widnau, 
Switzerland) speciﬁcally for 
use in low- and middle-
income countries (LMICs), 
which fulﬁls WHO 
requirements for suitability for 
use in low-resource settings.  
A trafﬁc light early warning 
system has been incorporated 
into the device, to alert users 
to abnormalities in blood 
pressure and pulse, using 
these developed shock index 
thresholds along with well-
recognized thresholds to 
indicate hypertension in 
pregnancy.” 
“The full PIERS model, which includes demographics, symptoms,  
pulse oximetry, and maternal laboratory tests identiﬁes clinical relevant 
risk categories (area under the curve of the receiver − operator 
characteristic [AUC ROC] 0 · 88 [95% CI, 0 · 84 − 0·92]. Currently, 
fullPIERS is undergoing external validation; a preliminary validation 
exercise is reassuring. 
The validated miniPIERS model is solely demographics-, symptom-and 
sign-based and can be administered by (1) cHCPs in the home and at 
primary health centres; and (2) facility-based practitioners as they 
initially triage women admitted with pregnancy hypertension prior to 
the availability of laboratory results (or in lieu of laboratory results in 
some less-developed settings) (AUC ROC 0.77 [95% CI, 0.74 − 0.80]). 
POM project results suggest that by adding pulse oximetry, using the 
same 25% risk threshold, the prediction rate is improved to 85% of 
women who will go on to suffer a severe complication. 
Engagement with decision makers and thought leaders from the initial 
design phase of an intervention will improve ownership and the 
likelihood of implementation at scale. 
In order to be attractive to those funding health care, strategies for 
mHealth-supported individualized care must be integrated into existing 
and evolving health systems, and health economic analyses should be 
carried out that clearly show to those who make often difﬁcult decisions 
what the return will be on the resources invested.” 
13. Watson et 
al., (2017b) 
 
Study assessing the reliability of 
risk prediction scores 
incorporating in the app. 
 
Comparison of the QUIPP 
predicted risk within 7 days to 
the actual delivery rates using 
data on a cohort of women who 
presented in threatened preterm 
labour between 2010 and 2015. 
Also to investigate the impact of 
using the QUIPP app relative to a 
treat-all strategy at 24-29+6 
weeks (as per NICE Preterm 
Labour guideline 2015). 
UK 
 








YES    Risk of preterm delivery in 
symptomatic women 
calculated using risk factors 
and test results. 
“Findings suggest the QUIPP app can safely and accurately inform 
clinician decision-making for women in threatened preterm labour, 
allowing outpatient management for the vast majority.  
The QUIPP app therefore confers considerable advantage over NICE's 
recommended treat-all strategy, which allows no women to be 
managed as outpatients.” 
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2.5. Themes emergent from review of the included papers 
 
A number of themes emerged from the review, which were: i) acceptability and 
satisfaction; ii) ease of use and portability; iii) multiple functionality and iv) the 
importance of user involvement in development and evaluation. These are discussed 
in detail below. 
 
2.5.1. Acceptability and Satisfaction 
 
All papers reporting on acceptability, feasibility, usability and/or satisfaction were 
generally positive, both with the mobile application being evaluated, and also with the 
care it was designed to support.  This was demonstrated by direct questioning and 
evaluation tools, but also by increased patient engagement with, for example, 
compliance with self-monitoring (Jeon et al., 2016; Mackillop et al., 2014; Peleg et al., 
2017).  Increased confidence of health providers, enhanced positive relationships and 
trust in the professionals and feelings of support and safety were also reported (Battle 
et al., 2015; Jeon et al., 2016; Mackillop et al., 2014; Marko et al., 2016).  Validation of 
data and monitoring readings were often a feature of the application, and this was 
recognised by clinicians as a valuable improvement in care (Dunsmuir et al., 2014; 
Stroux et al., 2016).   Additionally, the app could help clinicians identify priorities and 
they recognized the potential for the system to be time saving.  The automatic transfer 
of data to electronic central databases or health records was also identified as a useful 
mechanism which could save clinicians’ time as they could remotely review the data in 
advance of the patient’s hospital appointment (Peleg et al., 2017; Vélez et al., 2014).  
Alerts systems were utilised in some applications to remind patients of, for example, 
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appointments, medication, and monitoring (Mackillop et al., 2014; Marko et al., 2016), 
or alert remote clinicians who could either respond with advice, either directly to the 
patient or their local care givers (Mackillop et al., 2014; Stroux et al., 2016).  
 
 
2.5.2. Ease of use and portability 
 
Most medical app users were familiar with smart phones, and the benefit of portability 
was regarded as a great asset (Battle et al., 2015; Marko et al., 2016).  Some users 
reported problems which were often related to the phone’s features, e.g. difficulties 
with entering data on a small mobile phone screen and the need for scrolling 
(Dunsmuir et al., 2014; Lim et al., 2015).   Adaptation of features such as reducing the 
need for scrolling by having fewer data on each form, training and on-phone manuals 
were used to address these issues in later stages of app development (Jeon et al., 
2016; Stroux et al., 2016).   
 
With the relative low cost of smartphones and convenience in terms of weight and 
size, along with the increasing connectivity to mobile networks, mobile applications 
appear to be accepted as an excellent opportunity for improving healthcare, 
particularly for those in low resource settings.  One reason, proposed by a number of 
authors of the papers included in this review, is that less educated health care staff can 
be trained in providing front-line care using devices that are easy to use, with internal 
validation and warning alerts, with the added benefit of support from remote experts 
(Stroux et al., 2016; Tsai et al., 2014; von Dadelszen et al., 2015). 
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2.5.3. Multiple Functionality  
 
The versatility and multi-functionality of smartphones appeared to be an important 
issue in the papers reviewed.   As decision support tools, mobile apps can utilize 
statistical prediction models or decision trees and make recommendations for action 
based on input of individual risk factors and test results (Dunsmuir et al., 2014; Peleg 
et al., 2017; Watson et al., 2017b).  In addition to decision support, however, most 
apps (10/13) were also used for data collection, communication, or both.  Other apps 
also incorporated Bluetooth internet connectivity with other devices: pulse-oximetry 
(Lim et al., 2015; Stroux et al., 2016); blood glucose monitors (Mackillop et al., 2014; 
Peleg et al., 2017); blood pressure monitors (Marko et al., 2016; Peleg et al., 2017); 
digital weighing scales (Marko et al., 2016) and fetal Doppler devices (Stroux et al., 
2016).  One mobile app utilized the smartphone’s own camera for processing pictures 
used in the Congo Red Dot test, which assesses the presence of misfolded proteins in 
urine (Jonas et al., 2016).  This test has been proposed as a possible diagnostic test for 
pre-eclampsia that could be particularly useful in low resource settings where more 
sophisticated laboratory facilities are unavailable.   
 
Communication between patients and healthcare workers, or between healthcare 
workers and colleagues or other experts, was valued as an important element in the 
success of the projects in which the apps played a central role (Battle et al., 2015; 
Dunsmuir et al., 2014; Mackillop et al., 2014). This appeared to be so whether the 
communication was carried out directly through the app, or simply by the user being 
able to communicate using the same device, i.e. mobile phone.   
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Data collection, validation, transfer and integration with other health records and 
research databases, and the ability to set alerts, as noted above, along with other 
integrated features of mobile phone technology, such as time stamping and Global 
Positioning System (GPS) tracking of phone location, were also noted as important and 
useful attributes because, for example, the time and place of the clinical visit could be 
recorded (Dunsmuir et al., 2014; Mackillop et al., 2014; Peleg et al., 2017; Stroux et al., 
2016; Vélez et al., 2014).  
 
Delivering healthcare interventions through mobile technology also provided the 
opportunity to adapt programmes relatively easily to account for specific needs of the 
end-users.  Accessibility was enhanced, e.g. picture and video instructions for illiterate 
users (Stroux et al., 2016).  Language and cultural diversity issues were also relatively 
easily addressed and incorporated into different versions of the app (Dunsmuir et al., 
2014; Mackillop et al., 2014; Stroux et al., 2016). 
 
2.5.4. The importance of user involvement in development and evaluation 
 
The importance of user involvement in the development and evaluation of their app 
was emphasized in several papers (Dunsmuir et al., 2014; Lim et al., 2015; Vélez et al., 
2014; von Dadelszen et al., 2015).   The authors noted that this was not only a key step 
in enhancing the acceptability and usability of the device/programme, but also a 
mechanism by which they could foster engagement by local stakeholders, community 
leaders and healthcare funders.  This interaction was seen as part of the pathway to 
ensure acceptability of the programme and maximize its chances of being sustained. 
 




2.6. Summary and discussion 
 
This literature review has identified and considered a number of relatively recent 
papers, mainly reporting early stage development and feasibility or acceptability 
studies designed to inform further development of the mobile application the paper 
was concerned with.  The number of papers identified was relatively small compared 
to the number of medical apps readily available for download onto mobile devices.  It 
is likely that many clinicians and other health care professionals are using them on an 
ad hoc basis. However, there are still only very few peer-reviewed publications in high 
quality professional journals that can confirm their utility, reliability and effect on 
outcomes.  None of the papers reported application for regulatory approval by either 
the FDA or MHRA. 
 
It is possible that the search strategy employed may have missed some important 
papers due to the lack of standardised search terms associated with the relatively new 
field of mobile healthcare.   An extensive number of potentially eligible papers 
required a review of the full text because the nature of the decision support tool or 
mobile application was not clear from the title or abstract alone.   In addition, the 
speed with which new papers are published makes efforts to undertake a truly 
comprehensive review of such a fast growing literature base challenging. 
 
A number of themes emerged from the review and are reported above.  The issue of 
data security, however, briefly mentioned in two papers (Dunsmuir et al., 2014; Vélez 
et al., 2014) did not appear to be particularly important.  Where it had been raised as a 
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concern, password protection at app, rather than phone, level (Vélez et al., 2014) and 
data encryption (Dunsmuir et al., 2014) appeared to provide acceptable solutions.   
This may become a more important issue in the future, however, following recent 
scandals regarding the misuse of personal online data (Cadwalladr and Graham-
Harrison, 2018).     
 
 
This literature review has considered papers reporting on mobile phone applications 
for clinical decision support in pregnancy.  It appears that the body of literature 
relating to this precise area remains sparse and relatively recent.  No papers were 
found of studies reporting effects on clinical outcomes, although the two papers on 
programmes to improve healthcare utilization reported success.  It is expected, 
however, that more publications will follow in due course, as the papers reviewed 
were largely reporting results of feasibility studies of projects that will have entered 
later phases of development.   The findings of this review will be considered and 
incorporated into the later discussion around the development of the mobile 
application clinical decision support tool (the QUIPP app) which is the focus of this PhD 
thesis. 
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3. Literature review 2: Women's experience of threatened preterm 
labour 
 
3.1. Introduction to literature review 
 
A major element of this PhD project was to establish a deeper understanding of the 
experience from the woman’s perspective in order to highlight areas for potential 
improvement in TPTL care.   This second literature review aims to explore what is 
currently known about women’s experience of threatened preterm labour and/or 
being at risk of preterm birth and how the care they received affected that experience.     
 
3.2. Search Strategy 
Inclusion and exclusion criteria for the review were devised in order to achieve the aim 
of the review and are listed in Table 4.  
Table 4. Inclusion and exclusion criteria for the literature review “Women’s 
experience of threatened preterm labour”. 
Inclusion  Exclusion 
Focus on women’s experience of threatened 
preterm labour, preterm labour and/or 
being at risk of preterm birth and related 
tests (i.e. fetal fibronectin and cervical 
length measurement) and interventions, (i.e. 
steroids and tocolysis) 
Women’s experience of other aspects of 
pregnancy or birth at term and related 
interventions 
Primary research or literature reviews 
published in peer reviewed journals 
Commentaries or editorials 
 
Studies or reviews including studies using 
qualitative methodologies 
Studies or reviews relating only to studies 
using quantitative methodologies  
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The following electronic data bases were searched; Medline, CINAHL, HMIC, PsycINFO, 
Embase, Scopus, Maternity and Infant Care for papers published up to October 2017.  
Terms used included: “Obstetric Labor, premature OR preterm labour”, “preterm” AND 
“birth”; “MH Labor, premature”, “experience*” OR “views” OR “perceptions” OR 
“beliefs” OR “attitudes”; “fetal fibronectin” OR “cervical length” OR “cervical length 
measurement” OR “steroids” OR “tocolys*” AND “experience* OR “views”.  Reference 
lists of papers considered suitable for inclusion were also reviewed. As the focus was 
on women’s experience the search was restricted to papers reporting studies using 
qualitative methods, or reviews including studies which had used qualitative methods.  
There was no geographical restriction on where studies had been carried out or year of 




3.3. Results of search strategy 
 
After removal of duplicates, searching the databases produced a total of 290 articles 
for screening.  After review of the titles and abstracts 264 were deemed to be 
ineligible for inclusion in the review, Twenty six papers were assessed for eligibility by 
full text review, of which 11 were subsequently excluded for the reasons shown in the 
PRISMA flow diagram (Figure 9). 





Figure 9. PRISMA 2009 Flow Diagram of search results for the literature review 
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3.4. Characteristics of the papers included in the review 
 
Details of the 15 included papers are shown in Table 6.  Thirteen primary research 
papers were included along with two literature reviews.  One literature review focused 
on bed rest for women at risk of preterm birth (Maloni, 2010) while the other sought 
to identify research papers on TVS CL that reported additional, psychosocial effects 
(Vis et al., 2011).  A quality assessment of the 13 papers reporting primary research 
was carried out using the Critical Appraisal Skills Programme (2018) CASP Qualitative 
checklist.  As there is no consensus on the best method for assessing quality in reports 
of qualitative research (Dixon-Woods et al., 2004; Leung 2015) this method was 
chosen because it was designed to assist healthcare professionals assessing qualitative 
research and its application to practice.   In order to reduce the danger of excluding 
important concepts, a decision was taken not to exclude studies on the basis on quality 
unless they were “fatally” flawed (Dixon-Woods et al., 2006, p.4). However, all of the 
papers were of sufficient quality to be included.  The results of this quality assessment 
are shown in Table 5. 
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Table 5. Quality assessment of studies included in the literature review “Women’s experience of threatened preterm labour” using CASP 
Qualitative Checklist (Critical Appraisal Skills Programme, 2018). 
Study 
reference 
1. Was there 
a clear 
statement of 
the aims of 
the research? 





3. Was the 
research design 
appropriate to 
address the aims 
of the research? 
4. Was the 
recruitment 
strategy appropriate 
to the aims of the 
research? 
5. Was the data 




6. Has the relationship 
between researcher 
and participants been 
adequately 
considered? 




















Adler et al.,  
2002           
Barlow et al., 
2007            
Coster-Schulz & 
Mackey, 1998            
Hoglund and 
Dykes, 2013            
Lowenkron,  
1999            
Mackey & Coster-
Schulz, 1992           
MacKinnon,  
2006           
O’Brien et al., 
2010           
Palmer and Carty, 
2006           
Patterson et al., 
1992           
Peterson et al.,  
2014            
Porcellato et al., 
2015           
Weiss et al.,  
2001            
Key: Result of evaluation denoted by use of traffic light icons  = yes;  = no  = can’t tell. 
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3.5. Themes emergent from review of the included papers 
 
A review of the included studies revealed a number of common themes that throw 
light on women’s experience of threatened preterm labour.  These themes are 
discussed below, and include: the onset of threatened preterm labour; living with 




3.5.1. Theme 1 - The onset of threatened preterm labour.  
 
The experience of threatened preterm labour begins with the onset of symptoms that 
may not be immediately recognised by the woman as signs of early labour.   A women 
may go through a process of attempting to understand what is causing the symptoms 
and whether they represent a threat to herself or her baby, before deciding to call for 
professional help. 
 
3.5.1.1. Sub-theme 1:  Seeking to understand the symptoms and being 
unbalanced 
 
Pregnancy is a period of bodily transformation and it is difficult for women to 
recognise whether the symptoms of TPTL are simply part of normal pregnancy changes 
(Mackey and Coster-Schulz, 1992; Weiss et al., 2002).  TPTL symptoms can be varied, 
from an increase in frequency or intensity of tightenings, abdominal or back pain, or 
watery or blood stained vaginal discharge.  Symptoms are often difficult to distinguish 
from other symptoms that may have other causes.  Tightenings may be Braxton Hicks 
contractions, abdominal or back pain could be a result of a gastric disturbance, urinary 
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tract infection or increased weight and posture changes, watery discharge could be 
caused by stress incontinence. 
 
 
Patterson et al. (1992) describe this period as a state of “Diagnostic confusion”.   This 
confusion arises from the fact that PTL symptoms often lack clear distinguishing 
features or pattern and that it is difficult for women to differentiate between these 
and the “normal” discomforts of pregnancy.   Another factor in this confusion is that 
most women have not considered that their symptoms might be early signs of labour.   
They will go through a process of becoming aware of the symptoms before comparing 
with past experiences, gathering extra data, such as timing their contractions, and 
seeking information from a variety of sources.  They will then develop a “working 
diagnosis” which will direct their next actions.  Strategies to deal with symptoms 
depend on the “working diagnosis” and the woman’s assessment of whether the 
symptoms were “normal” or potentially threatening and could include ignoring the 
symptoms, trying not to think about it, positive thinking or waiting until perceived 
threat has become serious enough to warrant seeking professional help. 
 
“Diagnostic confusion arises from the interplay of several factors.  First, 
the nature of the symptoms of preterm labour contributes to confusion.  
The symptoms most likely to be attended to, i.e. pain, cramps, 
contractions, and pressure, often begin subtly and lack clear distinguishing 
features”. (Patterson et al. 1992, p.369). 
 
 
Coster-Shultz and Mackey (1998) describe women’s experience of PTL in five stages, 
the first two of these are the awareness that something is wrong which gives them a 
sense of unbalance, making sense of the experience and seeking to understand why 
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labour had started.    Others report similar findings.  Barlow and colleagues (2007) 
found that the onset of symptoms was often unexpected and that while some women 
had no idea what had caused it, others had some ideas of possible causes.   Many 
women appear to attribute causes to something they had done, such as increased 
activity, the fact that they had been emotionally stressed, or other medical or physical 
problems (Mackey & Coster-Shultz, 1992; Weiss et al., 2001): 
“One half of women (n=8) thought that physical activity could be a 
cause of their preterm labour.  They primarily described excessive and 
continuous housework, sometimes on top of work outside the home, 
or coupled with caring for a small child.”  (Mackey & Coster-Shultz, 
1992, p.373). 
 
“Several women identified stress associated with the pregnancy as a 




3.5.1.2. Sub-theme 2: Deciding when to seek professional help 
 
The decision of when to seek professional help appeared to depend on the women’s 
judgement of the causes of the symptoms and whether they constituted a threat to 
their or their baby’s well-being.  Mackey & Coster-Shultz (1992) describe two types of 
women: the “waiters” and “non-waiters”.  The “non-waiters” were very anxious and 
called for help within minutes, while the “waiters” would first monitor the symptoms 
for some time, between 2 days and 2 weeks, before seeking help and in the meantime 
instigate strategies for dealing with the symptoms, such as resting, increasing fluid 
intake, taking warm baths and stroking their abdomens.   Women struggle as they 
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become increasingly concerned by the symptoms, but do not want to been seen as 
“over-reacting” (Palmer et al. 1992).  Both Patterson et al. (1992) and Weiss et al. 
(2001) found women often waited to seek help until the threat became immediate. 
   
“When the above strategies for making sense of and dealing with 
symptoms of preterm labor fail to alleviate the diagnostic confusion 
and when symptoms continue, recourse to a professional for evaluation 
and/or treatment is deemed in order.” Patterson et al., 1992, p.371 
 
“In highly certain situations with no perceived threat, interaction with a 
health care provider was not sought. In situations of uncertainty, 
precautionary health care seeking was initiated to provide verification 
or clarification of symptom meanings. In situations characterized by 
certainty and perceived threat, the provider was contacted with very 
little delay.” Weiss et al., 2001, p. 72 
 
 
Previous experiences with preterm labour or birth can affect a woman’s decision 
making in a subsequent episode or pregnancy.  Palmer and Carty (2006) explored the 
experience of women undergoing a second episode of TPTL and how they decided 
when to seek further help.  They found that women compared symptoms to the first 
episode and judged whether they were different or more intense.  They sensed that 
“something’s not right”, but still did not want to be seen as over-reacting.  Weiss and 
colleagues (2001) found that, after having decided that the threat was real and seeking 
help, if they were told that the symptoms were nothing to worry about, this would 
result in delays to help-seeking in future episodes of TPTL symptoms: 
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“Women who had substantial concern about the threat to their 
pregnancies self-referred to hospitals or urgent care facilities. In these 
cases, if a physical examination did not validate the onset of preterm 
labor, the woman received validation of the normalcy and nonthreatening 
nature of her symptoms. This validation of the symptoms as non-
problematic resulted in delays in care seeking for future symptom 
patterns.”p.72. 
Women who had experienced preterm birth in an earlier pregnancy were less 
concerned about over-reacting.  In their study of high risk women attending a 
specialist preterm clinic in a subsequent pregnancy, O’Brien et al. (2010) found that 
women often experienced guilt if they had dismissed symptoms they now considered 
may have been warning signs.  These women were determined to trust their intuition 
and seek help more quickly this time.    
 
3.5.2. Theme 2. Living with the threat of preterm birth 
 
3.5.2.1. Sub-theme 1: Fear and uncertainty 
 
The sense of imbalance and uncertainty that started in the early stages continues into 
the experience of TPTL.    The implications of preterm birth are widely known, so the 
development of symptoms or problems that may indicate premature labour can cause 
considerable stress and anxiety.  The women’s primary concern is for the life and 
health of their unborn baby, but the uncertainty and loss of control over their lives is 
often reported as making the situation even harder to cope with (Lowenkron, 1999; 
Maloni, 2010).    
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“Stress resulted from feelings of nervousness related to their situation, 
lack of ability to control important aspects of one’s life, and the 
happening of unexpected events.” (Lowenkron, 1999, p.557). 
 
 
Coster-Schulz and Mackey (1998) described how the participants of their study 
prioritised keeping their unborn baby and themselves safe, fearing loss of the baby 
while feeling their life was “on hold”.    MacKinnon (2006) also talked about women 
“suspending their lives” whilst under threat of preterm labour and the women in 
Hoglund and Dykes’ (2013) study described a great sense of insecurity, fear for the 
baby and lack of control over their bodies and symptoms.   
 
“The most common symptoms were fatigue, back muscle soreness, 
sleep cycle changes, round ligament pain, dry lips, nasal congestion, 
reflux, indigestion, mood changes, tenseness, and boredom.”p.470. 
 
Women with a previous history of preterm birth experience great anxiety throughout 
subsequent pregnancies, even before, or without, experiencing TPTL symptoms.  
Although they may find reassurance immediately following specialist preterm clinic 
appointments, the relief is only temporary and much of the pregnancy can feel like an 
emotional rollercoaster (O’Brien et al., 2010). 
   
  
3.5.2.2. Sub-theme 2: Adjusting to life changes, loss of control and identity  
 
Women whose symptoms do not quickly develop into established preterm labour 
appear to continue feeling this fear and sense of uncertainty.  They may be admitted 
to hospital or advised to rest at home, and this means having to make and come to 
terms with albeit temporary life changes.  This can have a profound effect on a 
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woman’s sense of identity, as well as control over her life and even her body.  As Adler 
and Zarchin (2002) explained:  
 
“Unlike a normal pregnancy, in which a woman balances her own needs 
with those of her developing fetus, the woman on bed rest gives up 
virtually all of her own needs to maintain the pregnancy. This unbalanced 
living can cause a woman to feel as though she has given up her former 
identity and sense of self.” (Adler and Zarchin, 2002, p.424). 
 
 
It can be very difficult for a woman to adjust to role changes from perhaps 
autonomous employee and/or caring for other children to focusing on herself and 
unborn baby while accepting support and practical help from others (Adler and 
Zarchin, 2002; Coster-Schulz and Mackey, 1998).  Although restriction of activities and 
rest is intended to reduce stress, it may reduce physical stress, but often leads to 
increased emotional stress, and can lead to feelings of boredom, frustration, isolation 
and depression (Hoglund and Dykes, 2013; Mackey and Coster-Shultz, 1992).  Coster-
Schulz and Mackey (1998) described how this additional stress can threaten the 
woman's ability to maintain a sense of balance as she tries to follow medical advice, 
while adjusting to her changing role and possibly even dealing with financial hardship if 
she is unable to work outside the home.     At the same time, women can feel a 
profound sense of personal responsibility for taking care of themselves and doing 
everything possible to reduce the risk of their baby being born too soon (MacKinnon, 
2006).  
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“Overall, preterm labor was experienced as a profound sense of personal 
responsibility for preventing preterm birth and was practiced as being 
‘careful’.” (p.703). 
 
3.5.2.3. Sub-theme 3: Effects on personal relationships  
 
The experience of threatened preterm labour may also have an effect on the woman’s 
relationships with other members of her family.  Many women worry about neglecting 
the needs of other children, or placing an additional burden on their partners, who 
may be required to take on more household or childcare duties.  Assistance may be 
sought from members of the wider family or friends and although some women do not 
find this is always forthcoming, others may develop deeper bonds with those who are 
able to help them at this time (Adler and Zarchin, 2002; Barlow et al., 2007).  The high 
risk women in O’Brien et al.’s (2010) study spoke about how the emotional burden of 
living with the threat of preterm birth had a profound effect on their partners which 
was often under acknowledged.       
 
“Women acknowledged that whilst their own physical and emotional 
needs were considered and addressed, partners who were already 
struggling to cope emotionally were effectively ignored by health 
professionals and also expected to take on the added pressures in the 
home and family plus continue working as well.”p.83. 
 
 
3.5.2.4. Sub-theme 4: Coping strategies 
 
The available evidence throws some light on how women living with the threat of 
preterm birth cope.   The women in Adler and Zarchin’s (2002) study appear to have 
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developed a number of coping strategies, which included learning to accept the 
emotional and practical help of others and developing their relationship with their 
unborn baby which they saw as a positive effect of the bedrest they had been 
prescribed.    Coster-Schulz and Mackey (1998) also described allowing others to take 
over responsibilities as a coping strategy employed by women in their study and, in an 
earlier paper, focusing on the baby and thinking positive thoughts (Mackey and Coster-
Shultz, 1992).  Thinking positively, not thinking at all or trying to think of something 
else, was a coping strategy identified by Höglund and Dykes (2013) in their study of 
women on sick leave for threatened preterm labour symptoms.  These women also 
coped by taking each day or week as it came, rather than thinking too far ahead, which 
was a strategy also employed by the women in O’Brien et al.’s (2010) study:    
 
“They were reluctant to look too far ahead to the future and would, 
instead, set themselves markers to reach, approaching the pregnancy 
journey through a series of ‘baby steps’… [describing] how they lived 
‘week to week’ and each successful clinic appointment was another 
target achieved”, (p.81). 
 
 
3.5.3. Theme 3:  Women's experience of PTL tests and healthcare 
interventions 
 
In this project, we sought to explore both the women’s experience of TPTL and the 
factors that influenced this experience, including women’s views on the healthcare and 
interventions they received.  The literature search revealed a notable paucity of 
evidence around women’s experience and views on specific tests used as part of TPTL 
assessment or common interventions.  There was only one study, identified in this 
literature review that explored the experiences of women who received fetal 
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fibronectin testing as part of their assessment for TPTL symptoms (Peterson et al., 
2014).  The authors concluded that the test was acceptable to women, but also 
described how participants felt increased anxiety as they waited for the results.  Vis et 
al. (2011) undertook a systematic review of papers assessing the additional effects 
(such as reassurance) of cervical length measurement in threatened preterm labour, 
but did not find a single study that had measured the psychosocial effects.   
 
In terms of interventions for reducing the risks associated with preterm birth, no 
qualitative studies were found on women’s experience of antenatal corticosteroid use 
for fetal lung maturity, or the use of tocolysis to stop contractions, which are both 
common interventions offered to women with TPTL symptoms.  One study described 
women’s experiences of in utero transfer (IUT), where the woman is transferred to 
another hospital if no neonatal cots are available locally.  Findings suggested that, 
despite little knowledge of IUT and feelings of unpreparedness, most women were 
resigned to accept the intervention (Porcellato et al., 2015): 
“…there was resigned acceptance from those transferred for a higher 
level of care that IUT was necessary to optimise the welfare of their 
unborn child.”(p.5). 
 
O’Brien et al. (2010) also found that women who had a cervical cerclage or received 
progesterone treatment to prevent preterm birth were prepared to accept them, 
without hesitation, despite being afraid of the procedure and unpleasant side effects.   
 
Studies reporting women’s experience of bedrest are included in the above as they 
demonstrate a more complete picture of the overall experience.   





3.6. Summary and discussion 
 
Literature on women’s experience of preterm labour or being at risk of preterm birth is 
limited with most published studies being qualitative in nature with few participants.  
A picture emerges, however, of a challenging experience where women with 
symptoms of preterm labour try to cope with anxiety and uncertainty.  They are called 
upon to make decisions on when to seek help, dealing with fears for the health of the 
baby, and often having to cope with a loss of control as they try to balance other 
responsibilities such as those to other children or work commitments.   The experience 
of hospitalisation or home bedrest for preterm labour has been described by a number 
of authors where similar themes describe women’s anxiety, loss of control and 
conflicting responsibilities.  There is greater paucity of evidence around women’s 
experience and views on specific tests used as part of TPTL assessment or common 
interventions, but that which exists tends to suggest that women are willing to accept 
them. 
 
Many of the studies included in this review were carried out several years ago, with 
only one study relating to women’s experience of TPTL in a UK setting (Barlow et al., 
2007).  Two other studies carried out in the UK related to women’s experience of a 
specialist preterm clinic for women at high risk (O’Brien et al., 2010) and women’s 
experience of in utero transfer (Porcellato et al., 2015).  There is clearly a need to 
further explore women’s experience of TPTL and related interventions in current UK 
setting.  The qualitative study undertaken as part of this PhD project was designed to 
contribute to this gap in knowledge. 





Table 6. Characteristics, main findings, conclusions and implications for practice of papers included in the literature review “Women’s 
experience of threatened preterm labour”. 
Reference 
Study Design Setting/Country 
Study time 
period 




















through the use 






was conducted via 
the internet and 
consisted of a 
series of sequential 
questions 
presented by the 
researchers to the 
participants via e-










A purposive sample 
of 7 women who 
were on home bed 





“Three major categories and seven 
subcategories regarding the lived 
experience of home bed rest were 
identified:  
 the effect of bed rest on participants’ 
lives (transitioning onto bed rest, loss of 
control and activities, changes in 
identity and role, coping and personal 
growth, transitioning off bed rest). 
 the effect of bed rest on relationships 
with others (relationships with the fetus 
and other children, relationships with 
husbands and extended family 
members), and  
 the virtual focus group as an online peer 
support group.  
Participants were unanimous in their 
appreciation of the virtual focus group. All 
participants stated that their participation 
was valuable and beneficial in helping 
them to cope with the hardships of bed 
rest.” 
“Confinement to bed rest at 
home dramatically alters 
women’s daily activities, self-
perceptions, and interpersonal 
relationships.” 
 










home bed rest, 











Study Design Setting/Country 
Study time 
period 
Participants Main findings Author Conclusions 
Implications for 
practice 




































were: admission to 
hospital at a 
gestational age of 
<37 weeks, 
singleton 
pregnancy, English-  
speaking, no 
physical or chronic 
condition, and no 
major cognitive or 




“A key aspect of women’s experiences 
concerned their search for meaning to 
help them make sense of their sudden and 
unexpected hospital admission. Several 
women continued to feel anxious despite 
assurances from staff that everything was 
‘OK’, whereas others had overcome initial 
anxiety and were excited about the 
imminent birth. 
 
There was consensus that the information 
received whilst in hospital was 
inconsistent, and some women believed 
that their concerns were being ‘ignored’. 
 
Some women attributed PTL to daily 
stress, such as working long hours. Social 
support from women’s mothers and other 
patients appeared important.” 
“Women admitted to hospital in 
PTL could be assisted in their 
search for meaning by provision 
of consistent information, having 
their views acknowledged, 
satisfactory social support, and 
dealing with any previous history 














inquiry. Part of 







women (24+ years) 
with private 
insurance 
hospitalised for PTL. 




“PTL experience occurred in 5 recursive 
stages: 
1. Awareness of something wrong 
and sense of unbalance. 
2. Making sense of experience, 
sought to understand why 
labour had occurred. 
3. Attempting different strategies 
to re-balance lives. 
4. Efforts to address other stressors 
that threatened ability to re-
balance 
5. Emergence from the PTL 
experience with added growth. 
Priority to keep unborn baby and 
themselves safe.  Needed to learn to 
accept support and assistance from 
others.” 
“PTL experience can be 
conceptualized…as being caught 
in a storm.”  Great conflict 
between meeting their own 
needs and those of unborn child. 
 
Mature women had more 
available resources, but 
adolescents found it easier to 





for women to 
exert control 
over how they 
manage their 











Study Design Setting/Country 
Study time 
period 











of women at 
home on sick 







10 antenatal clinics 




15 pregnant women 
who were on sick 
leave for premature 
labour. 
“Four categories were identiﬁed:  
 How to interpret unpredictable 
contractions in the uterus.  
 Having concern regarding premature 
labour of their child, 
 Handling the new situation and 
ﬁnding a balance, and  
 From work to sick leave.” 
“To be on sick leave for 
premature contractions can be 
compared with enduring a 
situation of inactivity.  
 
The woman ﬁnds herself in a 
stressful situation which she must 




































located in a large 


















“The women reported experiencing a 
moderate amount of stress. 
 
The women appraised their situation as 
both threatening and challenging.  
 
They described their emotional response 
most frequently as frustration because of 
fear concerning the pregnancy outcome, 
loss of control over their life, and inability 
to perform their usual roles of mother, 
wife, and worker.” 




























becoming a PTL 






hospitalised for PTL. 
“Women either waiting for a period of 
time before seeking care or sought care 
immediately.  
 
Women interpreted the experience by 
identifying causes of PTL and by worrying 
“Women did report typical 
symptoms of PTL but did not 
respond in the same way. Waiting 
appeared to be related to 
previous experience with PTL, 













Study Design Setting/Country 
Study time 
period 






living with a 
diagnosis of PTL 
























Eight women who 
experienced 
preterm labour.   
 
4 had PTB. 
4 term delivery. 
“Women spoke about their fear of going 
home and feeling alone with the 
responsibility for their work of “ keeping 
the baby in. ” 
 
Overall, preterm labour was experienced 
as a profound sense of personal 
responsibility for preventing preterm birth 
and was practiced as being “ careful. ”  
 
The work of keeping the baby in conﬂicts 
with family care work responsibilities and 
can cause signiﬁcant hardships for some 
women and families.” 
“The assumption that the family is  
privately responsible for care 
work in the home results in the 
lack of assessment of resources 
for managing the medical plan on 
discharge and the lack of 












and the work 
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Study time 
period 
Participants Main findings Author Conclusions 
Implications for 
practice 















analysis of the 
evidence for the 
practice of 
prescribing ABR 










effects of antenatal 
bedrest (ABR) , 17 
articles comparing 
antepartum 
hospital and home 
care, 5 meta-
analyses of RCTs of 
the effectiveness of 
ABR, and 4 articles 
about physician use 
of bed rest. 
“There is a body of research that has 
identified numerous adverse physiological 
and behavioural effects of ABR upon 
pregnant and postpartum women. 
 
The experience of bed rest for mothers is 
harrowing and characterized by fear for 
self and fetus, the presence of a variety of 
negative emotions including depression 
and anxiety, and altered temporality that 
makes enduring the present a major task. 
 
Additionally, some research suggests that 
the fetus/infant may also be affected, 
particularly in the critical area of infant 
birth weight. 
 
However, as there are few and conflicting 
reports, further research is needed on the 
effects of ABR on fetal and infant health 
and well-being.” 
 “Even with an 
understanding 
of some of the 





of bed rest. 
 
The continued 










for both the 
mother and the 
infant.” 




views of high 
risk pregnancy 












antenatal clinic at 
a major tertiary 
referral centre in 




14 pregnant women 
attending preterm 
surveillance clinic. 
“Women struggled with ‘balancing the 
risks’ associated with the threat of 
preterm birth, they developed ‘personal 
coping strategies to survive the pregnancy’ 
and they watched as the strain made their 
‘whole family crumble’.” 
“Women’s journey through 
pregnancy after a previous PTB 
experience is one of emotional 







be reached so 
that women 
feel they are 
successfully 
progressing 
through a high 
risk pregnancy 
through a 






Study Design Setting/Country 
Study time 
period 
Participants Main findings Author Conclusions 
Implications for 
practice 






















12 women who 
received 
antepartum care at 
home for preterm 
labour. 
“Study participants reported knowing 
something’s not right and followed 
decision guides to seek help. If, when they 
returned to the hospital to see what  s 
going on , they felt dissonance between 
what their bodies were telling them (body 
knowledge) and what their health care 
providers were telling them (professional 
knowledge) an overriding tension 
developed between not wanting to take a 
risk for the baby versus not wanting to 
overreact. 
 
These women re-established their 
baselines of nonthreatening symptoms at 
a higher level by setting a new normal to 
avoid the humiliation associated with 
appearing to overreact. 
 
Attempting to ignore recurring symptoms 
of preterm labour delayed help seeking 
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Participants Main findings Author Conclusions 
Implications for 
practice 





























28 women who had 
experienced PTL. 
“Ambiguous symptoms, absence of a 
meaningful label to attach to symptoms 
and the context of pregnancy with its 
expected discomforts come together to 
create a situation of diagnostic confusion.  
Deliberate and protracted efforts to make 
sense of and deal with symptoms of PTL 
are attempted.  
Making sense consists of 3 sub-processes: 
1. Comparing.  
2. Gathering data. 
3. Seeking information. 




3. Positive thinking. 
4. Waiting. 
5. Recourse to a professional is 
used as the strategy of last 
resort when symptoms can no 
longer be contained.” 
“Women who are not known to 
be at risk of PTL do not always 







duration of the 
care-seeking 
process and to 





during PTL and 
cervical status 
on admission.” 


























17 women. “Fetal fibronectin testing as an emotional 
process that moves from expecting, to 
feeling, to hoping for reassurance; and 
then to re-defining what is required to feel 
reassured.  
Women described feeling anxious while 
waiting for fetal fibronectin results.  
When test results were negative, women 
described feeling a sense of relief that 
their symptoms would not likely lead to an 
imminent preterm birth.  
Women with positive results expressed 
feeling reassured by the care decisions and 
quick action taken by the health care 
team.” 
“Fetal fibronectin testing was 
acceptable and beneficial to these 
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Study time 
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transferred in utero 
to a tertiary level 
maternity hospital; 
ﬁve male partners 
and two 
grandmothers. 
“Findings suggest that IUT is an emotional 
experience that ﬁnancially disadvantages 
patients and their families.  
Male partners were perceived to be most 
negatively affected by the experience.  
The quality of the IUT experience was 
inﬂuenced by a range of factors, including 
the lack of proximity to home and the lack 
of information.  
Patients had little knowledge or awareness 
of IUT, and most felt unprepared for 
displacement.  
Despite this, there was resigned 
acceptance that IUT was a necessary 
rather than adverse experience.” 
“The experience of IUT for service 
users could be enhanced by 
ensuring that they are better 
informed about the process and 
the circumstances that 
necessitate displacement, that 
they are better informed about 
the hospital to which they are 
being transferred, and that they 






impact of IUT 
on women and 
their families 
also need to be 
considered.” 


























12 articles that 
reported additional 




women, such as the 
reassurance or the 
sensory 
consequences 
related to the 
transvaginal 




“There appears to be a gap between the 
presumed effects of cervical length 
measurement on patient outcomes, such 
as patients’ reassurance, and the actual 
assessment of these effects during test 
evaluations.  They did not ﬁnd a single 
study that had measured the psychosocial 
effects of performing a cervical length 
measurement in women with symptoms of 
preterm labour.  However, such additional 
effects were considered relevant by 
several authors, who often referred to 
them in the discussion section of their 
articles. 
 
Multiple authors have pointed to the 
potential of cervical length measurements 
to affect a range of patient outcomes, such 
“This review illustrates that 
empirical evidence about an 
expected reassuring effect of 
cervical length measurement in 
women with threatened preterm 

























Study Design Setting/Country 
Study time 
period 
Participants Main findings Author Conclusions 
Implications for 
practice 
as reassurance and anxiety, but these 
effects have not yet been measured.” 













































stabilized and were 
tape recorded with 
the woman’s 
knowledge. Most 
of the interviews 
were completed 




30 pregnant women 
who were less than 
35 weeks gestation, 
had experienced 
PTL within the past 
7 days, and had no 
previous experience 
with PTL. 
“Themes that emerged from the interview 
data included the following: recognition 
and naming of sensations, a consistent 
pattern of attribution of symptoms, the 
threat or risk inferred by the attributed 
cause of the symptom pattern, the 
associated certainty or uncertainty about 
these attributions, the process of 
interpreting and verifying symptom 
meaning, and the decision to self-manage 
the symptoms or engage health care 
assistance. 
 
The core process of women experiencing 
the onset of PTL symptoms was identified 
as “resolving the uncertainty of PTL 
symptoms: recognizing and responding to 
the possibilities.  
 
PTL often is not within expectant women’s 
consciousness.   They may attribute the 
symptoms to nonthreatening causes, 
which results in delays in seeking care for 
PTL.  
 
Even previous term labour does not 
provide a good experiential background 
for recognizing PTL.” 
 
“The language used by expectant 
women in their descriptions of 
preterm labour symptoms should 
be incorporated in the 
educational materials available to 
all pregnant women to assist 
them in the early recognition of 
PTL.  Every expectant woman 
needs education about the cues 
to use in recognition of preterm 
labour as differentiated from 
term labour.  
 
Expectant women should be given 
decision guides to assist them 
with self-management, timely 
contacts with the provider, and 






























and birth with 
the need to 
maintain 
sensitivity 
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4. AIMS AND OBJECTIVES 
4.1. Overall aim and overview of the PhD research 
 
The overall aim of my PhD research was to improve the experience of women with 
symptoms of TPTL by addressing two issues: a) the need for better risk assessment in 
TPTL and b) the identification of areas where TPTL care could be enhanced.  I 
hypothesised that this could be achieved through: i) the development of a clinical 
decision support tool that predicts individual risk of preterm delivery and ii) a 
qualitative study exploring women’s experience of TPTL care.  Figure 10 illustrates how 
the different parts of the research project, from literature review, prospective cohort 
study, current QUIPP app users study and women’s experience study combine to 
achieve the intended outputs.   The timeline of project activities is demonstrated in 
Figure 11.   
 
The overarching study was called “PETRA”, an acronym derived from some of the 
letters of the study title: “Threatened preterm labour: a prospective cohort study of a 
clinical risk assessment tool & a qualitative exploration of women's experiences”.   
PETRA comprised three components. The first was a prospective cohort study for the 
collection of data on risk factors, test results and outcome which were used in the 
validation of risk prediction algorithms in the development of the QUIPP app.  PETRA 
Part 2 was the name of the qualitative study exploring women’s experiences, and 
PETRA Part 3, was an additional qualitative study exploring the views of the clinicians 
who were using the first version of the QUIPP mobile phone application.  This was 
known as Part 3 because it was the third part to be instigated, however, findings from 





the QUIPP users study informed development of the app and therefore relate to the 
first study objective.  







Figure 10. Schematic overview of the different elements of this PhD project. 
 









Figure 11. GANTT chart demonstrating PETRA project timeline. 
 





4.2. Rationale and research questions 
 
Building upon our previous research, generated by the preterm birth group at KCL 
Department of Women and Children’s Health, along with the knowledge that fFN and 
TVS CL are useful tools for prediction of preterm birth, the research questions 
addressed in this thesis were: 
1. Can a combination of risk factors, fFN test results and CL measurements 
generate a reliable individual risk score for women with TPTL?  
2. How can the QUIPP app be enhanced to increase its usefulness and 
acceptability to clinicians and women? 
3. What is the experience of women with symptoms of TPTL, and how could 
assessment and management be improved?  
 
 
4.3. Primary Objectives 
 
The primary objectives of the PETRA study were: 
1.   To develop and validate a risk assessment tool (QUIPP) that generates 
individualised risk scores indicating likelihood (% risk) of birth within clinically 
significant time points. 
2.   To identify potential areas for improvement in care of women with symptoms 
of TPTL. 
 
4.4. Secondary Objectives 
 
Although evidence suggests that using both fFN and CL together may aid risk 
assessment (DeFranco et al., 2013; van Baaren et al., 2013), CL measurement of 
women with TPTL is less common than fFN testing in the UK.  For this reason, the 
added value of using TVS CL in a UK setting was explored, along with appropriate use 





of TPTL interventions (in relation to subsequent outcome).   An overview of primary 
and secondary objectives, methods and intended outputs is shown in Table 7. 
Table 7. PETRA study objectives, methods and intended outputs. 
Objective Methods Intended outputs 
1. To develop and validate a risk 
assessment tool (QUIPP) that 
generates individualised risk 
scores indicating likelihood (% 
risk) of birth within clinically 
significant time points 
(primary objective). 
 Prospective cohort study combining 
risk factors and test results for 
quantification of risk of PTB (as per 
Kuhrt et al., 2016) (PETRA Part 1). 
 
 Survey of women’s and QUIPP app 
users’ opinions on risk illustrations. 
(PETRA Parts 2 and 3). 
 New QUIPP app with 
updated algorithms, 
including twins and 
CL in symptomatic 
women, and visual 
illustration of risk. 
 
 Inform next stage of 
development, the 
EQUIPTT study which 
will evaluate the app 
in clinical practice.  
2. To identify potential areas for 
improvement in care of 
women with symptoms of 
TPTL (primary objective). 
 Qualitative study using thematic 
analysis of women’s experience of 
TPTL risk assessment and care 
management. (PETRA Part 2). 
 
 Recommendations 
for practice and 
research. 
3. To explore the added value of 
CL in a UK setting (predefined 
secondary objective). 
 Comparison of risk prediction in 
women whose TPTL assessment 
included fFN alone, with those whose 
assessment included both fFN and CL.  
 Demonstrate value, 
or otherwise, in use 
of TVS for CL in TPTL 
assessment. 
4.  To assess use of steroids and 
other management (i.e. 
admission, tocolysis, in utero 
transfer) in relation to test 
results (post-hoc objective). 
 Analysis of administration of steroids, 
tocolysis, hospital admission and in-
utero transfer.  
 
 Steroid use in relation to time from 
administration to delivery, and 
whether guided by fFN/CL results, 
before and after 30 weeks (as per NICE 
guidance). 
 Demonstrate extent 
of intervention use in 
relation to preterm 











5. Patient and Public Involvement and Research Governance  
 
5.1. Patient and Public Involvement (PPI) 
 
The KCL Department of Women and Children’s Health Preterm Birth Studies PPI panel 
provides review and advises on study design and participant documents for all preterm 
studies.  Panel meetings are held twice a year, and further advice is sought by email 
should the need arise.  Advice was sought from this group prior to the PETRA protocol 
development and Research Ethics Committee approval application. The PPI group were 
kept informed on the progress of the study and utilised throughout, as shown in Table 
8.    
 
Table 8. Patient and public involvement (PPI) panel contribution to study development 
and implementation. 
 
PPI meeting date Feedback provided 
27th March 2013 An outline of study proposal was presented. Views on the value of the study 
were sought. Specific advice sought, and given, on appropriate methods for 
obtaining qualitative data on women’s experience and review of draft 
participant documents. 
4th April 2014 Presentation of cohort and qualitative study design.  Views were sought on 
design and planned outcome data points.  The group reviewed the 
participant information sheets. 
17th April 2015 The group was updated on the progress of the study, which started 
recruitment in early March 2015. The current recruitment strategy was 
discussed, which included attempting to meet up with women at future 
hospital appointments when they have been assessed for TPTL but have 
been discharged overnight and at the weekend.  For those women who do 
not have further hospital appointments the group were asked whether they 
would consider it acceptable for researchers to telephone these women 
“out of the blue”. The group felt that it would not be acceptable, unless a 
midwife or doctor mentioned the study at the time of TPTL assessment and 
obtained oral consent to call.  
4th Sept 2015 Presentation of study recruitment progress. 
6th May 2016 Progress of cohort and qualitative study discussed, as well as plan for 
interviews with current QUIPP app users.  The group was updated on 
recruitment which was going well at St Thomas’ and that although there had 
been delays with local governance approvals at other sites, this had now 





improved.   A discussion followed, and concerns were raised, about the 
variance in tests offered to women around the country.  We also spoke 
about the way fetal fibronectin results were given (i.e. qualitative vs 
quantitative), particularly the language “positive/negative”.  Having a 
negative test was perceived as more reassuring perhaps than being given a 
numeric value, but being given a “positive test” causes anxiety even if the 
value is relatively low.  A suggestion was made that a “traffic light” system 
may help, however an “amber” group may be too big a group to be useful.  
Generally, the group felt that being given a % risk was easier for women to 
understand.   
23rd Sept 2016 The group were updated on study recruitment and on initial themes that 
were beginning to emerge from analysis of the qualitative data.  Themes at 
this stage included “Coping”, “Conflicts and Responsibilities”, “Maternity 
Care”, and “Emotions”.  There was a general consensus that the themes 
resonated with the members, who were also given copies of the models 
incorporating the codes, and asked to consider these and provide feedback 
when they had had more time. 
19th May 2017 Presentation of study recruitment progress. 
1st Dec 2017 The group were informed that the cohort study had completed on time and 
target on 31st October.  The final qualitative findings were presented and 
members commented that they felt they were a credible representation of 
women’s experience of TPTL.  
 
5.2. Ethical considerations 
 
5.2.1. Informed Consent 
 
It was anticipated that women presenting with symptoms of threatened preterm 
labour may be anxious and unwilling, or unable, to consider research participation and 
give informed consent.  Potential participants were only approached if the midwife or 
doctor providing their clinical care considered it appropriate.  If deemed appropriate, 
they were given verbal information about the study, and informed there was no 
obligation to participate in this, or any other research.  If willing to consider 
participation, they were given a copy of the participant information sheet (Appendix 
17.2) to read.  If happy to proceed, they were asked to sign a written consent form.    
They were also asked if they would be willing to be contacted about the qualitative 
study, and if so, were asked to provide a contact number.  A further information sheet 





was provided that explained the qualitative part of the study and written consent was 
taken prior to the interview taking place.   
 
Participants were reminded that they are free to withdraw at any time, without giving 
a reason, and that their decision would not affect their care. It was also made clear 
that they could withdraw permission for the data to be used, at any time in the 
prospective cohort study, and within two weeks of the interview, after which time 




Participants were given a study identification number and data collected for the 
prospective cohort study was entered on to a secure study database.  Contact details 
were kept separately and securely to ensure confidentiality.  In the qualitative study 
transcripts, names and any information that makes it possible to identify participants 
were removed to maintain anonymity.  
 
5.2.3. Potential burdens to participants 
 
Women presenting with symptoms of threatened preterm labour were clinically 
assessed in exactly the same way whether or not they participated in this study.  The 
only difference was that they agreed to information about them and their care being 
collected and used to determine whether a risk assessment tool can accurately predict 
preterm birth.  The midwives and doctors undertaking the assessments knew all tests 
results and care was provided in the usual way.    
 





Participating in the prospective cohort study required the participant giving up some of 
her time, in the process of consent, and in answering some questions about her 
medical and obstetric history.  Those also agreeing to the qualitative study were 
required to give around another hour of their time. 
 
If they had been unhappy about their experience or the care they received it was 
possible that women participating in the qualitative study might find talking about it 
upsetting.  If this happened they were reminded that they were free to stop the 
interview at any time, and, if necessary, the interviewer could arrange for the provision 
of any further support, e.g. debriefing or counselling. 
 
 
5.3. Research Ethics Committee (REC) approval 
 
The study was conducted in compliance with the Research Governance Framework for 
Health and Social Care and Good Clinical Practice (GCP). The London – South East NRES 
Committee approved the study in December 2014 (REC reference 14/LO/1988) and 
local R&D approval was obtained in March 2015 (RJ115/N074). Approval documents 
are shown in Appendix 17.1.  Annual progress reports were submitted to the REC as 
required. 
 
5.4. REC Substantial Amendments 
 
Following commencement of recruitment in March 2015, four substantial REC 
amendments were approved.  Details and summary of changes are listed in Table 9.  





Other approved minor amendments related to addition of new sites and changes of 
Principal Investigators. 
 
Table 9. List of Research Ethics Committee (REC) substantial amendments and 





Summary of changes 
No. 1.  
28th May 2015 
 
Approved:  
17th June 2015 
1.  Addition of multiple pregnancy to eligibility criteria. In the original 
protocol, multiple pregnancies were excluded because "evidence 
supporting the predictive value of quantitative fetal fibronectin in 
multiple pregnancies is currently insufficient". Since then, a meta-
analysis (Conde-Agudelo and Romero, 2014) was identified that 
suggested that a negative (<50ng/ml) fetal fibronectin result could 
identify women with twin pregnancies who are unlikely to deliver 
within 7 days, and that further prospective studies in this area are 
needed.  
2.  Women who are assessed for TPTL are sometimes discharged before 
being given the opportunity to participate (e.g. overnight and at 
weekends when staff are not available to consent). These women can 
be identified from ward registers and fetal fibronectin machines. 
Permission was requested to identify and approach these women 
when they attend for follow up appointments. This was important 
because the majority of women with TPTL do not go on to deliver early 
and excluding those who are discharged quickly may result in an 
imbalanced sample.  
3.  Occasionally, participants experienced further episodes of TPTL, and 
the assessment and test results was recorded in the maternity notes. 
Permission was requested to capture data from these episodes and to 
amend the participant information sheet in order to highlight this 
possibility to the participants.   
4.  Revised study start and end dates (to 3rd March 2015 to 31st October 
2017) due to delays in R&D approval. 
No. 2  
9th Oct 2015 
 
Approved:  
25th Nov 2015 
1. Name of Sponsor's (Lead and Co-sponsor) Representatives changed. 
2.  Permission requested to change eligibility criteria to allow recruitment 
of participants who are assessed with either, or both, tests.   Current 
eligibility criteria stipulated that the TPTL assessment must include fFN 
testing, with or without TVS CL.  
No. 3 
11th July 2016 
 
Approved:  
2nd Nov 2016 
1.  New sites added where site specific information (SSI) form was started 
prior to HRA changes in April 2016 but not completely through 
approval process. 
2.  New sites expressing an interest since April 2016. 
3.  Amendment to Part 2 (qualitative study) interview schedule asking 
women to consider cards showing different ways of illustrating risk and 
explain their views on them.  This was in order to enable us to develop 
the risk assessment tool in ways that are most useful from the 
women's perspective. 





4.  Addition of Part 3: QUIPP app users' experience and views - a 
qualitative study exploring clinicians' use of the QUIPP app and views 
on illustrations of risk. The first version of the app was by this stage 
being used in practice in the care of high risk women.  Understanding 
the users’ experience and views of the app to date would inform 
further development. 
 
No. 4  
7th July 2017 
 
Approved: 
18th Oct 2017 
 
1.  Change to eligibility and extension to end date beyond 31st October 
2017.  The number of participants with TVS CL measurements over the 
initial study period was lower than anticipated. This amendment 
requested permission to continue recruitment of women having both 
tests for a further three years. The data collected will be used to 
further strengthen the prediction algorithms used in respect of cervical 
length measurements in later QUIPP app development.   
2.  Revision of the PIS and consent form to remove information about the 




5.5. Study management meetings 
 
As the Chief Investigator, my first supervisor, Rachel Tribe, other academic supervisors 
and myself, as the study co-ordinator, met at least monthly, to ensure satisfactory 
progress of the study and timely management of any arising issues, e.g. unanticipated 
problems with recruitment and data management.  Following an initial site initiation 
visit or teleconference, additional site Principal Investigators and research midwives 
were invited to contact me if they had any queries or problems.   
 
5.6. Study database and data quality assurance 
 
The KCL Department of Women and Children’s Health Preterm Birth Studies database, 
built by the Swedish company, MedSciNet, was adapted in order to accommodate data 
collection for the prospective cohort part of this study (Preterm Birth Studies 
Database, 2018).  MedSciNet develops and supports web-based databases for many 
research organisations, groups and universities throughout the world.  Their databases 





and web-based applications which allow access to the data are built using the 
MedSciNet Clinical Trial Framework, a self-contained environment that enables 
development, hosting, support and management of individual web-based solutions for 
clinical trials and studies, quality registries, medical biobanks and other required 
solutions within the field of academic medicine.  The databases conform to relevant 
FDA, NIH and UK and EU data protection regulations.    
 
Authorised users were provided access through individual login names and passwords.  
Data quality was assured by use of the MedSciNet database data monitoring facility.  
Data monitors, including myself, and other trained research midwives at GSTfT, 
regularly reviewed the forms throughout the recruitment period and raised queries if 
data were missing or appeared erroneous.  The site users then checked the data and 
responded to the query, after which the monitor either accepted the answer and 
locked the form, or raised another query.  
  





6. Methods 1: Prospective cohort study 
 
 
6.1. Study Design 
 
A multi-centre prospective cohort study design was chosen as the most appropriate for 
the collection of data necessary for creating and testing the prediction algorithms for 
use in the QUIPP app (PETRA Part 1).  This design was chosen as it reduced the risk of 
bias in subject selection as well as outcome interpretation, as the participant is 
recruited before the outcome is known, i.e. spontaneous onset of labour resulting in 




During the set up period an outline of the study was emailed to previous research 
collaborators and members of the UK Preterm Clinical Network (clinicians with an 
interest in preterm birth).  Sites expressing an interest were assessed for suitability, i.e. 
able to assess pregnant women in threatened preterm labour, including quantitative 
fFN (qfFN) testing and TVS CL, and with a reasonable expectation of recruiting 
approximately two participants per week, and/or approximately 200 participants in 
total.  Recruitment commenced on 4th March 2015 at the main site when final 
governance approvals were in place, with phased introduction of additional sites as 












Pregnant women presenting with symptoms of TPTL, i.e. abdominal pain and/or 
uterine contractions were approached by myself, and/or other research midwives, 
when they presented at participating sites with symptoms of threatened preterm 
labour, either at Antenatal Day Assessment Units (ADU), labour wards or other areas, 
such as specialist preterm clinics.   
 
When recruitment initially commenced in March 2015, the inclusion criteria stipulated 
that only women with singleton pregnancies with TPTL assessment that included fFN 
with or without TVS CL were eligible.  Later protocol amendments allowed for inclusion 
of multiple pregnancies and qfFN or TVS for CL (Section 5.4).  Final inclusion and 
exclusion criteria are detailed below: 
 
6.3.1. Inclusion criteria 
 
 Gestation between 23+0 and 34+6 weeks. 
 Symptoms suggestive of TPTL. 
 TPTL assessment includes qfFN and/or TVS for CL. 
 Willing and able to give informed consent. 
 
 
6.3.2. Exclusion criteria 
 
 Definitive diagnosis of labour (i.e. regular painful contractions with cervical 
change diagnosed on speculum or digital examination). 
 Confirmed ruptured membranes (on speculum examination). 
 Antepartum haemorrhage. 
 
 





The above exclusions were justified because: i) the study aimed to improve care where 
preterm labour is uncertain, rather than confirmed and ii) fFN testing is 
contraindicated when membranes have ruptured and in the presence of vaginal 
bleeding, as both liquor and blood can lead to false positive results (Hologic Inc., 2018).   
 
6.4. Clinical assessment and test procedures 
 
TPTL assessment was carried out according to individual sites’ local guidelines, but all 
included an assessment by midwife and/or doctor taking a medical and obstetric 
history, cardiotocographic (CTG) monitoring, speculum or digital vaginal examination, 
fFN swab and/or TVS CL.  Fetal fibronectin tests were analysed in the clinical area using 
Hologic Inc.’s Rapid fFN® 10Q System (Hologic Inc., 2018).  TVS CL was carried out by 
qualified clinical staff. 
 
 
6.5. Screening for eligible participants 
 
Participating sites employed site-specific methods for screening for eligible 
participants as procedures for registering women with TPTL symptoms varied.   At 
GSTfT, the main site, the procedure was as follows: 
 
The ADU patient register was regularly reviewed, by myself and/or other research 
midwives, at least daily, for women with potential TPTL symptoms who had arrived 
and were still waiting to be seen.  A message slip (Figure 12) was attached to the front 
of the women’s notes for the clinician to see prior to TPTL assessment to contact 





researchers, if they felt it appropriate, so the woman could be approached, informed 
of the PETRA study and offered TVS for CL measurement. 
 
 
Figure 12. Message slip to highlight potential recruit to clinical staff. 
 
The below sign (Figure 13) was placed next to the Rapid fFN® 10Q analysers in the ADU 
and Hospital Birth Centre, to encourage clinicians who were about to undertake an fFN 
test to contact researchers. 
 
 
Figure 13. Rapid fFN® 10Q analyser sign to highlight potential recruits to clinical staff. 
 





The number of fFN tests being carried out in the hospital was monitored and it soon 
became apparent that many women were not being recruited if they presented with 
symptoms of TPTL outside office hours when researchers were unavailable.  A 
substantial amendment to the protocol (Section 5.4) was, therefore, submitted 
requesting REC approval to approach eligible women at any time up to delivery of the 
baby.   In order for data to be considered prospectively, rather than retrospectively 
collected, participant recruitment had to occur prior to the outcome of interest (in this 
case, gestation at birth).   This change to recruitment strategy improved integrity of 
the study because the majority of women with TPTL do not go on to deliver early and 
excluding those who are discharged quickly may result in an imbalanced sample.  
Strategies were therefore developed in order to identify and approach eligible women 
before their babies were born as well as at the time of TPTL assessment.   
 
A screening log was devised, based on details retrieved from the Rapid fFN® 10Q 
analysers.  This included the date and time of test, hospital number and result. 
Gestation at time of test was checked by review of the hospital’s electronic maternity 
record (using hospital number).  If the gestation was within the eligible range for the 
study a note of the woman’s next hospital appointment and plans were made to meet 
her in order to confirm eligibility (e.g. appropriate symptoms) and consent, if willing.    
  
If the woman had no appointments arranged, the hospital appointments system was 
checked weekly until either she had delivered, or three weeks after her expected date 
of delivery.   After this time, it was assumed birth of the baby had occurred, and she 





would no longer be eligible, as the outcome data would then be retrospective in 
nature. 
 
6.6. Sample size 
 
The sample size was determined using data from the symptomatic cohort of the 
EQUIPP study (Abbott et al., 2013) which investigated the predictive value of fFN in 
300 women with symptoms of TPTL. This study was also carried out at GSTfT so the 
population was comparable to the principal recruitment site for PETRA. The true 
preterm labour (PTL) rate at 34 weeks’ in this cohort was approximately 10%.  
Combination of symptoms and fFN in the EQUIPP study identified a small higher-risk 
group with a 50% chance of delivery at less than 34 weeks’ and a larger standard risk 
group with a lower risk of approximately 7%.  In undertaking the power calculation for 
the PETRA study, we anticipated that clinicians would be willing to view women in the 
lower risk group as closer to the normal (i.e. standard risk) if the true rate of PTL in this 
group could be demonstrated (with 95% confidence) to be lower than the background 
rate (i.e. lower than 10% with a best estimate of 6.7%),  and concluded that full data 
on 550 standard risk women and 61 high risk women (total 611 women) in the 
proposed validation would be sufficient to achieve 80% power in the PETRA study. 
Allowing for 95% compliance & completion, a recruitment target of 643 women was 
considered adequate to validate the predictive value of each test (qfFN and CL) with 
data from an additional 300 to be used as a training set. 
 





FFN testing in TPTL was, and remains, more common than CL measurement in the UK 
(only 155 of the 300 women in the EQUIPP study had CL measurement).  So while qfFN 
testing was a mandatory requirement for inclusion in this study, all recruiting sites 
were encouraged to undertake CL measurement if possible, but it was not mandatory.  
Training initiatives were planned and it was anticipated that, as more clinicians were 
trained in transvaginal ultrasonography, CL measurement would become increasingly 
common.  It was estimated that of the first 300 participants (weeks 1 to 41), 
approximately 50% would also have had CL measurement.  After this, with raised 
awareness and increased number of trained clinicians, it was estimated that 90% 
would have also have CL measurement. To ensure an adequate sample to validate the 
predictive value of both qfFN and CL a total sample of 1181 participants was set (Table 
10). 
 











(50% of total) 
TVS training initiatives initiated 
42-140 881 
793 
(90% of total) 
Training initiatives ongoing 
Total 1181 943 300 training set plus 643 validation set 
 
 
6.6.1. Feasibility of sample recruitment target. 
 
The overall recruitment target of 1181 represented the total for all sites recruiting over 
period of 32 months. For the main site the target was 540 participants. This was based 
on a feasibility calculation using ADU records which indicated that approximately 30-40 





women every month between 23+0 and 34+6 weeks' pregnant presented with 
symptoms of TPTL.  This estimate provided an adequate number of potential 
participants from which to approach the approximately 25 women per month needed, 
if 80% agreed to participate. The study was not considered to be particularly onerous 
for participants as it required only consent to use of clinical data.  Experience of 
previous similar research recruitment, carried out at this hospital, suggested that it 
would be reasonable to assume that 80% of women approached would consent. It was 
estimated that if approximately 20 women consent each month (four per week), the 
local target recruitment (n=540) would be achieved in 32 months (140 weeks).  It was 
planned that the remaining 641 participants would be recruited from additional sites 
over 29 months (allowing three months from start at main site for local approvals).  If 
three additional sites were ready to commence recruitment by week 14, it was 
considered reasonable to expect that each site would be able to recruit 214 
participants overall (1.7 per week, per site). 
 
6.6.2. Recruitment of participants with cervical length measurement  
In order to achieve sufficient recruitment to develop and validate the risk assessment 
tool with CL, it was estimated that at least 50% of participants would need this 
measurement in addition to the mandatory qfFN test.  Prevalence of CL measurement 
was monitored, and within 3 months it was clear that the target was not being 









Table 11. Participants with cervical length (CL) measurement in first 3 months of 
recruitment at main site. 
 
 
Participants (n) with CL 
Mar-15 8 3  (38% of total) 
Apr-15 27 4  (15% of total) 
May-15 44 6  (14% of total) 
 
 
The study management team concluded that this was likely to be due to a number of 
factors: 
 Clinical staff engagement and referral of potential participants to research 
teams is slow when a study is new and unfamiliar. 
 Cervical length measurements were not routinely performed on women with 
symptoms of TPTL, even at the main site.  
 Ultrasound scanners were not always available even when trained staff are on 
hand to use them.  
 
In order to address these factors, the following actions were undertaken: 
 
 Efforts were made to increase the profile of the study, through face to face 
communications and on clinical study days, encouraging ADU staff to call me or 
the research team if a woman presented with symptoms. 
 Clinical staff were encouraged to train in TVS CL (an in-house focused course 
was developed with support from the ultrasound training department). 
 Availability of USS machines was addressed by the purchasing of vaginal probes 
for the hospital birth centre USS machine and the Medical Ultrasound MSc 
course machine.  These probes were purchased using funds from the Preterm 
Surveillance Clinic NHS Innovations Challenge Prize fund, which was won by 
Professor Shennan and his team in 2013. 
 
 





6.7. Data collection 
 
After participants had provided written consent, data was collected via either paper 
forms, or entered directly onto the study database (www.medscinet.net/ptbstudies) 
via electronic case report forms which included:  
 
i. Demographic data: age, ethnicity, postcode (for conversion to indicator of 
socio-economic index code), height and weight.  
ii. Risk factors: previous preterm birth or late miscarriage, history of cervical 
surgery, history of recurrent urinary tract infections, group B streptococcal 
infection, bacterial vaginosis recreational drug use, smoking, uterine 
abnormality, domestic violence. 
iii. Obstetric history: year of pregnancy, gestation at delivery, onset of labour, 
mode of delivery. 
iv. Current pregnancy: expected date of delivery, obstetric or medical problems 
this pregnancy. 
v. Current episode: gestation; symptoms, qfFN result, cervical length.  
vi. Outcomes: antenatal inpatient nights, steroid administration for fetal lung 
maturation, tocolytic drug administration for TPTL symptoms, intra-uterine 
transfer to unit with appropriate level of neonatal care, date of delivery, onset 
of labour, mode of delivery, neonatal unit admission, neonatal complications. 
 
6.8. Data Monitoring and Cleaning 
 
Data monitoring, as outlined in section 5.6, occurred throughout the study recruitment 
period.  After the recruitment period was complete, on 31st October 2017, and before 
data were analysed, a number of additional data monitoring checks were performed 
and sites contacted and asked to make every effort to address shortcomings.  These 





included: outstanding queries; missing data (e.g. ethnicity, lower super output area 
(LSOA)); visit outcome (e.g. discharge or admission); antenatal and postnatal nights; 
eligibility of visits (e.g. within gestational range, appropriate symptoms, test results); 
correct recording of interventions (e.g. two doses of steroids recorded as one full 
course); that onset of labour and gestation at delivery matched primary outcome 
indicator; that if congenital abnormality was recorded whether it was appropriate for 
exclusion. 
 
6.9. Data analysis 
 
Using SPSS version 23.0 (IBM SPSS Statistics), data were first analysed descriptively in 
order to explore the characteristics, use of interventions and outcomes of the cohort 
and also to investigate the predictive value of qfFN and CL by category.  The 
development and validation of the new risk prediction algorithms for use in the QUIPP 
app was then carried out using enlarged datasets, consisting of new and previously 
analysed data from earlier studies, as described in section 1.8.3. 
 
6.9.1. Participant characteristics 
 
Participant characteristics, including demographics and risk factors, were explored 
using descriptive statistics (i.e. frequencies and percentages) and stratified by delivery 
outcome, sPTB <34 and <37 weeks’ gestation.  Means and standard deviations (e.g. 
age and BMI) were compared using independent samples Student’s t-tests, while other 





categorical variables were compared using Pearson’s Chi-squared tests.  Differences 
were considered statistically significant if the p value was ≤0.05. 
 
6.9.2. Prediction of preterm birth by fFN and CL test category  
 
Prior to development of quantitative fFN bedside analyser machines, which now 
provide exact fFN concentrations ranging from 0 ng/ml to >500 ng/ml, fFN test results 
were presented as negative or positive, depending on a threshold of 50 ng/ml.  
Although awareness of the actual fFN concentration is likely to be much more useful 
than a qualitative result, NICE Preterm Labour guidance still uses the threshold of 50 
ng/ml as a basis for recommending or withholding intervention (NICE, 2015).  Our 
group, however, have suggested that using categories of ranges of concentrations, 
such as  <10, 10-49, 50-199, 200-499 and 500 ng/ml or more may be more useful 
(Abbott et al., 2013).  Using data from the whole PETRA cohort, the prediction utility of 
qfFN by these categories was examined using Kaplan Meier survival analysis.  This is a 
commonly used non-parametric statistical method for predicting the “survival” i.e. 
whether an event of interest has occurred, in this case spontaneous preterm birth, 
within certain time points (Goel et al., 2010).  A survival curve can be created which 
allows the reader to visually compare different categories of the test result (as these 
cannot be measured in the same way as continuous variables).  Relative risks for 
spontaneous PTB at less than 34 and 37 weeks, and within 7 and 14 days of testing 
were also calculated, using the lowest category, 0-9 ng/ml as the reference category 
using binomial logistic regression.  This method was chosen because the dependent 
variable (sPTB – yes or no) is dichotomous, whereas in linear regression the 





relationship between the independent and dependent variables is assumed to be 
linear, and it cannot be used with categorical data (qfFN and CL groups). 
 
Cervical length was similarly investigated by categories: <15, 15-24 and 25+ mm.  
These categories were chosen because literature suggests risk of preterm birth 
increases with CL measurement of less than 25 mm (Iams et al., 1996).  Additionally, 
25 mm is generally accepted by preterm birth specialists as a threshold under which 
interventions are indicated (Carter et al., 2016) and current NICE guidance 
recommends withholding treatment for symptomatic women with a CL >15 mm after 
30 weeks’ gestation (NICE, 2015). 
 
6.9.3. Intervention use in the PETRA cohort 
 
Further objectives of the PETRA study included exploring use of steroids and other 
management, i.e. admission, tocolysis, IUT, neonatal unit (NNU) admission, in a cohort 
of women with TPTL symptoms and these were explored by independent sample 
Student t-tests for comparing means of continuous variables with normal distribution, 
or Mann Whitney U tests for comparing medians where data are not normally 
distributed.  Non-parametric chi-squared tests were used for comparing categorical 
data (e.g. whether steroids had been given or not). 
 
The use of steroids was examined in more detail than the other interventions because 
it was the most prevalent intervention in this cohort, and because of the increasing 





concern about its overuse in women with symptoms of threatened preterm labour 
(Levin et al., 2016).    
 
The prevalence of preventative interventions (e.g. cerclage, progesterone) in this 
cohort was also compared between high and low risk women, and whether they went 
on to experience spontaneous preterm birth. 
 
6.9.4. Predictive model generation 
 
As explained in section 1.8.3, it was necessary to update the prediction algorithms 
prior to completion of the PETRA study before the start of the EQUIPTT study.  The 
generation of the prediction models was, therefore, based on data already gathered in 
PETRA (as at the end of May 2017) along with relevant participant data from earlier 
studies (EQUIPP REC Ref. 10/H0806/68 and POPPY REC Ref. 09/H0802/97).   This 
pragmatic decision meant the data was not split randomly between “training” and 
“validation” sets, as is customary, and that there was a time delay of approximately 10 
months between model generation (which was tested by calibration before being used 
in the new version of the QUIPP app) and formal validation using the latest PETRA 
data.   
 
In total, six prediction algorithms were needed for the new version of the QUIPP app. 
The algorithm is selected according to whether the woman is asymptomatic high risk 
or symptomatic (any risk status) and whether her TPTL assessment includes qfFN 
testing alone, CL measurement alone, or both tests.  Data were therefore split and 





tested in six groups: i) asymptomatic high risk with fFN test result; ii) asymptomatic 
high risk with CL measurement;  iii) asymptomatic high risk with both test results; iv) 
symptomatic (any risk status) with fFN test result; v) symptomatic (any risk status) with 
CL measurement;  vi) symptomatic (any risk status) with both test results.   Data from 
women with symptoms were used in three of the six data sets. For the purposes of this 
thesis, the methodology below relates to development of the three algorithms 
appropriate for the symptomatic cohorts. 
 
The advanced statistical analysis required for the development and validation of the 
prediction algorithms was carried out using Stata SE software (version 14.2; StataCorp, 
College Station, Texas, USA) by the KCL Department of Women and Children’s Health 
statistician, Mr Paul Seed, with support from this PhD candidate who worked closely 
with him throughout the analyses.  As explained above, the “training set” was 
comprised of PETRA, EQUIPP and POPPY data.   Exclusions were made for: incomplete 
data; invalid visits (out of gestation range, inappropriate symptoms, invalid or missing 
test results, sexual intercourse within 24 hours) and major fetal abnormality.  Women 
with twin pregnancies were included, using the first twin gestation at delivery, but 
triplets and higher order multiples were excluded due to inadequate numbers.    
Women whose labour was induced or had caesarean section following PPROM were 
regarded as having had spontaneous preterm birth. 
 
Cox’s proportional hazards regression was used to determine which predictive risk 
factors to use in the model. This is a simple, widely used, statistical method that is 
used to indicate which factors have an effect on outcome (Lin and Wei, 1988).  Factors 





tested included demographic characteristics (i.e. age, BMI, ethnicity, deprivation score 
and smoking), risk factors (i.e. previous history of preterm birth or PPROM, late 
miscarriage, cervical surgery, twin pregnancy) and test results (qfFN and TVS CL).   
 
Simple regression methods were not sophisticated enough for creation of the QUIPP 
app prediction models because time to delivery after testing has to be very precise, 
with very smooth survival curves, and therefore parametric survival analysis was used.  
This process involved testing the data using several different parametric survival 
analysis functions, namely exponential, gamma, Gompertz, log-logistic, log-normal and 
Weibull.  The different models function differently depending on the statistical 
distribution of the data and describe the probability of an outcome, in this case  sPTB, 
at any given time point (gestation) between testing and delivery.   
 
When an individual woman had more than one visit for TPTL assessment, later results 
were introduced as time-updated covariates, i.e. if delivery has not occurred before 
the next visit, prediction was recalculated with the next visit gestation.    
 
In survival analysis, data are “censored” if the outcome of interest has not occurred 
during the follow up period (Kleinbaum and Klein, 2010).  In this study, the data were 
censored, if spontaneous preterm birth had not occurred by 37 weeks’ gestation.   A 
number of ways were considered for dealing with data from women who experienced 
iatrogenic preterm birth.  The options were: i) to exclude them from the analysis 
altogether; ii) to censor them at the time of the iatrogenic, i.e. medically indicated, 
preterm birth and iii) to treat them as non-events and censor them at term.  Although 





none of the options are perfectly satisfactory, due to the limitations of current 
statistical methods, option iii) was chosen.   This was for a number of reasons: (a) when 
the data were collected, the outcome was unknown, and this reflects the situation 
when the app is used for prediction of outcome in future cases; (b) censoring at time 
of iatrogenic preterm birth would lead to an over-estimation of the number of events 
and (c) excluding all iatrogenic cases from the analysis would be a post-hoc decision 
which may introduce bias. 
 
Checks were undertaken to determine whether the data needed to be transformed 
before analysis using fractional polynomials.  Fractional polynomial regression 
compares possible power transformations (here powers -3, -2, -1 -0.5 0 (log 
transformed), 0.5, 1 (unchanged or identity transformation), 2, 3) of a continuous 
predictor, to see which fits best with, and in particular whether any of them is better 
than power 1.    The entire procedure was repeated for each of the three datasets of 
symptomatic women, and different models produced in each case.   
 
 
The best model to use with this data was then determined by reference to Akaike’s 
Information Criterion (AIC) and Bayesian Information Criterion (BIC).  This is a method 
developed for comparing non-nested regression models where significance tests are 
not available (Royston and Sauerbrei, 2008). When comparing models, the lowest 
values are considered to have the best fit to the data.  
 
Before formal validation could be undertaken after completion of the PETRA study, the 
prediction models were tested by simple calibration. This meant comparing individual 





tests of clinically significant groups to confirm the actual event rates were consistent 
with the predicted probability of the event.  A 5% prediction rate for spontaneous 
preterm birth within 7 days of testing was used as the threshold because this was the 
lowest value of a range of 5-15% that our TPTL Delphi consensus survey suggested 
should be recommended for intervention (Carter et al., 2016).  The calibration tests 
provided reassurance that the models were acceptable to proceed with development 
of the QUIPP app before formal validation was undertaken. 
 
 
6.9.5. Predictive model validation 
 
As explained in section 1.8.3, the “validation set” comprised the remainder of PETRA 
participants whose data had not be used for the model development and where 
outcome data had been gathered after the end of May 2017.   
 
Predictive statistics, including sensitivity, specificity, balanced accuracy 
[(sens.+spec.)/2], likelihood ratios, positive (PPV) and negative predictive values (NPV) 
and separation probabilities (PPV+NPV-100%) were calculated using a % risk of ≥5% as 
an indication of a positive test. This cut off was chosen because, as stated above, it is 
the lower end of a 5-15% range above which clinicians would recommend intervention 
(Carter et al., 2016).  Results are presented in tables with statistics for both the training 
and validation sets, by test group (fFN, CL and fFN+CL) for prediction of spontaneous 
preterm birth at less than 30, 34 and 37 weeks’ gestation, and within 7 and 14 days 
post-test.  These time points were chosen because: i) the gestations at delivery are 
clinically important indicators for likely neonatal morbidity and ii) they are useful in 
guiding appropriate management, such as the timing of steroids.  Receiver operating 





characteristic (ROC) curves were drawn and areas under the curve (AUC) were 
calculated.  The ROC curve is a graphical plot which demonstrates the diagnostic ability 
of a test by showing the true positive rate (sensitivity) over the false positive rate (100-
specificity).  The AUC indicates how accurate the diagnostic test is, with 1.0 
representing a perfect test, with no false positives or false negatives, and 0.5 being a 
worthless test.  Receiver Operating Characteristic (ROC) curves are particularly 
appropriate for evaluating the predictive ability of the QUIPP app because they 
demonstrate the predictive ability of a test at different thresholds (in this case % risk of 
sPTB) rather than using a threshold under which a result is negative, and over which a 
result is positive. 
 
In addition to development of the risk assessment tool, which was a primary aim of the 
PETRA study, further objectives included exploring the added value of CL in a UK 
setting.  This was investigated by the production of ROC curves and comparing AUCs of 
the prediction models using fFN alone, CL alone and both tests in the cohort of women 
who had had both tests.  
 
 





7. Methods 2: QUIPP app users and Women’s experience and views 
qualitative studies 
 
The two qualitative studies explored i) current QUIPP app users’ experience and views 
and ii) women’s experiences of risk assessment and management of threatened 
preterm labour, perception of risk and the factors that influence decision making.   The 
same methods were employed for both qualitative studies and are thus addressed 
together in this chapter. 
 
7.1. Introduction to chapter 
 
The overall aim of this research project was to improve the management and 
experience of women with symptoms of TPTL, which included addressing the 
emotional burden associated with being at risk of PTB.  In the cohort study (Part 1) 
data were collected for the development of an algorithm that would be used in a risk 
assessment tool for assessing the individual likelihood of preterm birth.    As described 
in section 1.8.2, the first version of the QUIPP app had been released just prior to the 
recruitment phase of the PETRA project (January 2015) and clinicians assessing 
preterm birth risk in asymptomatic high risk women started to use it in practice.     
After its use had become established, the opportunity was taken to explore the 
experiences and views of current users, how it was used in practice, and identify 
potential enhancements to its utility, for example, alternative and visual methods of 
illustrating individual risk.   An addition to the PETRA protocol was approved by the 
REC as detailed in section 5.4.   In the women’s experience study, I aimed to explore 





the experience of women with TPTL symptoms, their views on the care they received 
and the aspects they believed could be improved.  A proportion of women were also 
asked to consider, comment and express preferences on a series of visual risk 
illustrations in order to inform development of the risk assessment tool.   This chapter 
gives a detailed account of the methods and qualitative methodology utilized in 
undertaking both qualitative parts of the study. 
 
“Qualitative research is a generic term that refers to group of methods and 
ways of collecting and analysing data that are distinctly different from 
quantitative methods because of the absence of quantification and statistical 
analysis.” (Smith et al., 2011, p.3). 
 
Qualitative methods are based on an ontology, that is, an understanding of being, that 
holds that human experiences are subjective and both the subject and the researcher 
will be influenced by their background, culture and experience.  Quantitative methods, 
that seek to measure a phenomenon using objective measures, are therefore not 
appropriate in these parts of the study. 
 
7.2. Selecting a theoretical perspective 
 
From the vast choice of theoretical perspectives available, the qualitative researcher 
must select the most appropriate for their particular study and be confident that the 
chosen methodology gives the best chance to both answer the research question and 
that the robustness of its findings can be soundly evaluated.    Within qualitative 





research, many different philosophies and theoretical frameworks have been 
developed over recent decades.  Examples of these are Phenomenology (Husserl, 
1982), Grounded Theory (Strauss and Corbin, 1994) and Narrative Analysis (Riessmann, 
1993).   Each have their place in the “paradigm” of qualitative research, and come with 
their own rules and structures which guide the researcher.  As Reeves et al., (2008) 
explain: 
 
“Theories give researchers different ‘lenses’ through which to look at 
complicated problems and social issues, focusing their attention on different 
aspects of the data and providing a framework within which to conduct their 
analysis.”  (p.631). 
 
Some have argued, however, that being restricted to a particular theoretical 
perspective can constrict the researcher and possibly even lead to the findings being 
made to “fit” rather than truly speak for themselves.  Sandelowski (2000) suggests that 
researchers using strict theoretical frameworks may be “obliged to put much more of 
their own interpretive spin on what they see and hear…” and that “…This spin derives, 
in part, from these methodologies themselves.” (p.336).     
 
Some commentators argue that, particularly in healthcare research, simpler 
approaches can be used legitimately and to good affect (Milne and Oberle, 2005; 
Neergaard et al., 2009; Sandelowski 2000; Smith et al., 2011).   Neergaard et al., (2009) 
describes one such approach, Qualitative Description, as allowing for “a rich, straight 
description of an experience or an event…” and proposes that it is “…founded in 





existing knowledge, thoughtful linkages to the work of others in the field and clinical 
experience of the research group.” (p.2). 
 
The aims of the qualitative parts of this study were to not to investigate phenomena 
where very little is known, nor the development of explanatory theories.  A Qualitative 
Description methodology was selected for both, utilizing thematic analysis and Ritchie 
and Spencer’s Framework Approach (Richie and Spencer, 1994).  The QUIPP app users 
study was a simple exploration of clinicians’ experience of using the tool.   In the 
women’s experience study, the consequences of preterm birth are well known and 
therefore women experiencing symptoms of TPTL are likely to be anxious.   Therefore, 
the aim was to gain a deeper understanding of women’s experience and also to 
identify specific aspects of their care that had an effect on that experience, particularly 
those with negative effects that could be modified.   
 
7.3. Qualitative Description and thematic analysis 
 
Milne and Oberle (2005) describe “Qualitative Description” as “…a stand-alone method 
that affords a comprehensive summary of human experience without an in-depth level 
of interpretation.  The goal is to stay close to the surface of data while capturing all the 
elements of that experience” (p.413). 
 
Neergaard et al., (2009) suggests that Qualitative Description is particularly useful in 
mixed methods healthcare research where gaining “first-hand knowledge of patients’, 
relatives’ or professionals’ experience with a particular topic” is the goal (p.5).  They 





also explain that Qualitative Description can be influenced by and have “overtones” of 
other theoretical perspectives.  They consider this both acceptable and preferable to 
trying to fit the whole study into a theoretical framework which is not entirely suitable 
(Neergaard et al., 2009).  In the women’s experience study, I suggest two overtones 
that influenced my perspective: i) phenomenological, because the “lived experience” 
of the participants, a concept in phenomenology, was being explored, and ii) feminist, 
because I intended to listen for hints that women may be feeling pressured into 
accepting treatments they were not entirely happy with and if there remained any 
remnants of a medical model of childbirth that was so prevalent in the 1970s and 80s.     
 
Miles and Huberman (1994) describe six analytical strategies in Qualitative Description: 
a. Coding of data from notes, observations or interviews. 
b. Recording insights and reflections on the data. 
c. Sorting through the data to identify similar phrases, patterns, themes, 
sequences and important features. 
d. Looking for commonalities and differences among the data and extracting 
them for further consideration and analysis.  
e. Gradually deciding on a small group or generalizations that hold true for the 
data. 
f. Examining these generalizations in the light of existing knowledge. 
 
This is very similar to straightforward thematic analysis which, according to Braun and 
Clark (2006), should be considered an analytical tool in its own right and which, 
“through its theoretical freedom…provides a flexible and useful research tool, which 
can potentially provide a rich and detailed, yet complex, account of data” (p.78).   They 
go on to define it as “… a method for identifying, analysing and reporting patterns 





(themes) within data.” (Braun and Clarke, 2006, p.79).   The phases of thematic 
analysis, and their descriptions are listed in Table 12: 
Table 12. Phases of thematic analysis (from Braun and Clarke, 2006, p.87). 
Phase  Description of the process 
1. Familiarizing 
yourself with your 
data. 
Transcribing data (if necessary), reading and re-reading the 
data, noting down initial ideas.  
2. Generating initial 
codes. 
Coding interesting features of the data in a systematic fashion 
across the entire data set, collating data relevant to each code. 
3. Searching for 
themes. 
Collating codes into potential themes, gathering all data 
relevant to each potential theme. 
4. Reviewing themes. 
 
Checking if the themes work in relation to the coded extracts 
(Level 1) and the entire data set (Level 2), generating a 
thematic ‘map’ of the analysis.  
5. Defining and 
naming themes. 
 
Ongoing analysis to refine the specifics of each theme, and the 
overall story the analysis tells, generating clear definitions and 
names for each theme.  
6. Producing the 
report. 
 
The final opportunity for analysis. Selection of vivid, 
compelling extract examples, final analysis of selected 
extracts, relating back of the analysis to the research question 
and literature, producing a scholarly report of the analysis. 
In order to provide further structure and elements that are considered to add to the 
research rigour, a decision was made to also utilise the Framework Approach for data 
analysis (Ritchie and Spencer, 1994).  This method will be discussed in more detail in 
the Data Analysis section, below.   
 
7.1. Study procedures – QUIPP app users study 
 
Current users of the QUIPP app were invited to participate and were identified through 
the UK Preterm Clinical Network, which is a network of clinicians with an interest in 
preterm birth clinical care and research.  Data were collected through semi-structured, 
one-to-one interviews, in person and by telephone during March and April 2017.  





Following informed consent, participants were asked by the researcher, using a pre-
determined interview schedule (Appendix 17.4), to talk about their experience and 
views of the QUIPP app.  Participants were asked specific questions about what they 
considered to be positive attributes of the QUIPP app, as well as what they saw as its 
limitations, and how they thought the app could be improved.  At the end of the 
interview they were asked to consider a number of visual illustrations of risk (Figure 
14) and encouraged to discuss how they felt about each one and which they would 
find most useful if it was included in the next revision of the app.  Interviews were 
audio recorded, data were transcribed verbatim and managed using NVivo software.   















7.2. Study procedures – Women’s experience study 
 
7.2.1. Participant selection and recruitment 
 
A number of cohort study participants, who had indicated on the PETRA Part 1 consent 
form they were willing to be contacted, were invited to participate in the women’s 
experience study.  Willing participants were given written information to consider 
before an interview was arranged.  In an effort to capture the experience of a wide 
variety of women, a purposive sampling strategy was used.   Sample size was 
determined using maximum variation sampling (Patton, 2005) in order to explore the 
experiences of women with different backgrounds (e.g. ethnicity, parity), risk factors 
(e.g. no known risk factors, previous preterm birth) and interventions (e.g. discharge, 
hospitalisation). Required sample size was estimated to be 20-30 (Bourgeault et al., 
2010), however, no new themes appeared to be emerging after 19 interviews, so data 





Participants received care at a large inner city teaching hospital which provides a 
specialist service for women at risk of preterm birth.  The team, led by an 
internationally renowned expert in the field, offers clinical care through their preterm 
surveillance clinic and provides information and advice for both women and clinicians, 
locally and nationally. 
 
 





7.2.3. Data collection 
 
Data were collected through semi-structured, one-to-one interviews which were 
carried out by myself between March 2015 and January 2017.  Following the taking of 
written informed consent, participants were asked to talk about their experience and 
views on their care and any interventions they may have received.    Interviews took 
place in a private room in the hospital or at home, at a time convenient to the 
participant as soon as possible after the initial assessment for TPTL, in order to reduce 
the chance of recall bias.  The interviews lasted approximately one hour and were 
recorded, with participants’ consent, on digital audio equipment.  The interviews were 
then transcribed, by myself and a professional transcriber, and prepared for analysis. 
 
As discussed in Section 1.7, the ways people perceive risk can be substantially 
different.  The ongoing PETRA study provided the opportunity to discuss different 
visual illustrations of risk with women who had experienced threatened preterm 
labour and to explore their views. The findings were then used to inform development 
of the second version of the QUIPP app.  An amendment to the interview schedule of 
the ongoing qualitative study was submitted in order to capture the women’s views on 
proposed illustrations.  All women interviewed following REC approval of the 
amendment, as outlined in Section 5.4, (n=10) were asked to consider a selection of 
cards showing different ways of visually illustrating risk (Figure 14) and to elaborate on 









7.2.4. Interview schedule  
 
The interview schedule (Appendix 17.4) was designed following literature review, 
consultation with clinical colleagues and in collaboration with the local preterm birth 
studies PPI panel.  A second version of the interview schedule which included extra 
questions about visual illustrations of risk was used following Research Ethics 
Committee amendment approval (Section 5.4).  
 
7.3. Data analysis 
 
Alongside the Qualitative Description method, the Framework Approach (Ritchie and 
Spencer, 1994) was used for data analysis.  This approach was developed by 
researchers at the National Centre for Social Research as a method to manage and 
analyse qualitative data in policy research where aims are highly focused and topic 
guides structured to allow for exploration of specific a priori issues.  (Smith and Firth, 
2011).    Although similar to thematic analysis, Framework allows the researcher to 
easily explore the data by theme or by case and guides the researcher through a 
transparent, systematic process which enhances rigour and therefore the credibility of 
the findings (Smith and Firth, 2011).   The key features of the Framework Approach are 
that it is: 
i) Grounded or generative:  it should be heavily based in, and driven by, 
the original accounts and observations of the participants. 
ii) Dynamic: it is open to addition and amendment throughout. 
iii) Systematic: allowing methodical treatment of all similar units of 
analysis. 
iv) Comprehensive: allowing full review of the material. 





v) Enables easy retrieval and access to the original material. 
vi) Allows between and within case analysis: enabling comparisons and 
associations to be made. 
vii) Accessible to others: so that the analytic process, and the resulting 
interpretations, can be viewed and evaluated by others. 
 
Framework shares a similar approach to thematic data analysis, with five key stages, 
which are:   
1) Familiarisation of the data: where the researcher listens to the interview 
recordings and reads and re-reads the transcripts.  
2) Identification of a thematic framework:   which can be drawn from a priori 
issues drawn from the research aims, new issues raised by the 
participants’ testimonies or analytic themes arising from patterns of 
issues identified as the analysis progresses.  
3) Indexing: (or coding) of the data.  
4) Charting: where codes are organised into categories and themes. 
5) Mapping and interpretation: where cases, categories and themes are 
considered in relation to each other and the researcher attempts to bring 
the key characteristics of the data together and interpret the data set as a 
whole. 
 
Analysis of the data collected for the qualitative parts of this study followed these 
stages.  As soon as possible after the interviews had been carried out and transcribed, I 
listened and re-listened to the recordings whilst reading through the transcripts.  I 
used NVivo qualitative data management software (version Pro.v11) and before 
reviewing each interview I created a memo for each participant, where I documented 
participant characteristics, my thoughts and reflections on the interview itself, where it 





had occurred, how long it had taken, how I perceived the participant had felt during 
the interview and any initial ideas and thoughts I had about emerging themes. 
 
I began coding the data and although I had an initial structure based on the elements 
of the interview schedule, the number of codes continued to expand at a considerable 
pace.  I created a “code book” where I listed and defined the meaning, as I interpreted 
it, and regularly reviewed the coding structure as it developed.  This code book was 
revised on several occasions as I started to organise the codes into categories and then 
the categories into themes.   
 
Throughout the process I also kept a research journal, where I documented my 
thoughts on emerging themes, relationships between cases, how issues I saw in the 
data related to the literature I had read on relevant topics, and where I felt issues were 
missing or not being discussed by the participants as much as I had expected.  I also 
reflected on how my experience as a midwife, and one that had worked with women 
at risk of preterm birth for several years, may be influencing my interpretation of the 
data. 
 
7.4. Demonstrating study rigour 
 
To demonstrate study rigour, a framework proposed by Whittemore et al. (2001) for 
ensuring rigour in generic qualitative studies was chosen. This framework consists of 
four elements, and are described by Milne and Oberle (2005, p.414) as:   
(1) Authenticity, or attention to the voices of participants.  
(2) Credibility, a reﬂection of how believable results are.  





(3) Criticality, the critical appraisal of every decision made throughout the 
research process. 
(4) Integrity, demonstrated by on-going reﬂection and self-criticality of the 
researcher. 
 
The rigour of this study is demonstrated in the following sections that pair: 
Authenticity and Credibility, and Criticality and Integrity, as suggested by Milne and 
Oberle (2005): 
“The credibility of a qualitative study is a factor of strategies to promote 
authenticity, the ability to remain true to the phenomenon under study, 
while the integrity is a reﬂection of its criticality, or the attention paid to 
each and every research-related decision.” (p.414). 
 
7.4.1. Authenticity and Credibility 
 
A starting point for evaluating the authenticity and credibility of a qualitative study’s 
findings is whether, and to what extent, the research question has been answered.  In 
the qualitative parts of this study, the aim was to explore clinicians’ experience of the 
first version of QUIPP and women’s experience of TPTL and the factors that affected 
that experience.   In order to answer the research questions, then, it was important to 
explore the experience of a variety of enough clinicians and women with different 
experiences and backgrounds, to allow them to speak freely and comprehensively 
about their experience, and to ensure that the process of analysing the data 
represented these experiences accurately. 
 





It was important to first recruit an appropriate and varied selection of participants who 
had had the experience in question.  The purposive, maximum variation sampling 
strategy allowed for a constant review of participant characteristics, including parity, 
ethnicity and preterm birth risk, which ensured that the final participant group 
consisted of women with a variety of backgrounds and experience.   The semi-
structured interview method and interview schedule allowed participants to talk 
freely, and the women to reflect and talk, in their own words, while keeping focused 
on the TPTL experience.  The use of probing, for clarity and depth, ensured that the 
recounting of the experience was as complete as possible.  In terms of whether 
enough participants were recruited, it is customary in qualitative research that data 
collection continues until no new themes appear to be emerging from the data, a 
phenomenon commonly known as “data saturation”.  Whether this can ever truly 
occur, however, is open to debate. As Milne and Oberle (2005) point out:  
“Theoretical saturation means that a qualitative sample may be 
considered adequate when data inform existing ﬁndings but do not add 
anything new to them.  True saturation, however, may be a myth in that a 
second interview with the same participants could yield new information.” 
(p.415) 
 
So, whilst accepting that true “saturation” may be impossible, in this study it became 
obvious, after ten QUIPP app users and nineteen women had been interviewed, that 
the main issues important to participants had been identified.  
 
Ensuring that participants’ perspectives are accurately represented in the analysis is 
more difficult, but use of a systematic method of data management and analysis, and 





reporting of the steps taken, can make evaluation easier and adds credibility to the 
findings.    
 
The analysis process begins with the transcribing of the interviews verbatim.  In this 
study, while for most cases, this was carried out by a professional transcriber, I listened 
to the recordings and read through the transcripts as soon as they were available, 
checking them for accuracy, dealing with errors and omissions, if my memory was 
certain, in any areas of text where the recording had been unclear to the transcriber.  
Because I had taken field notes and recorded memos about the interviews, I was able 
to maintain a sense of context and relate the actual words spoken by the participants 
to feelings and unspoken language not always apparent in the written transcripts or 
even the sound recordings. 
   
Another factor that contributes to the credibility of the study is the credibility of the 
researcher, and how capable they are of carrying out a study and producing a report of 
quality.  Although a novice qualitative researcher, this being my first qualitative study, I 
have been fortunate to have had the opportunity to undertake high quality training in 
qualitative methods, organised not just by KCL (Advanced Qualitative Methods, Spring 
2015;  Qualitative Data Analysis, Summer 2016; Introduction to NVivo workshop); but 
also the National Centre for Social Research (NatCen) (Depth Interview Skills, May 
2015; Introduction of Framework in NVivo, Nov 2015); the University of Surrey (2 day 
NVivo workshop, Jan 2016) and Social Research Association (SRA) (Reporting 
Qualitative Data, Dec 2017). 
 








7.4.2. Criticality and Integrity 
 
The authenticity and credibility of a qualitative study are also dependent on integrity, 
which can only be evaluated, let alone established, if there is evidence of constant 
critical appraisal of every aspect of the study.  It is particularly important that 
consideration is given to how the researcher themselves may influence both what the 
participant says, as well as how it is interpreted.  This is often described, in qualitative 
research, as reflexivity, which can be defined as: 
 
“…thoughtful, conscious self-awareness. Reflexive analysis in research 
encompasses continual evaluation of subjective responses, intersubjective 
dynamics, and the research process itself. It involves a shift in our 
understanding of data collection from something objective that is 
accomplished through detached scrutiny of “what I know and how I know 
it” to recognizing how we actively construct our knowledge.” (Finlay, 2002, 
p.532). 
 
Being a midwife, with experience of working with women at risk of preterm birth, may 
have been an advantage and contributed to accuracy of the interpretation.  However, 
in other ways, preconceived ideas and understanding may have influenced my 
understanding of the women’s experience and led to bias in the analysis.  I was aware 
of this possibility from the beginning and endeavoured to minimize this by constantly 
questioning myself as to whether I was truly representing the voices of women or 
merely reporting what I expected to hear. 






Another method of ensuring integrity, as well as accuracy, in qualitative data collection 
is to feedback to the research participant and ask them to confirm, or refute, whether 
what they see in the report is a true representation of their experience.  This is 
difficult, however once the data has been synthesised as the participant may not 
recognise their own individual experience.  Additionally, later understanding of their 
experience may be affected by recall bias and may differ after further reflection, time 
and, indeed, the outcome of their pregnancy.  In this study, attempts to confirm that 
data collection reflected the true experience were made at the end of every interview, 
when the researcher summarised the issues raised and asked the participant to 
confirm whether the summary was correct and whether there was anything else they 
wanted to add. 
 
Peer review is also an important part of establishing integrity in qualitative research.  A 
proportion of transcripts, and identification and development of categories and 
themes, were regularly reviewed by, and discussed with, an academic supervisor.   
Interim findings were periodically presented at meetings of the preterm birth studies 
PPI panel, which comprised of women with experience of TPTL and preterm birth.  
Panel members were asked to reflect on the findings and their feedback was taken 
into consideration in further development of the thematic structure and final analysis.  






8. Results 1: Prospective cohort study 
 
8.1. Recruitment over time  
 
Recruitment commenced at the main site, GSTfT, in March 2015.  Delays with local 
governance approvals meant additional sites were unable to start until 10 months 
later, which resulted in monthly recruitment targets being missed. Despite these 
delays, however, recruitment rates improved and final target was met, on time, at end 
of October 2017. Figure 15 shows recruitment compared to monthly target along with 
indicators when new sites commenced recruitment. 
 
8.2. Recruitment by site 
 
By the end of cohort study recruitment, 11 sites were participating. Table 13 shows 
start dates and total recruitment for each site. 
 
Table 13. PETRA cohort study recruitment numbers and percentages by site with 
start dates. 
 
NHS Trust Site name Start date n= % 
Guy’s & St Thomas’ St Thomas'  04/03/2015 560 47 
Northumbria Healthcare Northumbria  11/01/2016 17 1 
Isle of Wight St Mary's, IOW 08/02/2016 55 5 
Royal Devon & Exeter Exeter 09/02/2016 16 1 
Pennine Acute Hospitals Pennine 19/02/2016 215 18 
University College London Hospital UCLH 01/07/2016 174 15 
City Hospitals Sunderland Sunderland  31/08/2016 63 5 
Airedale NHS Foundation Trust Airedale 10/02/2017 37 3 
Kingston Hospital Kingston 15/02/2017 21 2 
Royal Cornwall Hospital Truro 17/02/2017 9 1 
South Tees Hospitals South Tees 05/05/2017 19 2 







Figure 15. PETRA study recruitment numbers (red line) plotted against target recruitment (green line) and month additional sites started. 






8.3. Final recruitment process and numbers 
 
.   As explained in Section 6.5, each site devised its own screening strategy. Figure 16 
shows flow of potential participants at St Thomas’ only. 
 
Figure 16. Flow chart showing number of women screened and approached at main 
site, St Thomas’, with outcome of approach. 
 
Of the 1143 women who were screened for eligibility, it was not possible to pursue 
450 for consent.  When women were discharged before they could be recruited, 
hospital records were checked for further opportunities to approach them (i.e. further 
antenatal hospital appointments) an average of 7.9 times (range 1-17).  The number of 
times depended on gestation at testing and delivery. For example, if a woman was 34+6 
weeks pregnant at testing, and delivered at 38 weeks, records were checked 3 times.  





Despite these efforts, 207 women delivered before they could be approached. Other 
reasons why potential participants were not approached are shown in Table 14. 
Table 14. Number of women screened at main site with reasons for non-recruitment. 
 
Number of women screened at St Thomas’  
  
 n % 
Unable to identify hospital number 114 10.0% 
Not booked at this hospital 126 11.1% 
Delivered before could be approached 207 18.2% 
Clinician was not happy for the woman to be approached 3 0.3% 
Total number of women approached 693 60.8% 
TOTAL 1143 100% 
 
Of the 693 women who were approached, 560 (80.8%) consented, 49 (7.1%) declined 
and 84 (12.1%) were subsequently deemed ineligible. Of the 84 ineligible women: 13 
had had inappropriate symptoms; 16 were unable to understand English sufficiently; 
five were outside the gestation range (where it had not been previously confirmed) 
and two were subsequently diagnosed with spontaneous ruptured membranes.  In 
addition, one woman was ineligible because she had been diagnosed with established, 
rather than threatened, preterm labour, one was under 18 years old, one was planning 
to move outside the UK for delivery and one had learning disabilities and her ability to 
give informed consent was unclear.  
 
Of those who declined (n=49), 34 women did not provide a reason, eight had concerns 
about confidentiality, three were too busy or too stressed, three “just didn’t want to 
do research” and one declined because her husband did not want her to take part. 
 
 





8.4. Participants  
 
The full dataset including participants from all sites, was finalised after exclusions, as 
shown in Figure 17.  Participants were excluded if: i) they did not have at least one 
valid visit (i.e. no qfFN or CL test or inappropriate symptoms); ii) they had reported 
sexual intercourse within 24 hours of qfFN test (as this is known to interfere with fFN 
test results); iii) their pregnancy outcome was unknown; iv) their baby was found to 
have a major congenital abnormality that may have affected their risk of preterm birth 
(as listed in Table 15) or v) they had an iatrogenic preterm birth (e.g. for preeclampsia 
or other clinical indication for terminating the pregnancy preterm).   
 
Table 15. Participants excluded for major fetal congenital abnormality with details of 
abnormality. 
 
Participant  Major congenital abnormality details 
A Absent cavum septum pellucidum, possible mild facial dismorphism and mild 
dolichocephaly 
B Congenital diaphragmatic hernia  
C Congenital heart disease (double outlet right ventricle, VSD and coarctation of the aorta). 
D Congenital malformation of lung, respiratory system, patent ductus arteriosis, patent 
formen ovale, renal dysplasia congenital scoliosis, talipes equinovarus 
E Congenital malformations of trachea 
F Costello syndrome (Dysmorphology) - SVT; Ventriculomegaly -Macroglossia 
G Downs Syndrome 
H Exomphalos minor, absent corpus callosum, bilateral diaphragmatic hernia with small 
lung. Suspect Donnai Barrow Syndrome 
I Gastroschisis 
J Gastroschisis 
K Imperforate anus, congenital absence atresia/stenosis anus with fistula 
L Mitochondrial cytopathy with associated muscular hypotonia 
M Trachea oesophageal fistula 
N Trisomy 21 

































8.4.1. Participant characteristics – demographics 
 
Participant demographic characteristics are reported in Tables 16 and 17, below, 
stratified by the primary outcome, spontaneous onset of labour or premature rupture 
of membranes leading to preterm birth (sPTB), at less than 37 and 34 weeks 
respectively. There were no neonatal deaths in any group. 
Table 16. Comparison of participant demographic characteristics by birth at term and 
spontaneous preterm birth (sPTB) < 37 weeks’ gestation. 
 
 Term birth sPTB  
< 37 weeks 
p value All 
n (%) 912 (87.9) 125 (12.1)  1037 (100) 
  
Age – mean (SD) 30.7 (5.7) 30.3 (5.6) 0.683a 30.1 (5.7) 
BMI (kg/m2) – mean (SD) 26.2 (6.0) 25.7 (4.8) 0.336a 26.2 (5.9) 
  
n (%) 849 (88.0%) 116 (12.0%)  965 (100%) 
IMD deprivation score – 
mean (SD)†  31.2 (14.7) 30.7 (15.8) 0.706
a 31.1 (14.8) 
  
Ethnicity n  
(% within group) 
n 
(% within group) 
0.243b 
n 
(% within cohort) 
European 544 (87.3) 79 (12.7)  623 (60.1) 
African or Caribbean 200 (88.9) 25 (11.1)  225 (21.7) 
Asian 
(India/Pakistan/Bangladesh) 59 (83.1) 12 (16.9)  71 (6.8) 
Other (incl. Chinese) 109 (92.4) 9 (12.1)  118 (11.4) 
  
SD=standard deviation; BMI=Body Mass Index; IMD=Index of Multiple Deprivation. 
†some values missing 
a Independent samples t-test. 












Table 17. Comparison of participant demographic characteristics by birth after 34 
weeks and spontaneous preterm birth (sPTB) <34 weeks’ gestation. 
 
 Birth >34 
weeks 
sPTB  




n (%) 997 (96.1) 40 (3.9)  1037 (100) 
  
Age – mean (SD) 30.0 (5.7) 30.4 (5.7) 0.756 a 30.1 (5.7) 
BMI (kg/m2) – mean (SD) 26.2 (5.9) 25.9 (5.3) 0.738 a 26.2 (5.9) 
  
n (%) 928 (96.2%) 37 (3.8%)  965 (100%) 
IMD deprivation score – 
mean (SD)† 31.1 (14.8) 32.1 (15.4) 0.679
 a 31.1 (14.8) 
  
Ethnicity n 
(% within group) 
n 
(% within group) 
0.134 b 
n 
(% within cohort) 
European 599 (96.1) 24 (3.9)  623 (60.1) 
African or Caribbean 217 (96.4) 8 (3.6)  225 (21.7) 
Asian 
(India/Pakistan/Bangladesh) 65 (91.5) 6 (1.7)  71 (6.8) 
Other (incl. Chinese) 116 (98.3) 2 (1.7)  118 (11.4) 
  
SD=standard deviation; BMI=Body Mass Index; IMD=Index of Multiple Deprivation. 
†some values missing 
a Independent samples t-test. 
b Pearson Chi-Square Asymptotic Significance (2-sided). 
 
There was no difference between the groups, either at 37 or 34 weeks, in respect of 
age, BMI, IMD deprivation score or ethnicity. 
 
 
8.4.2. Participant characteristics – risk factors 
 
Participant risk factors are shown Tables 18 and 19, below, by spontaneous onset of 
labour or premature rupture of membranes leading to preterm birth at less than 37 
and 34 weeks’ respectively. 
 
 





Table 18. Comparison of participant risk factors by gestation at term and spontaneous 





< 37 weeks 
 All 
n (%) 912 (87.9) 125 (12.1)  1037 (100) 
  











Major risk factors 
 
At least one major risk factor 209 (72.8) 78 (27.2) <0.001 287 (27.7) 
Previous PTB < 37 weeks 116 (79.5) 30 (20.5) 0.001 146 (14.1) 
Previous PPROM < 37 weeks 57 (71.3) 23 (28.8) <0.001 80 (7.7) 
Previous late miscarriage  44 (77.2) 13 (22.8) 0.014 57 (5.5) 
Cervical surgery 40 (72.7) 15 (27.3) 0.001 55 (5.3) 
Uterine abnormality 10 (76.9) 3 (23.1) 0.199 13 (1.3) 
Twin pregnancy 16 (41.0) 23 (59.0) <0.001 39 (3.8) 
  
Other risk factors (Past or present history of): 
  
Recurrent UTI in pregnancy 91 (87.5) 13 (12.5) 0.492 104 (10.0) 
Group B Strep 123 (89.1) 15 (10.9) 0.384 138 (13.3) 
Bacterial Vaginosis 60 (83.3) 12 (16.7) 0.145 72 (6.9) 
APS/Lupus antibodies 18 (90.0) 2 (10.0) 0.559 20 (1.9) 
Fibroids 39 (92.9) 3 (7.1) 0.233 42 (4.1) 
Domestic Violence 55 (88.7) 7 (11.3) 0.940 62 (6.0) 
Recreational drug use  36 (87.8) 5 (12.2) 0.563 41 (4.0) 
Current smoking 110 (87.9) 20 (12.1) 0.136 130 (12.5) 
  
PTB=preterm birth; PPROM=prelabour preterm ruptured membranes; UTI=urinary tract infection. 
APS=antiphospholipid syndrome. 














Table 19. Comparison of participant risk factors by birth after 34 weeks’ and 





< 34 weeks 
 All 














Major risk factors 
 
At least one major risk factor 261 (90.9) 26 (9.1) <0.001 287 (27.7) 
Previous PTB < 37 weeks 135 (92.5) 11 (7.5) 0.017 146 (14.1) 
Previous PPROM < 37 weeks 71 (88.8) 9 (11.3) 0.002 80 (7.7) 
Previous late miscarriage 51 (89.5) 6 (10.5) 0.019 57 (5.5) 
Cervical surgery 48 (87.3) 7 (12.7) 0.004 55 (5.3) 
Uterine abnormality 13 (100) 0 (0.00) 0.598 13 (1.3) 
Twin pregnancy 32 (82.1) 7 (17.9) <0.001 39 (3.8) 
  
Other risk factors (Past or present history of): 
  
Recurrent UTI in pregnancy 102 (98.1) 2 (1.9) 0.215 104 (10.0) 
Group B Strep 132 (95.7) 6 (4.3) 0.445 138 (13.3) 
Bacterial Vaginosis 71 (98.6) 1 (1.4) 0.218 72 (6.9) 
APS/Lupus antibodies 19 (95.0) 1 (5.0) 0.548 20 (1.9) 
Fibroids 42 (100) 0 (0.0) 0.185 42 (4.1) 
Domestic Violence 62 (100) 0 (0.0) 0.223 62 (6.0) 
Recreational drug use  41 (100) 0 (0.0) 0.193 41 (4.0) 
Current smoking 126 (96.9) 4 (3.1) 0.423 130 (12.5) 
  
PTB=preterm birth; PPROM=prelabour preterm ruptured membranes; UTI=urinary tract infection. 
APS=antiphospholipid syndrome. 
a Chi squared tests of significance 
 
There were statistically significant differences between women with and without 
major risk factors in both outcome groups. Women with any one of the major risk 
factors, apart from uterine abnormality, were more likely to have spontaneous 
preterm birth at both less than 37 and less than 34 weeks.  None of the other factors 
recorded for this study, identified in literature as potential risk factors for preterm 
birth, were found to be statistically significantly different in this cohort. 
 





8.4.3. Prevalence of preventive preterm birth interventions 
 
As demonstrated above, 27.7% of participants had at least one major risk factor, and 
may have been under the care of specialist preterm clinics.  This specialist care may 
have included regular surveillance (qfFN and TVS CL) with and without interventions 
intended to prevent preterm birth, such as progesterone therapy, cervical cerclage or 
Arabin pessary (a silicon ring placed around the cervix).   Although data on specialist 
clinic attendance and surveillance were not captured in this study, data on 
preventative interventions were recorded and are shown in Table 20. 
Table 20. Prevalence of preterm birth prevention interventions within cohort. 
 
 All participants* (n=1016) 
Intervention** No Yes (%) 
  
Progesterone 955 61 (6.0) 
Transvaginal cerclage 972 44 (4.3) 
Transabdominal cerclage 1008 8 (0.7) 
Arabin pessary 1010 6 (0.6) 
No intervention 101 915 (90.1) 
  
*where status known 
**some women may have had more than one intervention, therefore % totals do not equal 100% 
 
 
Unsurprisingly, women with at least one major risk factor for preterm birth were more 
likely to have had a preventative intervention (Table 21). 
Table 21. Comparison of preterm birth prevention interventions in women with and 






High (n=279) Low (n=737) p value a 
Intervention 
n (% of women 
with intervention)  
n (% of women 
with intervention)  
Progesterone (n=61) 44 (72.1) 17 (27.9) <0.001 
Transvaginal cerclage (n=44) 39 (88.6) 5 (11.4) <0.001 
Transabdominal cerclage (n=8) 8 (100) 0 (0.0) <0.001 
Arabin pessary (n=6) 5 (83.3) 1 (16.6) 0.007 
No intervention 199 (21.7) 716 (78.3) <0.001 
  a Pearson Chi squared test 





Interventions to prevent preterm birth were also more likely in women who 
experienced spontaneous preterm birth in this cohort (Table 22).  It is difficult to draw 
conclusions from these comparisons, however, as these interventions were much 
more likely in high risk women who were, of course, more likely to have preterm birth, 
and the aim of this study was not to evaluate the efficacy of these interventions.   
Table 22. Comparison of preterm birth prevention interventions in women with and 
without spontaneous preterm birth (sPTB) <37 weeks’ gestation. 
 
 
sPTB < 37 weeks 
 
 
Yes (n=125) No (n=912) p value a 
Intervention n (% of women 
with intervention)  
n (% of women 
with intervention)  
Progesterone (n=61) 24 (39.3) 37 (60.7) <0.001 
Transvaginal cerclage (n=44) 15 (34.1) 29 (65.9) <0.001 
Transabdominal cerclage (n=8) 1 (12.5) 7 (87.5) 0.652 
Arabin pessary (n=6) 3 (50.0) 3 (50.0) 0.027 
No intervention 89 (9.7%) 826 (90.3%) <0.001 
  a Pearson Chi squared test 
 
As these preventative interventions are intended to reduce risk of sPTB, although the 
number of women receiving them in this cohort was small, their use may have 
influenced the prediction algorithms.  
 
8.4.4. Participant characteristics by centre 
 
 
Although the proportions of participants by Index of Multiple Deprivation (IMD) 
quintile varied across the sites, as demonstrated by Figure 18, a comparison of mean 
IMD scores by centre did not show statistical difference (Figure 19).   
 
 






Figure 18.  Percentage distribution of Index of Multiple Deprivation (IMD) quintiles* by 
recruitment centre. 
*IMD_q1=IMD score falls within 1-20% in UK population, most deprived (orange); IMD_q2=IMD score 
within 21-40% (yellow); IMD_q3=IMD score within 41-60% (blue); IMD_q4=IMD score within 61-80% 





Figure 19. Box plots of mean Index of Multiple Deprivation (IMD) scores with 
confidence intervals, by recruitment centre. 
 






Overall, approximately 30% of women in this cohort were high risk (i.e. had at least 
one major risk factor) (Figure 20).  It appears that a larger proportion of participants 
from Truro were high risk (defined as having at least one major risk factor, however, 
the overall numbers for this site were small (total n=9). 
 
 
Figure 20. Participant risk status by recruitment site. Low risk=no major risk factors for 




8.5. Prediction of preterm birth by fFN and CL categories 
 
In this cohort, the utility of fFN test and CL by category was examined using Kaplan-
Meier Survival Analysis (Figures 21 and 22) and relative risks for sPTB at less than 34 
and 37 weeks’ gestation, and within 7 and 14 days of testing (Tables 23 and 24).  For 
the purposes of this analysis, the last TPTL assessment visit and test results were used.   
 
 






Figure 21. Kaplan-Meier survival curve showing probability of sPTB by fFN categories 0-
9, 10-49, 50-199, 200-499 and 500+ ng/ml. Where participant had more than one TPTL 




These data demonstrate increasing risk of sPTB with fFN categories higher than 50 
ng/ml and CL measurement of less than 15 mm, which correlates with findings from 
the current body of literature on the subject, except in the 500+ ng/ml category.  







Figure 22. Kaplan-Meier survival curve showing probability of sPTB by CL 
categories 25+, 15-24 and <15 mm. Where participant had more than one TPTL 
episode, the latest CL measurement is used.   † indicates censoring of deliveries at 
term (37 weeks’ gestation). 
 
Rates of sPTB outcomes by fFN and CL category are shown in Table 23, while relative 
risk between categories, using as reference categories fFN 0-9 ng/ml and CL 25 mm 
plus are show in Table 24.   These findings again confirm the higher the fFN and the 












Table 23. Number and rates (%) of spontaneous preterm birth (sPTB) at <34 and 37 
weeks’ gestation, and within 1 and 2 weeks of testing by fFN and CL categories. 
 
  Spontaneous preterm birth 
  
< 34 weeks < 37 weeks 
< 1 week of 
testing 
< 2 weeks of 
testing 
Predictive test N n (%) n (%) n (%) n (%) 
fFN category (1026 tests)  
<10 ng/ml 624 7 (1.1) 48 (7.7) 4 (0.6) 8 (1.3) 
10-49 ng/ml 210 5 (2.4) 17 (8.1) 0 (0.0) 0 (0.0) 
50-199 ng/ml 108 9 (8.3) 23 (21.3) 1 (0.9) 5 (4.6) 
200-499 ng/ml 74 17 (23.0) 32 (43.2) 14 (18.9) 19 (25.7) 
500 ng/ml plus 10 1 (10.0) 2 (20.0) 1 (10.0) 2 (20.0) 
CL category (226 tests)  
25 mm plus 130 5 (3.8) 19 (14.6) 2 (1.5) 5 (3.8) 
15-24 mm 46 2 (4.3) 12 (26.1) 0 (0.0) 3 (6.5) 
Less the 15 mm 50 20 (40.0) 31 (62.0) 9 (18.0) 13 (26.0) 
  




Table 24. Relative risk of spontaneous preterm birth (sPTB) at <34 and 37 weeks’ 
gestation, and within 1 and 2 weeks of testing by fFN and CL categories. 
 
 Spontaneous preterm birth 
 < 34 weeks < 37 weeks < 1 week of testing < 2 weeks of 
testing 
Predictive test RRa 95% CIb RRa 95% CIb RRa 95% CIb RRa 95% CIb 
fFN category          
10-49 ng/ml 2.1 0.7-6.6 1.1 0.6-1.8 3.016E-8† .000 1.508E-8† .000 
50-199 ng/ml 7.4 2.8-19.5 2.8 1.8-4.4 1.4 0.2-12.8 3.6 1.2-10.8 
200-499 ng/ml 20.5 8.8-47.8 5.6 3.9-8.2 29.5 10.0-87.3 20.0 9.1-44.1 
500 ng/ml plus 8.9 1.2-65.9 2.6 0.7-9.3 15.6 1.9-127.4 15.5 3.8-64.4 
         
CL category         
15-24 mm 1.1 0.2-5.6 1.8 0.9-3.4 1.257E-8 .000 1.7 0.4-6.8 
Less the 15 mm 10.4 4.1-26.2 4.2 2.7-6.8 11.7 2.6-52.3 6.8 2.5-18.0 
RR=relative risk, fFN=fetal fibronectin; CL=cervical length. 
afFN relative risk relative to fFN cat 0-9 ng/ml; CL relative risk relative to CL cat 25mm+ 
b95% Wald Confidence Intervals for Exp(B) 
† “set to system missing due to overflow” 
 
 
Although relative risk (RR) of sPTB generally rises as the fFN concentration increases, 
the RR of sPTB was lower in the fFN 500+ ng/ml than the 200-499 ng/ml category (8.9 
vs 20.5).  The 95% confidence interval is also particularly wide for the 500+ ng/ml 





category, most likely due to the small number of events in the group.  It is also possible 
that some test results were carried out within 24 hours of sexual intercourse, but they 
were not excluded because either the women did not disclose this information, or the 
attending clinician did not record it in the woman’s maternity notes.  
 
8.6. Interventions following TPTL assessment and healthcare utilisation  
 
Another aim of the PETRA study was to assess use of steroids and other management 
(e.g. admission, tocolysis, IUT).  Table 25 shows prevalence of these interventions 
within the whole cohort. 
 
Table 25. Prevalence of interventions, and number of antenatal day unit visits and 
antenatal ward nights in whole cohort. 
 
All participants 
Intervention  n* No (%) Yes (%) 
  
Steroids 1024 715 (69.8) 309 (30.2) 
Tocolysis 1022 936 (91.6) 86 (8.4) 
In utero transfer 1023 1002  (97.9) 21 (2.1) 
Admission to Neonatal unit 1015 896 (88.3) 119 (11.7) 
In Neonatal unit at 28 days 1015 999 (98.4) 16 (1.6) 
Antenatal day unit visits** – median (range) 1022 3 (0-33) 
Antenatal ward nights** – median (range) 1022 1 (0-87) 
*where intervention status is known. 
** Mann U Whitney non-parametric test was used for comparison as data not normally distributed. 
 
 
When these interventions, ADU visits and antenatal ward (ANW) nights were assessed 
by pregnancy risk factors, women with at least one major risk factor were more likely 
to have received all interventions, except for the number of antenatal day unit visits 
(Table 26).   
 





Table 26. Prevalence of interventions and numbers of antenatal day unit visits and 
antenatal ward nights by risk group. 
 Risk group 
 
 High (n=287) Low (n=750) p value* 
Intervention n (%) n (%) 
 
Steroids 129 (44.9) 180 (24.0) <0.001 
Tocolysis 36 (12.5) 50 (6.7) 0.007 
In utero transfer 13 (4.5) 8 (1.1) 0.001 
Neonatal unit admission 57 (19.9) 62 (8.3) <0.001 
In Neonatal unit at 28 days 10 (3.5) 6 (0.8) 0.003 
  Antenatal day unit visits* – median (range) 3 (0-22) 3 (0-33) 0.057 
Antenatal ward nights* – median (range) 2 (0-87) 1 (0-37) <0.001 




8.6.1. Steroid use by outcomes 
 
The use of steroids was examined in more detail than the other interventions as it was 
the most prevalent intervention in this cohort, and because of the increasing concern 
about its overuse in women with symptoms of threatened preterm labour.  Table 27 
shows steroid use by the outcomes of term delivery and sPTB or PPROM at <34 weeks’, 
<37 weeks’ gestation and within 1 week of testing. 
 
Table 27. Administration of steroids by spontaneous preterm birth (sPTB) <37, <34 










 n (%) n (%) n (%) n (%) n (%) 
Steroids - YES 216 (24.0) 93 (74.4) 36 (90.0) 18 (90.0) 309 (30.2) 
Steroids - NO 683 (76.0) 32 (25.6) 4 (10.0) 2 (10.0) 715 (69.8) 
TOTALS 899 (100) 125 (100) 40 (100) 20 (100) 1024 (100) 
 
 
Three quarters (74.4%) of women recruited to the study with TPTL resulting in PTB 
received steroids.  However, this was not necessarily within the crucial 7 day window 
where the benefits are optimal.  Reassuringly, 76% of women with TPTL but a term 





delivery did not receive steroids.  Of the 32 women who delivered preterm, but did not 
receive steroids, all were over 32 weeks, and 28 of them were over 34 weeks. 
 
Regarding administration of steroids within the optimum 7 days before delivery 
window, 90% of women (18/20) in TPTL who delivered within 7 days did receive 
steroids.  Of the two women who were not given steroids but did deliver within 7 days, 
one was 32+3, and the other was 34+6 weeks.  Of the women who did not deliver within 
7 days, 71.0% (713/1004) did not receive steroids (Table 28), which was appropriate 
management. 
 
Table 28. Number of women given steroids by delivery within 7 days of administration. 
 del >7 days del ≤ 7 days ALL 
 n (%) n (%) n (%) 
Steroids - YES 291 (29.0) 18 (90.0) 309 (30.2) 
Steroids - No 713 (71.0) 2 (10.0) 715 (69.8) 
TOTALS 1004 (100) 20 (100) 1024 (100) 
 
TPTL test results appear to have influenced steroid administration.  The NICE preterm 
labour guideline (NICE, 2015) recommends steroids are given to symptomatic women 
if they have a cervical length of less than 15 mm or a fetal fibronectin of 50 ng/ml or 
more.  Approximately 85% of women were treated according to the guideline (Table 
29) with 87.4% (181/207) receiving steroids, while 84.3% (689/817) with longer cervix 
or lower fetal fibronectin did not receive steroids. 
Table 29. Number of women given steroids according to NICE (2015) guidance (cervical 








n (%) n (%) n (%) 
Steroids - YES 128 (15.7) 181 (87.4) 309 (30.2) 
Steroids - NO 689 (84.3) 26 (12.6) 715 (69.8) 
TOTALS 817 (100) 207 (100) 1024 (100) 





8.6.2. Repeated courses of antenatal corticosteroids 
 
There is growing concern about the unnecessary administration of antenatal 
corticosteroids, particularly when repeated doses are given.  This is because there is an 
increasing body of evidence of possible long term harm to the children (Asztalos et al., 
2014; Murphy et al., 2008; Norberg et al., 2013).  In the PETRA cohort, of the 1024 
women where steroid administration status was known, 309 (30.2%) received steroids 
on at least one occasion.  In 289 cases, they had received the full course (2 doses 12-24 
hours apart).   Reassuringly, only 14 women in this cohort required steroids for a 
second episode of TPTL, and of these 11 were “rescue” doses, i.e. only one dose was 
given, rather than the full course, as per American College of Obstetricians and 
Gynecologists (ACOG) guidelines (ACOG, 2017).  Three women had steroids three 
times, two of which had “rescue” doses. This was probably because they had not 
delivered within seven days of previous administration and the attending clinician felt 
a further dose, or course, was advised.  
 
 





8.7. Development and validation the QUIPP app risk prediction algorithms  
 
As explained in Section 1.8.3, the “training set” comprised all women included in the 
QUIPP app development carried out in June 2017, while the validation set comprised 
PETRA participants whose outcomes were gathered after this time point and were not 
included in the training set.  The master “training” dataset included symptomatic 
women between 23+0 and 34+6 weeks’ gestation, with and without risk factors. After 
exclusions, 1173 observations from 1032 women with fFN test results and 229 
observations from 204 women (with both fFN and CL) were available for analysis.  
Twenty four sets of twins were included, where the first baby outcomes were used in 
the analysis. 
 
8.7.1. Participant characteristics of the training and validation sets 
 
None of the predetermined demographic factors affected prediction of sPTB.  In 
testing the model with the cohort of women who had both fFN and CL test results, 
multivariate regression showed that only previous cervical surgery provided additional 
predictive power to fFN and CL test results in women with symptoms of TPTL.   
However, the composite of risk factors used in the asymptomatic prediction algorithm 
for the QUIPP app (i.e. multiple pregnancy, history of sPTB or PPROM, late miscarriage 
or cervical surgery) was tested to establish whether it affected the prediction in the 
symptomatic model.  There was little difference, so a decision was made to use the 
composite of risk factors for the symptomatic algorithms for consistency. 
   





Participant characteristics for each set are shown in Tables 30 and 31.  The sets were 
further split and analysed by groups of women who had had fFN, CL and both tests. 
Whether differences are significant or not between the groups in training and 
validation sets is not important.  If they are too similar the test is not necessarily useful 
in other cohorts. The best test would work in all situations with all cohorts (Altman and 
Royston, 2000). 
Table 30. Demographic characteristics of women in the predictive model training and 
validation sets. 
 Training  





AGE                                                            n=                                            
n= 
1032 506 1538 
mean (SD) 29.9 (5.7) 29.8 (6.0) 29.9 (5.8) 
BMI (kg/m2)                                             n=                                                
n= 
1025 506 1531 
mean (SD) 26.1 (5.9) 26.0 (6.1) 26.1 (5.9) 
IMD deprivation score                            
n=             n= 
947 504 1451 
mean (SD) 31.3 (13.5) 30.2 (15.2) 30.1 (14.1) 
ETHNICITY                                                 n=                                                
n= 
1024 (%) 506 (%) 1530 (%) 
European 562 (54.9) 326 (64.4) 888 (58.0) 
African or Caribbean 70 (6.8) 33 (6.5) 103 (6.7) 
Asian (India/Pakistan/Bangladesh) 277 (27.1) 92 (18.2) 369 (24.1) 
Other (incl. Chinese) 115 (11.2) 55 (10.9) 170 (11.1) 
  
SD=standard deviation; BMI=Body Mass Index; IMD=Index of Multiple Deprivation. 
†Numbers in groups differ when data is missing. 
 
 




Validation set      




  n (%) n (%) n (%) 
Previous PTB < 37 weeks 158 (15.3) 83 (16.4) 241 (15.7) 
Previous PPROM < 37 weeks 74 (7.2) 34 (6.7) 108 (7.0) 
Previous late miscarriage  79 (7.7) 13 (2.6) 92 (6.0) 
Cervical surgery 65 (6.3) 26 (5.1) 91 (5.9) 
Twin pregnancy 41 (4.0) 33 (6.5) 74 (4.8) 
   
PTB=preterm birth; PPROM=prelabour preterm ruptured membranes. 
 





As explained in Methods section 6.9.4, three algorithms were developed so that the 
QUIPP app could be used in different scenarios, i.e. when a women has: i) fFN testing 
alone, ii) CL measurement alone, or iii) both tests.  Data were, therefore sub-divided 
and are presented in these three groups.  Tables 32, 33 and 34 (one table for each 
group) show the similarity or differences in fFN concentration and CL measurement 
between the training and validation sets.  In the fFN group, data was included from 
1,534 women having had 1749 fFN tests: 1,173 (from 1,032 women) in the training set 
and 576 (from 502 women) in the validation set.   
 
Table 32. Number of women by fetal fibronectin (fFN) concentration category for 
training and validation sets in the group of women who have had fFN test. 
 
fFN test group 
Training set    
n=1173  
(1032 women) 
Validation set       
n=576    
(502 women) 
Comparison  
 (95% CI)  
p= 
 median* (quartiles) median* (quartiles)    
 5.0 (2.0, 26.0) 8.0 (4.0, 44.5) 2.0 (3.0, 1.0) <0.001 
fFN category n (%) n (%) RR (95% CI) 0.264 
< 10 ng/ml 704 (60.0) 317 (55.0)    
10 – 19 ng/ml 128 (10.9) 64 (11.1) 1.09 (0.83-1.44)  
20 – 49 ng/ml 118 (10.1) 61 (10.6) 1.12 (0.85-1.49)  
50 – 99 ng/ml 72 (6.1) 36 (6.3) 1.10 (0.75-1.61)  
100 – 199 ng/ml 59 (5.0) 40 (6.9) 1.45 (0.99-2.12)  
200 ng/ml + 92 (7.8) 58 (10.1) 1.34 (0.99-1.82)  
        
*median is used as more appropriate than mean, as distribution of fFN is skewed. 
RR = risk ratio as compared to reference group < 10 ng/ml.  
 
Overall the median of the fFN concentration differed between the training and 
validation groups.   However, the proportion of women in each fFN category did not 
differ significantly.    
 





In the CL measurement group, data was included from 336 women having had 344 CL 
measurements. 229 (from 204 women) in the training set and 155 (from 132 women) 
in the validation set.   
 
Table 33. Number of women by cervical length (CL) measurement category for training 
and validation sets in the group of women who have had CL measurement. 
 
CL test group 
Training set  
n=229  
(204  women) 
Validation set      
n=155 
(132  women) 
Comparison (95% CI)  p value 
 mean (SD) mean (SD)    
 25.2 (12.7) 25.7 (12.7) 0.54 (-2.1-3.13) 0.685 
CL length category n (%) n (%) RR* (95% CI) 0.377 
< 15 mm 56 (24.5) 36 (23.2)    
15 – 24 mm 48 (21.0) 42 (27.1) 1.17 (0.87-1.56)  
25 mm + 125 (54.6) 77 (49.7) 0.99 (0.84-1.16)  
 
       
*RR = risk ratio as compared to reference group < 15 mm  
 
 
The proportion of women in each CL category did not differ significantly between 
training and validation sets.  Where women had had both fFN and CL test, data was 
included from 332 women having had 372 CL measurements. 229 (from 204 women) 




















Table 34. Number of women in fetal fibronectin (fFN) and cervical length (CL) 
categories for training and validation sets in the group of women who have had both 
tests. 
 




Validation set       
n=143 
(128 women) 
Comparison       
(95% CI)  
P 
value 
fFN concentration median* (quartiles) median* (quartiles)    
 14.0 (4.0, 101.0) 32.0 (5.0, 162.0) 3.0 (7.0, 0.0) 0.027 
fFN category n (%) n (%) RR* (95% CI) 0.433 
< 10 ng/ml 99 (43.2) 57  (39.9)    
10 – 19 ng/ml 24 (10.5) 9  (6.3) 0.70 (0.35-1.41)  
20 – 49 ng/ml 24 (10.5) 12  (8.4) 0.89 (0.48-1.67)  
50 – 99 ng/ml 23 (10.0) 15  (10.5) 1.11 (0.62-1.98)  
100 – 199 ng/ml 21 (9.2) 18  (12.6) 1.37 (0.78-2.40)  
200 ng/ml + 38 (16.6) 32  (22.4) 1.30 (0.88-1.91)  
        
CL measurement mean (SD) mean (SD)    
 25.2 (12.7) 25.7 (12.8) 0.49 (-2.18-3.17) 0.717 
CL length category n (%) n (%) RR* (95% CI) 0.446 
< 15 mm 56 (24.5) 34 (23.8)    
15 – 24 mm 48 (21.0) 38 (26.6) 1.14 (0.85-1.55)  
25 mm + 125 (54.6) 71 (49.7) 0.98 (0.83-1.15)  
        
*RR = risk ratio as compared to reference group <10 ng/ml for fFN and reference group < 15 mm for CL  
 
Again, overall the median of the fFN concentration differed between the training & 
validation groups.   However, the proportion of women in each fFN category did not 
differ significantly between training and validation sets, and neither did the proportion 
of women in each CL category. 
 
 
8.7.2. Comparison of outcomes in the training and validation sets 
 
The prevalence of outcomes of spontaneous preterm birth at 30, 34 and 37 weeks’ 
gestation, and at or less than 7 and 14 days of test for each of the test groups, and 
between training and validation sets are shown in Tables 35, 36 and 37. 






Table 35. Number of tests in the fetal fibronectin test group with outcomes by training 
and validation set and spontaneous preterm birth (sPTB) at less than 30, 34 and 37 
weeks’ gestation and within 1 and 2 weeks of testing. 
 
Women with fFN test 
 Training set Validation set 
sPTB Total n=sPTB (%)  95% CI Total n=sPTB (%) 95% CI 
<30wk* 574 22 (3.8) 2.4-5.7 272 10 (3.7) 1.8-6.7 
<34wk** 1066 60 (5.6) 4.3-7.2 520 26 (5.0) 3.3-7.2 
<37wk 1173 144 (12.3) 10.5-14.3 576 68 (11.8) 9.3-14.7 
<1wk 1173 15 (1.3) 0.7-2.1 576 13 (2.3) 1.2-3.8 
<2wk 1173 38 (3.2) 2.3-4.4 576 18 (3.1) 1.9-4.9 
 
 
Table 36. Number of tests in the cervical length group with outcomes by training and 
validation set and spontaneous preterm birth (sPTB) at less than 30, 34 and 37 weeks’ 
gestation and within 1 and 2 weeks of testing. 
 
Women with CL test 
 
Training set Validation set 
sPTB Total n=sPTB (%) 95% CI Total n=sPTB (%) 95% CI 
<30wk* 147 17 (11.6) 6.9-17.9 92 9 (9.8) 4.6-17.8 
<34wk** 214 41 (19.2) 14.1-25.1 150 17 (11.3) 6.7-17.5 
<37wk 229 69 (30.1) 24.3-36.5 155 32 (20.6) 14.6-27.9 
<1wk 229 8 (3.5) 1.5-6.8 155 7 (4.5) 1.8-9.1 
<2wk 229 21 (9.2) 5.8-13.7 155 8 (5.2) 2.3-9.9 
 
 
Table 37. Number of tests in the fetal fibronectin test and cervical length group with 
outcomes by training and validation set and spontaneous preterm birth (sPTB) at less 
than 30, 34 and 37 weeks’ gestation and within 1 and 2 weeks of testing. 
 
Women with fFN and CL test 
 
Training set Validation set 
sPTB Total n=sPTB (%) 95% CI Total n=sPTB (%) 95% CI 
<30wk* 147 17 (11.6) 6.9-17.9 83  8 (9.6) 4.3-18.1 
<34wk** 214 41 (19.2) 14.1-25.1 138  16 (11.6) 6.8-18.1 
<37wk 229 69 (30.1) 24.3-36.5 143  31 (21.7) 15.2-29.3 
<1wk 229 8 (3.5) 1.5-6.8 143  7 (4.9) 2.0-9.8 
<2wk 229 21 (9.2) 5.8-13.7 143 8 (5.6) 2.4-10.7 
*some women were recruited after 30 weeks therefore not included here.  
**some women were recruited after 34 weeks therefore not included here. 
 





As demonstrated by the 95% confidence intervals shown on these tables, the 
prevalence of the outcomes in the training and validation sets is similar in all test 
groups.  This is confirmed by the overlap of confidences intervals in all outcomes. 
 
 
8.7.3. Predictive statistics 
 
 
The prediction models created generated formulae that provide individual risk scores 
dependent on risk factors and test results (Appendix 17.5).  Predictive statistics were 
calculated using a % risk of ≥5% as an indication of a positive test.  Tables 38, 39 and 40 
show predictive statistics when the algorithms are tested on both the training and 
validation set, by test group (fFN, CL and fFN+CL) for prediction of sPTB at less than 30, 



















Table 38. Predictive statistics for spontaneous preterm birth (sPTB) at less than 30, 34 
and 37 weeks’ gestation and within 1 and 2 weeks of testing in the group of women 
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Table 39. Predictive statistics for spontaneous preterm birth (sPTB) at less than 30, 34 
and 37 weeks’ gestation and within 1 and 2 weeks of testing in the group of women 
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Table 40. Predictive statistics for spontaneous preterm birth (sPTB) at less than 30, 34 
and 37 weeks’ gestation and within 1 and 2 weeks of testing in the group of women 
with both fetal fibronectin (fFN) and cervical length (CL) by training and validation set. 
 
fFN test + 
CL group 
sPTB at less than sPTB within 
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0.00 - 0.14 
(0.04-
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Validation 0.00 - 0.16 
(0.02-
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Tables 39 to 40 show a reasonable similarity between the training and validation sets 
at most outcome time points and for each of the test (fFN, CL, fFN+CL) groups.  In the 
fFN group (the largest group) the ability of the algorithms to predict sPTB at less than 
30 weeks’ gestation appears to be most impressive with, in the validation set, a 
sensitivity of 90.0%, specificity of 90.8%, a positive likelihood ratio (LR+) of 9.83, a 
negative likelihood ratio (LR-) of 0.11, positive predictive value (PPV) of 27.3% and a 
negative predictive value (NPV) of 99.6%.    
 
While the balanced accuracy statistics noted in Tables 39 to 40 above reflect the 
balance of sensitivity and specificity using the 5% risk cut off, the ROC curves shown in 
Figures 23, 24 and 25 indicate overall test performance, using validation set only, at all 





Figure 23. ROC curves showing QUIPP app prediction of spontaneous preterm birth (sPTB) at less than 30, 34 and 37 weeks’ gestation and 
within 1 and 2 weeks of testing in the group of women with fetal fibronectin (fFN) test results in the validation set. 






Figure 24. ROC curves showing QUIPP app prediction of spontaneous preterm birth (sPTB) at less than 30, 34 and 37 weeks’ gestation and 
within 1 and 2 weeks of testing in the group of women with cervical length (CL) in the validation set. 






Figure 25. ROC curves showing QUIPP app prediction of spontaneous preterm birth (sPTB) at less than 30, 34 and 37 weeks’ gestation and 




For the fFN test group, the AUC for predicting sPTB at less than 30 weeks’ indicates 
good prediction, at 0.9634, with similarly impressive AUCs for predicting sPTB at less 
than 1 week and 2 weeks post-test. Confidence intervals here are also relatively 
narrow which means it is very likely that similar results would be seen in a similar 
population (Tables 41). 
 
 
Table 41. ROC curve statistics table showing QUIPP app prediction of spontaneous 
preterm birth (sPTB) at less than 30, 34 and 37 weeks’ gestation and within 1 and 2 
weeks of testing in the group of women with fetal fibronectin (fFN) test in the 
validation set. 
 
fFN test group 
Prediction of sPTB  n AUC Std Err 95%CI 
<30 weeks 272 0.9634 0.0128 (0.93821-0.98851) 
<34 weeks 520 0.8500 0.0353 (0.78069-0.91925) 
<37 weeks 576 0.7711 0.0307 (0.71088-0.83127) 
<1 week 576 0.9147 0.0224 (0.87080-0.95869) 
<2 weeks 576 0.9190 0.0222 (0.87541-0.96250) 
 
The risk prediction algorithm using cervical length appears to perform best at 
prediction of sPTB < 30 weeks, but this is inferior to the fFN test (Table 42).  
 
Table 42. ROC curve statistics table showing QUIPP app prediction of spontaneous 
preterm birth (sPTB) at less than 30, 34 and 37 weeks’ gestation and within 1 and 2 
weeks of testing in the group of women with cervical length (CL) in the validation set. 
 
CL group 
Prediction of sPTB  n AUC Std Err 95%CI 
<30 weeks 92 0.8568 0.0731 (0.71357-0.99995) 
<34 weeks 150 0.7935 0.0534 (0.68885-0.89805) 
<37 weeks 155 0.7175 0.0503 (0.61894-0.81602) 
<1 week 155 0.6950 0.1274 (0.44531-0.94465) 










When both test results are combined, the prediction improves, but is inferior to fFN 
alone at all time points (Table 43).   
 
Table 43. ROC curve statistics table showing QUIPP app prediction of spontaneous 
preterm birth (sPTB) at less than 30, 34 and 37 weeks’ gestation and within 1 and 2 
weeks of testing in the group of women with both fetal fibronectin (fFN) and cervical 
length (CL) in the validation set. 
 
fFN test + CL group 
Prediction of sPTB  n AUC Std Err 95%CI 
<30 weeks 83 0.9533 0.0276  (0.89914-1.00000) 
<34 weeks 138 0.8309 0.0520 (0.72912-0.93277) 
<37 weeks 143 0.7307 0.0512 (0.63040-0.83101) 
<1 week 143 0.8750 0.0555 (0.76623-0.98377) 






8.7.4. Risk prediction using results of  fFN test alone, CL alone and both test 
results 
 
In addition to development of the risk assessment tool, a primary aim of the PETRA 
study, further objectives included exploring the added value of CL in a UK setting.  This 
was investigated by creating ROC curves and comparing areas under the curve (AUC) in 
the validation set of women who had had both tests for difference outcomes, i.e. sPTB 
at less than 30, 34 and 37 weeks’ gestation, and at 1 and 2 weeks following the test 
(Figure 26 and Tables 44 to 48).   






Figure 26. ROC curves showing ability of QUIPP app to predict spontaneous preterm 
birth (sPTB) at less than 30, 34 and 37 weeks’ gestation and within 1 and 2 weeks of 
testing in the group of women with both fetal fibronectin (fFN) and cervical length (CL) 
in the validation set, based on fFN alone, CL alone, or combination of both tests. 
 







Table 44. Significance test comparing area under the ROC curve (AUC) between QUIPP 
prediction of spontaneous preterm birth (sPTB) at less than 30 weeks’ gestation, using 
fetal fibronectin (fFN) test alone, cervical length (CL) alone, and both tests.   
 
Area under ROC for prediction of sPTB < 30 weeks (n=83*) 
 
AUC Std Err 95%CI Pr>chi2 ** 
Both fFN & CL 0.9533 0.0276 (0.89914-1.00000) standard 
fFN alone 0.9067 0.0384 (0.83148-0.98185) 0.1437 
CL alone 0.8483 0.0791 (0.69327-1.00000) 0.1714 
*number of observations. Some women were recruited at later gestations. 
** Pr>chi2 test of significance 
 
 
Table 45. Significance test comparing area under the ROC curve (AUC) between QUIPP 
prediction of spontaneous preterm birth (sPTB) at less than 34 weeks’ gestation, using 
fetal fibronectin (fFN) test alone, cervical length (CL) alone, and both tests.   
 
Area under ROC for prediction of sPTB < 34 weeks (n=138*) 
 
AUC Std Err 95%CI Pr>chi2 ** 
Both fFN & CL 0.8309 0.0520 (0.72912-0.93277) standard 
fFN alone 0.7833 0.0622 (0.66146-0.90514) 0.0945 
CL alone 0.7894 0.0545 (0.68266-0.89623) 0.3534 
*number of observations. Some women were recruited at later gestations. 
**Pr>chi2 test of significance 
 
 
Table 46. Significance test comparing area under the ROC curve (AUC) between QUIPP 
prediction of spontaneous preterm birth (sPTB) at less than 37 weeks’ gestation, using 
fetal fibronectin (fFN) test alone, cervical length (CL) alone, and both tests.   
 
Area under ROC for prediction of sPTB < 37 weeks (n=143) 
 
AUC Std Err 95%CI Pr>chi2* 
Both fFN & CL 0.7307 0.0512 (0.63040-0.83101) standard 
fFN alone 0.6921 0.0528 (0.58859-0.79563) 0.2406 
CL alone 0.7189 0.0509 (0.61911-0.81867) 0.7446 












Table 47. Significance test comparing area under the ROC curve (AUC) between QUIPP 
prediction of spontaneous preterm birth (sPTB) within one week of testing, using fetal 
fibronectin (fFN) test alone, cervical length (CL) alone, and both tests. 
 
Area under ROC for prediction of sPTB < 1 week (n=143) 
 
AUC Std Err 95%CI Pr>chi2* 
Both fFN & CL 0.8750 0.0555 (0.76623-0.98377) standard 
fFN alone 0.8929 0.0418 (0.81089-0.97483) 0.6475 
CL alone 0.6975 0.1262 (0.45017-0.94479) 0.0199 
*Pr>chi2 test of significance 
 
 
Table 48. Significance test comparing area under the ROC curve (AUC) between QUIPP 
prediction of spontaneous preterm birth (sPTB) within two weeks of testing, using fetal 
fibronectin (fFN) test alone, cervical length (CL) alone, and both tests. 
 
Area under ROC for prediction of sPTB < 2 weeks (n=143) 
 
AUC Std Err 95%CI Pr>chi2* 
Both fFN & CL 0.8889 0.0491 (0.79264-0.98514) standard 
fFN alone 0.9037 0.0362 (0.83266-0.97475) 0.6687 
CL alone 0.7306 0.1126 (0.50978-0.95133) 0.0219 
* Pr>chi2 test of significance 
 
 
Although the addition of CL to fFN appears to be useful, the significance tests as shown 
in Tables 44 to 46, indicate there is no difference between the tests or combination of 
both tests for predicting sPTB at 30, 34 or 37 weeks.  However, at 1 and 2 weeks post-
test, fFN alone appears to be the best predictor although not statistically different 
from combined fFN and CL.  CL alone, however, has reduced ability to predict sPTB, 
with AUCs of 0.6975 and 0.7306, respectively (Tables 47 and 48).   The number of 
women in this cohort having both tests was small (particularly so for prediction of sPTB 
at less than 30 weeks) so these results must be interpreted with caution.   
 





8.7.5. Review of PETRA cohort participants with sPTB < 30 weeks 
 
The ROC curves demonstrating the QUIPP app’s ability to predict sPTB < 30 weeks 
appear to be particularly useful, both the in fFN group validation set (AUC 0.963, 95% 
CI 0.938-0.989) and the fFN+CL group (AUC 0.953, 95% CI 0.899-1.000).  In order to 
confirm these findings, a review of all PETRA cohort participants with sPTB < 30 weeks 
was carried out, including individual calculation of their % risk of delivery using the 
QUIPP app.  Table 49 shows the results of this investigation. 
 
 
Seventeen women in the full PETRA cohort had sPTB < 30 weeks.  The QUIPP app 
predicted risk of sPTB <30 weeks to be ≥5% in all cases.   In two cases (5766 and 7132) 
fFN was <50 ng/ml, the commonly accepted threshold under which reassurance is 
given.  However, in both cases, the CL was short, and the risk of delivery was calculated 
at over 5% for delivery at less than 30 weeks and within four weeks.  This means that 
using the app to guide practice, using a threshold of 5% for recommending 
intervention, would be safe and unlikely to result in false reassurance.  
 
Three women (5193, 5740 and 6928) delivered within one week with a QUIPP % risk of 
less than 5% within one week, but over 5% within two weeks.  In one of these cases 
(6928) a CL of 29 mm was recorded alongside an fFN of 465 ng/ml.  In this case, QUIPP 
% risk calculated with the fFN alone increased the risk to 6.6% for sPTB <1 week.  This 
demonstrates the importance of maintaining clinical judgement in the final decision 





Table 49. Individual QUIPP % risk calculations for PETRA cohort participants with spontaneous preterm birth (sPTB) at less than 30 weeks' 
gestation, including risk status, test results, interventions, gestation at, and interval to, delivery with QUIPP % risk scores for prediction of 
sPTB at < 30 weeks’ gestation and within 1, 2 and 4 weeks of testing. 
 
 





9. Results 2: QUIPP app users study 
 
Findings from the QUIPP app users study, where clinicians were asked to express their 
views, are presented below. 
 
9.1. Participant characteristics 
 
Ten QUIPP app users agreed to be interviewed.  Participant characteristics are shown 
Table 50).  Of the 10 participants, 7 were Consultant Obstetricians, one described their 
grade as ST5 and two were ST4.  All were members of the UK Preterm Clinical Network. 
Years of experience making management decisions in respect of women at risk of 
preterm birth ranged from 3 to 23 years (median 13 years), and the number of months 
using the QUIPP app ranged from 9 to 28 (median 18 months).  The majority used the 
app every week in managing the care of selected women. 
 
Table 50. Participant characteristics of PETRA QUIPP app users study. 
Study 
ID. 







How often do you use the 
app? 
CQ001 ST4 3 18 Every week, selected women 
CQ002 ST5 5 18 Every week, selected women 
CQ003 Consultant 20 18 Once a month, selected 
women 
CQ004 Consultant 19 9 2-3 times a month 
CQ005 ST4 5 28 Every week, selected women 
CQ006 Consultant 8 18 Every week, selected women 
CQ007 Consultant 6 14 Every week, selected women 
CQ008 Consultant 23 18 Every week, selected women 
CQ009 Consultant 18 28 Every week, selected women 
CQ010 Consultant 20 28 Every week, selected women 
 
 
9.2. Positive elements identified by users 
 
All participants said they had, and would continue to recommend, the QUIPP app to 
colleagues.  The themes emerging from data relating to questioning as to what they 
liked about, or saw as positive attributes of the app, included: reassurance for women, 





clinical management assistance and how the app provides both objective and 
simplified risk assessment. 
 
9.2.1. Reassurance for women 
 
Many users spoke about how they found the app very useful in reassuring women who 
were very anxious.  In addition, being able to show her the % risk based on her test 
results made it easier to explain and reassurance was more readily accepted. 
 
[do you think that helps them to accept what you’re saying to 
them?]...”yeah, and I think it gives them confidence… and that’s why I do it 
4 weeks before the earliest [previous] delivery, because at the time when 
women are really starting to worry, and they come in, and we risk assess 
them, and let them know, you know, and I think they find it very reassuring.  
I know they find it very reassuring.” [CQ009] 
 
“… it’s another instrument to help inform the conversation between yourself 
and the women who may be very worried about things.” [CQ003] 
 
"I guess the things that I use it for mostly are just straight off reassurance 
for the woman…it allows me to reassure women in a number of ways ... 
some women will just be really anxious about getting past 30 weeks 
because they had a baby at 29 weeks.  So therefore I look at the app and 
say ‘ok, actually 90% of women will deliver more than 30 weeks’ and then 
they feel happy." [CQ001] 
 
“I think it’s fairly reassuring [to see something simple].  Most women are 
reassured even if it’s …even if they are quite high risk actually.  Actually 
even quite high risk women normally the risk is only around 5% or 











9.2.2. Clinical management assistance 
 
Users found that using the app helped them with making clinical management 
decisions, and this could reassure them that intervening at this point was unnecessary. 
 
“… I think it has two benefits. Firstly by helping the doctor make difficult 
decisions, but also for explaining risk, and I think those two aren’t 
necessarily the same thing.” [CQ002] 
 
“The woman can see either before the weekly threshold or … weeks in 
pregnancy, or weeks from the test.  There’s quite a lot that you can point to 
that is reassuring, and avoids the need for hospitalisation or steroids, or you 
know, other sort of interventions that one is keen not to use.” [CQ003] 
 
“I think it stops doctors overreacting.” [CQ002] 
 
“…and it makes me think about management decisions in a way that you 
maybe wouldn’t before, because , you know, what’s a percentage risk of 
giving birth rather than, you know, what’s their fibronectin level.  It makes 
me think about what percentage risk, would I want to do X, Y or Z.” [CQ005] 
 
 
9.2.3. Objective risk assessment 
 
Participants described how the felt the app provided risk assessment that supported 
their clinical judgement in more objective way. 
 
“…it’s useful I think for women to actually see it on an objective calculator 
rather than just, you know, me telling them.  I think it makes it more 
believable.” [CQ005] 
 





“…and also with the confidence that that is based on something, rather than 
the clinician on the day saying ‘I’m worried’ or the patients really worried, 
because actually it is our responsibility really to be worried or not worried 
and not be guided … not be fully guided by the patient’s worry.” [CQ001] 
 
“…it lends weight to your clinical judgement, and that’s … your clinical 
judgement is from the woman’s point of a view a qualitative subjective 
expert assessment, but something that states in black and white an 
absolute percentage tends to reinforce that or it tends to incarnate that 




9.2.4. Simplified risk assessment 
 
Another benefit participants spoke about was the way the risk assessment tool 
reduces the combination of risk factors and test results into a simple % individual risk. 
 
“there are a number of different factors going on here … continuous 
variables and that sort of thing … fetal fibronectin and the length of the 
cervix as well… Yeah, so it puts it in to the one thing to take home the 
message”. [CQ002] 
 
“…with the serial ones [women having repeat appointments] they can see 
that’s going up or down more easily.” [CQ006] 
 
“I think it’s excellent because it actually gives you … it integrates fetal 
fibronectin with cervical length.” [CQ007] 
 
 
9.2.5. Simple and easy to use 
 
A number of users commented that a very positive feature was the app’s simplicity 
and ease of use: 






“Very simple.  Really, really simple and really quick.” [CQ008] 
 
“…it’s very easy to use because you just plug in the details and it gives you 
an immediate risk.” [CQ007] 
 
“The main thing I like is it’s easy.  So it’s not that many clicks and it gives 




9.3. Limitations and suggestions for improvement 
 
9.3.1. More definition of risk factors 
 
Some users stated that they thought the risk factors could be more specific.  For 
example, they would like to be able to denote how many previous preterm births a 
woman had experienced, and at what gestations, as a woman who had had a number 
of early preterm births was likely to be at a greater risk than one who had had one 
previous preterm birth at 35 weeks.  One participant pointed out the range of different 
invasive cervical surgery methods and that it may be useful to be able to stipulate this. 
 
“…if we could expand on the risk factors a bit more it might be more useful… 
how many previous preterm and what was the earliest, or what were the 
gestations … I suppose the statisticians will have to see whether or not it 
turns out to be important.” [CQ009] 
 
“It doesn’t take into account more than one preterm birth…the other thing 











9.3.2. More options for entering single or combined test results 
 
Several users highlighted the fact that not all preterm clinics are able to use qfFN 
testing with all women, so they would like the app to be more flexible and be able to 
give results based on either qfFN or TVS CL alone, or a combination of both. 
 
 
“Most preterm clinics I think all do a cervical length but they don’t all use 
fetal fibronectin, so it would be useful if they could just go on cervical 
length.” [CQ001] 
 
“We tend to use transvaginal scans as our primary screening test.  The use 
of fibronectin is generally restricted to women beyond 24 weeks [so being 
able to use it with CL only would be useful] ….” [CQ003] 
 
 
Although one participant was concerned that restricting the algorithm to one test 
might undermine the predictive value: 
 
“ …you could do the app with just cervical length, [but] your margins of 
error are going to be huge and I think that would play on the good name of 
the app.” [CQ008]   
 
 
9.3.3. Comparison with background risk 
 
One user thought it was important to be able to contextualise the woman’s individual 
% risk with the background risk and that this would help the high risk woman to put 
her situation into perspective. 
 
“I think for women it’s quite useful for them if you can just eyeball it and say 
‘well this would be a background risk in a population who don’t have risk 
factors for preterm labour, where your risk relative to this is this’.” [CQ007] 
 





9.3.4. Access to validation information 
 
A number of users said they would find it reassuring if they were able to instantly 
access, through the app, information about the validation. 
 
“It would be quite useful to maybe have a page somewhere where or button 
for information or something that you could press so that you could see 
what that validated data is just to give you extra confidence.” [CQ009] 
 
“[I would like it to show] just how many women are in the database that 
forms that data”. [CQ008] 
 
“It would be good if we had a bit more information on it about how it’s been 
validated and what, you know, how many …I’m not really, really brilliant at 
keeping up with, um, all the literature so I wouldn’t know how often it’s 
been updated from the point of view of how many patients are in at the 
back end.” [CQ004] 
 
9.3.5. Links to management guidelines 
 
Several users felt the app could be used to provide guidance, dependent on results, or 
at least links to other sources of information, such as NICE guidelines. 
 
“…if we had some sort of protocol for management pathways and, you 
know, even just links to, you know, NICE guidelines or our sort of protocols 
in prem clinic according to risk.” [CQ005] 
 
“It would just be a flag…  So you know how for example… if you put ‘bulging 
membranes’ a thing pops up that says ‘are you going to consider a rescue 
stitch in the patient?’…or you could have something that said ‘given the 
gestation of this patient are you going to consider …?… [or]…think about 
this and talk to the consultant’.” [CQ001] 
 





Not everyone agreed with this, however: 
 
“I think [building in management guidance] is an option but I think you need 
to leave it up to clinicians and women, because I think it depends on their 
situation.  Because a 4% risk to one lady in one context is different to 
[another’s]… I’m not sure that’s necessary.”  [CQ002] 
 
9.3.6. Ability to provide feedback on the app. 
 
The current version of the app does not allow users to provide feedback, and this was 
noted by one participant as a potential improvement. 
 
“I think it is really important that the new version should have feedback… 
feedback of people who are using it.” [CQ002] 
 
 
9.3.7. Availability for android devices 
 
 
It was noted that the availability of app would be improved if it was available for 
android phones and not just through the Apple store. 
 
“Interestingly one of my colleagues actually phoned me because they …were 
struggling to download it.  I don’t know why they were struggling, but they 
basically just gave me the measurements and I put it into my version of the 
app…[we are working on it being on android if that was the problem]… I 
think that might have been the issue.” [CQ007] 
 













9.3.8. Additional information on interventions and outcomes 
 
 
One participant said he would like to be able to note whether a woman had undergone 
an intervention to reduce her risk of preterm birth, such as cervical cerclage or 
progesterone therapy, which might affect her risk.  Another suggested that the app 
could be used to collect information on outcomes, possibly even by the women 
themselves who could be given access to complete them.  This extra data could be 
used for further revisions to the predictive algorithms.   
 
9.4. Visual illustrations of risk 
 
 
All users indicated that their preferred risk illustration was, by far, the icon array with 
women (card A, Figure 14, page 135).  Where they expressed further preferences the 
icon array with dots (card C) came in second place with one clinician stating the donut 
chart (card B) would be their second choice. 
 
All were happy using percentages themselves but some indicated that they felt that 
not all women found them easy to understand and that they often converted the 
percentage risk into number in 100, or another denominator that they felt the woman 
would be most likely to understand (e.g. out of the number in your class, on a bus, 
chances of winning the lottery etc.).  
 
Many indicated they would individualise the way they described the risk to the woman 
and this may depend on her background risk, previous history and anxiety levels. 
 
Data collected in the women’s experience study suggests that the women also favour 
the icon array with women (card A) the most, followed by the percentage (card E) and 





the donut chart (card B).  The clinicians, however, seemed to favour the icon array-
women only, and felt that if the women were struggling to understand a percentage, 
the other “mathematical” charts would not help. 






10. Results 3:  Women’s experience study 
 
10.1. Participants 
Data saturation was achieved after 19 women had been interviewed.  Eleven were low 
risk for preterm birth, while eight were high risk (e.g. with a history of preterm birth or 
late miscarriage).  Seven of the eight high risk women had experienced previous 
preterm birth or late miscarriage, and one had a twin pregnancy.  Eleven women were 
admitted because of their symptoms and test results.  A summary of participant 
characteristics is shown in Table 51 while individual participant profiles are shown in 
Table 52. 
Table 51. Summary of PETRA qualitative study showing number of 
participants by age group, ethnicity, parity, risk status and whether 
admitted for threatened preterm labour (TPTL)  (n=19). 
 
Age Range 
> 20 1 5% 
20-24 1 5% 
25-29 3 16% 
30-34 4 21% 
35-39 7 37% 
40-44 1 5% 
45+ 2 11% 
Ethnicity 
Black African 7 37% 
Black Caribbean 2 11% 
White British 7 37% 
White Other European 3 16% 
Parity 
Multiparous 7 37% 
Primiparous 12 63% 
Risk status 
No risk factors 11 58% 
Other risk factors 1 5% 
Previous PTB/late misc. 7 37% 
Admitted for TPTL 
No 8 42% 
Yes 11 58% 






Table 52. Profiles of PETRA qualitative study participants showing admission for threatened 
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Four main themes were identified, two of which captured the women’s experience of 
threatened preterm labour, “Coping with Uncertainty” and “Dealing with Conflicts” 
and two which elucidated elements of care which had an important effect on the 
experience, “Aspects of Care” and “Interactions with Professionals” (Figure 27).  
Findings in relation to the specific questions about risk illustration are dealt with 
separately.   
 
Figure 27. Thematic overview of findings from the qualitative study, showing main 
themes and subthemes. 
 
 
10.2.1. Theme 1: Coping with Uncertainty 
 
Threatened preterm labour is a state of uncertainty, where women experience 
symptoms that may, or may not be early preterm labour.  The sense of unease that 
comes with this state is evident from the data gathered in this study.  The whole of 
pregnancy itself, particularly for primiparous women, can be a time of great anxiety, 
caused largely from simply not-knowing what is currently going on and what is going to 





happen in the near future.  For those with experience of pregnancy and preterm birth 
or late miscarriage, the possibility that it could happen again can cause great anxiety.  
Data from this study suggests that women, both worried first time mothers and 
women with a history of preterm birth, will initially try to make sense of the symptoms 
they are experiencing, go on to seek reassurance and then try to maintain a sense of 
control over this unpredictable state as they “try to hold it together”.  
 
 
10.2.1.1. Trying to make sense of the symptoms 
Many women appeared to have spent some time trying to rationalise their symptoms 
as something other than PTL, although this was less likely in women with a history of 
PTB: 
 
"… I had a kidney infection as well five weeks ago, and the pain I was feeling 
seemed similar to that."  [10_5864] 
 
"...but I guess with the pain it might be something surgical.” [07_4789] 
 
""... the pains are still coming, the cramping is still coming, and I’m kind of 
confused because I don’t think it’s labour but I know it’s not Braxton Hicks 
either.” [18_6174] 
 
There was also a sense that some women were worried that the symptoms had been 
caused by something they had done, for example, activity, sex or not resting enough, 
and they felt responsible.  
 
"... I felt like after sex I would feel more of the tightness of the tummy…but I am 
wondering if it is something about the anatomy and the physicality of it, or if it 
has to do with the semen or something like that..." [04_4492] 
 





"...  I thought it was maybe because I was feeling a little bit upset and 
panicked.” [06_4658] 
 
"Maybe because I was walking a lot more than usual … I don’t know.” 
[12_6239]  
 
Where symptoms remained unexplained, some women accepted that sometimes 
there are no answers.  However, others were not happy, and felt “shrugged off” by the 
health care professionals, which could also diminish their trust in the doctors. 
 
" …it’s quite scary actually, especially when I get …tightening, and sometimes 
it’s kind of painful.  It’s just … I just feel I’m everywhere right now.  I don’t know 
what’s going on." [15_5991] 
 
"... if there was anything that needed attention the midwife would have said 
‘you need to see a doctor’, and because they didn’t I just assumed ‘well that’s 
fine’, but clearly it’s not fine, not for me…" [05_4258] 
 
 
10.2.1.2. Seeking reassurance 
 
Most women were aware that symptoms may have indicated TPTL and seemed happy 
to approach their midwife, or call for advice, and knew how to do this.  
 
“…and I sort of thought ‘oh, this is sounding a little bit like what they told us in 
NCT classes, could be your early stages of labour’…and so we decided to ring 
the midwife number that is on the medical notes.” [06_4658] 
 
“… Sunday [the pain] was still there and was getting worse now, spreading to 
my lower abdomen.  And so I thought ‘well, I better just call the labour ward 
just in case’.” [10_5864] 
 





The low risk primiparous women, however, usually took some time to consider what 
might be happening before doing so, more time trying to make sense of their 
symptoms, while those with a history of preterm birth or late miscarriage were more 
certain and accessed help more quickly. 
 
Most found the fFN and cervical length test results helpful and that they reduced 
anxiety.  This was particularly so with the high risk women who were already aware of, 
and trusted the tests, having had experience of them in the preterm clinic. 
 
"...But the fibronectin test is actually very reassuring because I know it’s still … 
it’s still signs and probabilities, but together with the cervical length and the 
fibronectin test kind of puts your mind at ease..." [17_6338] 
 
“... [I had] the transvaginal scan which was another good thing because …we 
weren’t just relying on I suppose the midwife looking at my cervix and saying 
‘oh yes, it’s good’...” [04_4492] 
 
If the symptoms continued, however, the reassurance was only temporary. 
 
"... they reassured me I wasn’t in labour …because that was my main worry.  
Then afterwards you think ‘ok, why am I going through … what is going on?’." 
[12_6239] 
 
 “... I think what is difficult is that you can only ever get a diagnosis or you know 
somebody explain what is happening now and then, so I can be reassured 
walking out of the ADU Unit and I’m kind of like ‘brilliant’, twelve hours later 
still experiencing the same symptoms and you are back to square one again." 
[05_4258] 
 





"... if there was anything that needed attention the Midwife would have said 
‘you need to see a Doctor’, and because they didn’t I just assumed ‘well that’s 
fine’, but clearly it’s not fine, not for me…" [05_4258] 
 
" … it’s quite scary actually, especially when I get …tightening, and sometimes 
it’s kind of painful.  It’s just … I just feel I’m everywhere right now.  I don’t know 
what’s going on." [15_5991] 
 
Women with a history of preterm birth were aware that their previous experience had 
a great influence on how their perceived their symptoms, and how this affected their 
need for reassurance.   
 
“… before I was admitted I used to go to the ADU a lot… just because of my 
experience with the previous one I am a bit more cautious.”  [15_5991] 
 
Another woman, although she knew she was not at high risk for preterm birth, was 
very anxious which she perceived to be a result of her previous history of early 
miscarriages and difficulty conceiving with IVF treatment.  She also found it very 
difficult to accept the reassurance she craved. 
 
“I think I have to just learn that when somebody reassures you that you just 
take it… You know… don’t try to create another story…. when you have had 
previous experiences so you are coming from quite a negative place to start 
with it is quite hard to see how there could actually be a positive outcome ….” 
[05_4258] 
 
10.2.1.3. Trying to hold it together 
Those that were hospitalised appeared to be attempting to “hold it together”, trying to 
stay calm, as they felt anxiety was not good for them or the baby. 
 





"… my husband stayed quite calm actually which was quite good and I calmed 
myself down.  I gave myself a minute to calm myself down with some breathing 
techniques that I used.  I was like ‘it’s not going to help me, I need to sort my 
bag out’..." [14_6317] 
 
Many spoke about how they tried to stay positive, or to distract themselves from 
thinking about it.  This could be quite difficult, particularly when other things 
happened on the ward.  
 
" … I try to think positive.  I try to, um, to have a look at the facts and not try to 
anticipate something that probably will not happen.” [13_6253] 
 
"... just try to think about what is on the other side as well and about being a 
parent." [05_4258] 
 
"...when I am not being stressed I am focused on the baby, on her dancing and 
what she is doing, and I am not so much thinking about how I felt when I lost 
the first baby again." [03_4410] 
 
Midwives tried to address women’s anxiety, sometimes by providing more 
information.  This was not always welcome.  One woman who had been given a book 
on neonatal unit care could not read it as it interfered with her trying to stay positive. 
 
"... I didn’t read it... [information book]… I wanted to read it but every time I 
opened it I went to the bad side... because you always sort of read what could 
happen … worst case scenarios … so I just sort of left it." [08_4770] 
 
Some women dealt with their anxiety by getting through from one day to the next, or 
one week to the next.   
 





"...  it is almost like I look forward to Monday as I know Monday is the start of a 
new week in the pregnancy, and then usually anxiety starts to rise probably 
about, yeah, Wednesday, you know, Thursday towards the end of that week, 
and then if I have completed the week and nothing has happened I kind of have 
a sort of mini celebration almost myself and think ‘great, that’s another week, 
brilliant’." [05_4258] 
 
"…  I was just sort of counting the days until I reached twenty six weeks, 
counting the days until I reached twenty seven weeks, and then, you know, sort 
of counting, and counting and counting." [08_4770] 
 
Some women found comfort in prayer and sometimes resolved that, providing 
everything had been done that could have been done, they were prepared to accept 
what happened. 
 
"... I believe in God, I have a personal relationship with him … that helps me.  I 
trust that he is going to see us through...  I study my bible and read positive and 
encouraging scriptures... I have a lot of people praying for me as well.  It’s 
encouraging." [10_5864] 
 
"...as far as I am concerned everything that could be done has been done…the 
medicine that the doctors have blessed me with have done all that they could 
already, so then they have kind of like left it up to [God] now, for him to decide 
what happens." [03_4410] 
 
 
10.2.2. Theme 2: Dealing with conflicts 
 
Women experiencing TPTL have to deal with a number of conflicts.  The unsettling 
experience of TPTL, its risk assessment and management can be exacerbated by 
conflicting information and advice, which may have come about from clinician 





uncertainty.  Hospitalised women may also be trying to deal with balancing the 
conflicting responsibilities of, for example, having to rest or be in hospital in order to 
protect their unborn baby, and the need to care for other children at home.  All this 
uncertainty and conflict can result in an emotional rollercoaster of conflicting feelings. 
 
 
10.2.2.1. Conflicting advice 
As PTL is very difficult to diagnose in its early stages, it is unsurprising that women can 
hear many differing opinions as to what may be causing the symptoms.  This was 
clearly an issue for several women in this study: 
 
"...different answers from different people.  I was told it was ligament pain, I 
was told it was fibroids, I was told it was a UTI, you know, all in the space of five 
days." [07_4789].  
 
“…having continuity of care with the same doctor or consultant I think probably 
is something that I would have benefitted …, because every time I come in …you 
see somebody different, and everyone has slightly different views." [05_4258]. 
 
"The doctor did tell me I can increase my activity level.  The midwife said ‘no, go 
back to bed’.  So I am sticking to the midwife." [08_4770]. 
 
 
10.2.2.2. Conflicting responsibilities 
 
Anxiety caused by being separated from other children appeared to be the most 
significant issue for women who were admitted to the antenatal ward.    They felt they 
were being pulled emotionally between their need to care for them and protecting 
their unborn baby.  
 





“…the last time she came she said quietly …’look, mummy, they are not looking, 
let’s leave now’”.  [ID. 4020]. 
 
Women described how they felt the need to protect current children from the 
potential pain of loss, but also wanted to be positive, both for themselves and their 
children, some of whom had borne witness to the grief and loss of earlier pregnancies.    
 
“…we want her to be positive and want to talk to her about it but we don’t 
know how much to say because we don’t want her to be really upset if it all 
goes wrong again.”  [01_4020] 
 
Although women felt sad and guilty for not being able to care for older children, they 
often talked about how they saw this time as an investment, and that the longer they 
stayed in hospital and the baby stayed inside, the less likely the baby would have 
problems when it was born. 
  
"I was quite happy [to be admitted] because I know that at the end of this my 
son would be a lot happier to have a sibling because I know that is what he 
really wants." [03_4410] 
 
For those women without other children at home there was some concern about work 
responsibilities, but most felt it was important to reduce stress for the sake of this 
baby.    Some expressed concerned that they were not able to do their job properly, 
and one that her job was at risk if she had time off. 
 
"...it’s the added pressures of wanting to be able to, you know, do well at work, 
obviously have a healthy pregnancy, you know... wanting to be able to do it all 
basically... commuting in and out of work, not have any problems etc. etc." 
[05_4258] 
 





"Sickness is a big thing and you can just get replaced so easily.  So um, yeah, I 
just done myself a favour and [went on maternity leave] early."  [09_5222] 
 
 
10.2.2.3. Conflicting emotions 
 
Women felt very anxious but tried hard to be positive and stay calm.  This was 
sometimes very difficult and could result in them feeling like they were swaying 
between calmness and confusion.   
 
"… I was waking up every hour to see if I had lost any water… And then it didn’t 
happen again for the next couple of days and I sort of got a bit relaxed and 
thought this isn’t going to happen... um, I’m calm now." [08_4770] 
 
"At first they just said everything’s fine so I thought I am having a nice 
pregnancy, but now sort of you get told certain information and … obviously 
you’re worrying so the baby is obviously feeling all your worry … so you just 
have to try and be calm and just take every day as it comes." [09_5222] 
 
They could feel reassured for a time, but then would experience a rising anxiety again, 
as the reassurance subsides if the pain continued, or fears that the baby could come 
early continued to haunt them. 
 
"...it is almost like I look forward to Monday as I know Monday is the start of a 
new week…and then usually anxiety starts to rise probably about, yeah, 
Wednesday, you know, Thursday towards the end of that week…"  [05_4258] 
 
 
10.2.3. Theme 3: Aspects of care 
 
What happens when a woman with symptoms of TPTL seeks maternity care can affect 
her experience, both positively and negatively.  This theme elucidates the aspects of 





care which appeared to be important to the participants of this study, and is presented 
as sub-themes: organisation of care; clinical procedures and relationships with other 
patients.  A significant aspect of maternity care is, of course, the interaction with 
healthcare professionals, however, as this is such an important topic, with its own sub-
categories, it is discussed separately. 
 
10.2.4. Organisation of care  
 
Overall, the women in this study appeared to be knowledgeable about how and when 
to contact a midwife for advice, and found it reassuring that they were able to do so at 
any time.    
 
“That has really put my mind at ease, knowing that you have that point of 
contact there, anytime day or night.” [06_4658] 
 
“… I feel so much more confident now that, were something to panic me again, I 
know that I can contact the midwives and they're there, and they really don’t 
mind.”  [06_4658] 
 
Easy access to information and advice from a trusted health professional was highly 
valued by women who were known to the specialist preterm clinic.  
 
“… It is really easy to get hold of her.  When I had my stitch done she informed 
them to let me know that they were in a conference and it was really good that 
I could get hold of her even though she wasn’t there.”  [03_4410] 
 
Several women spoke about the importance of continuity of carer, and how this could 
enhance relationships and trust, as well as making care potentially more efficient and 
safer.  Continuity of carer also helps with easy access to advice, knowing who and how 
to call, and feeling comfortable doing so.   
 





“…   I think it is because when you have a midwife you build up a rapport and a 
relationship so you are much more likely and willing to have discussions, 
whereas if you are seeing different people all the time …” [05_4258] 
 
“… the fact that I can see the same [professionals].  It almost feels that when I 
come in I don’t have to repeat myself anymore….” [03_4410] 
 
Women appreciated it when midwives reorganised the bays according to the care 
needs of the women, for example, women admitted for induction of labour were 
moved to a different room from those with TPTL.   
 
“And we have two others that are just crying because they want to get their 
babies out.  I am crying and thinking ‘please God we don’t have the same 
problems’ - I am trying to keep it in, they are trying to get it out.”  [03_4410] 
 
One women recalled a previous experience and how she could hear other babies 
crying while she was left holding her stillborn baby: 
 
“…I’ve been in that situation before.  It’s kind of surreal because you are sitting 
there with your child which you are going to send back, for intents and 
purposes, to a fridge, and then you can hear women with their children crying 
less than a few doors away and you are like ‘why would you put us here?’.”  
[18_6174] 
 
Waiting and delays were an important aspect of care that affected women’s 
experience.  Many had to wait a long time to be seen in the day assessment unit, 
however, most understood and were prepared for this.  They felt that it was worth it 
for the reassurance it would bring in the end.  
 
“… [it might be] a very long wait yeah, but it’s better to be at peace than worry 
yourself and not know what is going on really.” [15_5991] 






Waiting for interventions to be administered once they had been prescribed, however, 
was a different matter.  One woman was told how important it was that she had 
steroids but then had to wait a long time before she was given them: 
 
"...By then that had been an hour and a half, so he [her partner] got very upset 
because in his mind it was like ‘take these injections now if we have decided’…”  
[04_4492] 
 
Another had a long wait for ambulance for in utero transfer after being told it was vital 
the baby was born in a hospital with adequate neonatal care. 
 
“… they said ‘oh, the ambulance will come soon’…and you keep on asking and 
they say ‘well, it’s on its way’… You’ve been told it’s extremely urgent … and 
there is a six hour wait.” [08_4770] 
 
One women recalled having her planned cervical cerclage cancelled and delayed on a 
number of occasions.  She understood, to a degree, because she knew they are carried 
out on the labour ward where emergencies constantly disrupt the elective procedures, 
but found it very difficult. 
 
“…I got to the point where I just said ‘you know what, if I’m going to lose it I 
don’t want nobody to get my hopes up anymore …I said ‘if you are not going to 
operate then don’t string me along for so long’.” [03_4410] 
 
Women also talked about how getting test results quickly was very important to them. 
 “… the fact that we can get that test result back quick is a bonus. Yes, definitely, 
because you do feel quite anxious at the beginning.” [06_4658] 
 
The issue of discharge was an area of discussion that appeared to be important to the 
women who had been hospitalised and this could produce strong and mixed feelings.  





Although they really wanted to go home, particularly if they had other children, 
women generally felt they were in the right place, and sometimes wanted to stay in 
longer than the doctors thought necessary. 
 
“… and then I thought ‘ok, I will go home on the Monday’, and they told me 
Wednesday… and my heart sunk... and I went through it all over again…I kind of 
made my peace, by Monday, then it turned out to be Wednesday... And actually 
when it was time to go I wanted to cry.” [18_6174] 
 
“ …the doctor was saying as well, because I am out of the catchment area in 
case something would happen they don’t want me in an ambulance with a 
premi baby, or even having a premi baby at home… so I would rather stay here 
till thirty weeks…” [08_4770] 
 
Having to wait a long time to be discharged once the decision had been made was a 
problem for some women. They were aware that this not only led to anxiety for them, 
but also that they were effectively “blocking” the bed for someone else who might 
need it. 
 
"Every single person on that ward knew it was my son’s birthday…  I was 
bugging them slightly so I could go.… You sort of feel like you are taking care 
away, not in a bad way, but I was like ‘I don’t need to be here, I feel absolutely 
fine’..." [14_6317] 
 
Delay to discharge was often caused by waiting for medications to be ready.   One 
woman spoke of a “deal” she made with the midwife who let her go on the condition 
that she would return the following day to collect her anticoagulant medication. 
 
“…a midwife who said to me ‘do you know what, generally we don’t do this, the 
reason you are still here is because of your extremely high risk to develop a 
blood clot, and you’re supposed to be being taught and sent home with 





medicines’.  So she said ‘I will do your tonight one for you if you promise to 
come back tomorrow and collect your medication’.” [18_6174]. 
  
10.2.4.1. Clinical procedures 
 
Women spoke about their experiences of both the clinical assessment procedures and 
also interventions they had relating to preterm birth risk.  Clinical assessment included 
CTG monitoring, speculum examination, fFN testing and TVS CL. 
 
The women found CTG monitoring reassuring, both because it reassured them of the 
baby’s wellbeing, but also for some, because it “proved” they were having 
contractions.   
 
“… she put me on the monitor and, you know, it was quite reassuring.  I could 
see that the heartbeat and everything was fine.  I could see that I was having 
contractions.”   [06_4658] 
 
Although speculum examinations were often noted as unpleasant, women were 
prepared to tolerate them and found it very reassuring when they were told their 
cervix was closed. 
 
"As soon as the doctor had said my cervix was closed I felt really reassured 
because I felt that maybe I was worried the sharp pain that I was getting was 
perhaps the beginning of my cervix opening. … I didn’t know what was causing 
that pain." [06_4658] 
 
“…So when she told me my cervix was closed, I thought, ‘well I’m not having the 
baby tonight’.” [14_6317] 
 
Women were reassured by low fFN results, and appreciated the fact the results came 
quickly.  





“…when my fibronectin is very low and they put it in the app [risk assessment 
tool] and they show in one week, 0.0%, that makes me feel better, like ‘ok, I’m 
definitely maybe safe for a week, hopefully’.” [15_5991] 
 
However, they were often shocked and, unsurprisingly, worried by high results.  Some 
felt that the way they had been told the results could have been better if they had 
been presented in a less worrying way. 
 
“When I saw that amount… because she said before [low risk] was 50, I saw 200 
and I started to cry because I was like ‘oh my god, it’s not 51 or 52 it’s like 200’.” 
[04_4492] 
 
The women who had cervical length scans found them acceptable and valued the extra 
information.  They felt it was more reassuring to actually see the cervix themselves, 
and, of course, they always appreciated the opportunity to see their baby. 
“... [I had] the transvaginal scan which was another good thing because …the 
cervix was a good size, so it meant that we weren’t just relying on I suppose the 
midwife looking at my cervix and saying ‘oh yes, it’s good’..." [04_4492] 
 
“..so I think having a test, the fibronectin test…is great, but equally that only 
gives you an indication of what is happening from the outside , whereas ...on 
the inside there could be pressure effects from baby starting to change things in 
the cervix.” [05_4258] 
 
Some women spoke about the interventions intended to reduce the risks associated 
with preterm birth.  These included hospital admission for observation and bed rest, 
steroid administration for fetal lung maturation and IUT. 
  
Those admitted to hospital generally felt they were in the right place, and sometimes 
appeared to be very pleased because they knew they would not be able to rest 
properly at home, particularly with other children around. 






“… so I think just being on bed rest made a difference … and I would love to stay 
on bed rest, because I know if I go home ….” [08_4770] 
 
For those who had steroids, there was unanimous agreement that this is a very painful 
procedure.  All understood the reasons and accepted the intervention, and most said 
that they preferred to be warned about the pain, however, so they could prepare 
themselves. 
 
“I remember the first jab and I said to my husband ‘that was worse than these 
pelvic contractions’.  It’s stingy and you don’t get anything nice at the end of it.  
With labour you’ve got a baby’.” [14_6317]. 
 
With IUT, there were problems with waiting for ambulances and worries that it would 
have to be a long way from home. 
 
“… the next day they said because a lady just gave birth to twins at 23 weeks 
there is no bed available so they would have to transfer me out, and they 
mentioned Brighton…but that means I would never see my husband.”   
[08_4770] 
 
10.2.4.2. Relationships with other patients 
 
Being with, and relating to other patients on the ward could both help and hinder 
women’s ability to cope with the experience.  Developing relationships could be 
helpful, resulting in a sense of shared experience, and also helping them to put their 
own worries into perspective.   
 
“… we’ve had to come in for some reason, whether it was because we had 
contractions or our waters had started leaking … whatever the reason is we are 
all there for, you know, the same purpose.” [18_6174] 
 





 “…you become sort of kindred spirits in that, and there is something supportive 
and bonding about it... I think there’s something grounding about being with 
other people who have … circumstances that are more fortuitous than yours 
and some that aren’t."  [11_6237] 
 
However, being witness to emergencies on the ward could be extremely alarming, 
particularly when it happened to women they had developed relationships with, and 
especially if they were in for the same reason, i.e. in danger of preterm birth.  This 
made it very difficult for them to stay positive. 
 
“… this morning I woke up very early ‘cause the emergency bell went off… … I 
know when I see baby doctors they have a blue bag, a very big bag, so I had a 
clue that ok, something not so good was going on…  … straight away in my 
mind I said ‘oh my God, please just save the baby’… it was so frightening and I 
just started crying in the toilet.”  [15_5991] 
 
 “…in hospital you are just wondering when you hear someone’s buzzer go off 
you don’t know if you are the one next.”  [15_5991] 
 
"...one minute you can just be laughing and going to the toilet normal, having a 
shower, and next minute something else can happen [emergency on the AN 
ward] - it always makes me get on the edge like." [15_5991] 
 
 
10.2.5. Theme 4: Interactions with professionals 
 
Arguably the most important aspect of care is interaction with health professionals.  
The issues that emerged from this study were the attitude of the clinician, 
communication and trust in the professionals.   
 
 








10.2.5.1. Attitudes of clinicians 
 
It is reassuring that most of the women in this study felt the staff were very caring and 
supportive and this had a positive effect on their experience. 
 
“The midwives … are always smiling, always friendly, introduce themselves, 
asking do you need anything, just offering that care and that help.  I think it 
makes a huge difference in a situation like this...”  [10_5864] 
 
" ...the midwives were all lovely, all of them.  They were really great.  I felt really 
well cared for in there…" [14_6317] 
 
 
10.2.5.2. Communication with clinicians 
 
Communication was, on the whole, good.  Most women appeared to be comfortable in 
asking for further explanation if they did not understand, and this was provided on 
most occasions.     
 
"...so he, he stayed with me for a little while.  He explained everything that 
needed explaining basically... and he did make sure I understood everything 
that was going to happen." [14_6317] 
 
“Sometimes I can’t express myself properly. They could see that we come from 
other country, but they explained everything…. If I didn’t understand something 
I could ask it and they explained it another way.”   [02_4355]  
 





The women who had quick access to specialist advice and continuity of carer seemed 
most likely to have confidence in the health professionals. 
 
 
10.2.5.3. Confidence and trust in clinicians 
 
Overall, most women seemed to trust the health professionals caring for them and 
were prepared to take their advice. 
 
“… I trust them, so I go with trust.”  [18_6174] 
 
Feeling that the professional was confident in their own knowledge was important, 
unsurprisingly.  This was not always the case, however, and when there was 
uncertainty as to the diagnosis confidence was undermined.   
 
“…sometimes they said there’s nothing but I’m getting these pains but they 
don’t know why.  They said ‘it could just be your stomach getting bigger’ but I 
don’t really think they are that sure themselves." [09_5222Q] 
 
“ … I know there are different people.  They all have different opinions on 
everything.  Like on the issues of steroids ...  Some will say I will get it, some are 
saying I won’t get another one, which is confusing.  So what’s the plan if 
something actually happens?”  [15_5991] 
 
One woman was not happy to immediately accept the advice to have steroids and as 
she was not convinced the doctor advising her knew enough about it, first wanted to 
speak to her aunt who was a paediatrician.   
 
“I spoke to my aunt and she said straight away: ‘Oh no, there is no doubt, take 
the steroids.  There is absolutely no question.’  And once she said that I said ‘ok’, 
because although she didn’t give me a lot of scientific explanation she is 
someone I trust very much.”   [04_4492] 






This may have been due to the uncertainty displayed which undermined her 
confidence in the doctor who was assessing her. 
 
 
10.3. Women’s views on illustrations of risk 
 
 
10.3.1. Participant characteristics 
 
The characteristics of all the women who took part in the second part of PETRA are 
presented in Section 10.1.  Of the last ten, who also expressed their views on the risk 
illustration cards, five had experience of preterm birth or late miscarriage, one had a 
twin pregnancy and four were low risk for preterm birth.  Six were of Black ethnic 
origin while four were White European.  Of the ten, six had been admitted to hospital 




10.3.2. Risk illustration preferences 
 
Participants were asked to consider the risk illustration cards (Figure 14, page 135) and 
to express their preferences.  They were also prompted to give an explanation for their 
answers and encouraged to expand on how a risk of preterm birth should to be 
explained to women.  The most popular illustration was Card A, an icon array with 
female figures.  The simple percentage (Card E) appeared to be the second most 
popular. Figure 28 illustrates first and second preferences along with least preferred 











Figure 28. PETRA qualitative study participants’ favourite (green), second favourite 
(blue) and least favourite (yellow) risk illustrations. 
 
Table 53. Individual participant preferences of risk illustration with parity and risk 
status. 
Study ID 









No risk factors for PTB 




Other risk factors for PTB 




No risk factors for PTB 




No risk factors for PTB 











Previous PTB  or late miscarriage 




No risk factors for PTB 
A-female E-% No clear least favourite 
17_6338 
Multiparous 
Previous PTB  or late miscarriage 




Previous PTB  or late miscarriage 




Previous PTB  or late miscarriage 










10.3.3. Key issues arising from discussion of risk illustrations 
 
In order to explore the women’s views in more depth, a qualitative analysis of the data 
was undertaken and revealed a number of key issues.  These were the variation in 
preference, the use of numbers versus pictorial representations of risk and the 
importance of the denominator.   
 
10.3.3.1. Variation in preferences 
 
In a small qualitative study, it is not possible to generalise results, however, the icon 
arrays, particularly those with the female shapes, appeared to be most popular (6/10 
first and 2/10 second preference).   
 
“…this one you see some people so maybe it’s more representative of … 
you’re talking about a child… I would say is more question of a feeling, of 
emotion…because it’s a picture of people… makes it more real.” [13_6253] 
 
“Because it’s visual and it’s done with people rather than blobs, so you 
relate to the people more as yourself.”   [11_6237] 
 
“I really, really like these little people.  The ones that are highlighted with 
the amount.  I think that gives a really nice visual aid to show that actually 




Most women said they felt comfortable with percentages (3/10 first and 4/10 second 
preference).   
 
“I mean without explaining, I can quickly grab what 5% means.” [15_5991] 
 
“… figures and charts no, percentages are fine.” [18_6174] 
 
“I have done a lot of statistics … I am perhaps not your typical person that 
might be having this data presented to them, so I am perfectly 
comfortable with this [percentage]”. [11_6237] 
 
The donut chart (Card B) was also popular, and much preferred to the bar chart (Card 
D). 





“I think this one is the best because it tells you exactly.  So without 
speaking to anyone I could immediately tell what the graph is about.”  
[10_5864] 
 
“…Because on this graph you see the 95%, you see that it’s big and you are 
in the low 5% which is small compared to the other one [B].” [13_6253] 
 
This variation in the way people preferred risk presented to them is in line with current 
advice on presentation of risk as discussed in Section 1.7.3.   
 
10.3.3.2. The use of numbers versus pictorial illustrations of risk 
 
Although most women said they found percentages easy to understand, one woman 
spoke about how difficult she found it when she was asked to consider the ratio cards 
F and G: 
“… when I’m talking about risks of preterm… one minute I’m here and I’m 
thinking preterm, and then you're throwing me figures of 5 out of 100 or 1 
in 20 …….taking me somewhere else and asking me to concentrate, sort of 
like a maths lesson.” [18_6174] 
 
Many appeared to prefer the pictorial illustrations: 
 
“I think this is a bit better.  There’s obviously the thing, how it's going to be 
received by that person, especially when they are going to moments of 
anxiety and not really thinking clearly, and so visually this looks better.”  
[17_6338] 
 
“I certainly prefer those.  I feel you get more information, because when 
you had that one I thought was the least helpful I thought ‘1/20, what 
does that mean’.” [10_5864]   
 
It appears that using visual illustrations can aid understanding, particularly if women 
are very anxious.  As the majority of women with TPTL symptoms will be low risk and 
not go on to birth their babies prematurely, using this method could provide speedy 










10.3.3.3. The importance of the denominator 
 
One woman was comfortable with the different numerical illustrations and, as a 
scientist herself, did not see any difference between 5%, 5:100 and 1:20.  However, 
other women did, and spoke about how they “preferred” 5:100 rather than 1:20 
because it felt more reassuring. They didn’t “like” the 1:20, because it felt like the risk 
was higher: 
 
“… I would need it explained to me more… Like 1/20 people which is quite 
high to me.  Like 1 in every 20 people there’s a possibility - that’s how I 
read it.  [Interviewer:  That seems higher than 5/100?]… Yes definitely.”  
[15_5991] 
 
“I am more willing to take the treatment if it was 1/20 than 5/100.  Less 
likely to do it 5%, because you are so used to hearing it.  5% is nothing.  
You need to think about it a bit more.”  [12_6239] 
 
“I can imagine someone being more worried by 1/20 than 5/100… Maybe 
they can think of 20 women that they know that are pregnant or in labour, 
and think of the fact that one of those might have it early.” [14_6317] 
 
  
The chosen denominator appears to affect women’s perception of risk, and whether 
they will accept, or decline, advice and intervention.  It is important, then, that 




10.4. Summary of findings 
 
In this study, women spoke about unsettling feelings of uncertainty and conflict 
associated with TPTL and how these affected their ability to cope.  They also talked, 
largely positively, about the care they received and interactions with the professionals 
providing that care.  An analysis of women’s opinions on how useful they perceived a 
number of visual illustrations of risk demonstrated that icon arrays with female 
symbols and simple percentages were the most popular. 








This PhD project sought to address two issues: i) improving risk assessment in TPTL by 
developing a clinical decision support tool, the QUIPP app and ii) understanding the 
experience of TPTL from the woman’s perspective and identifying areas of TPTL 
management that could be improved.  In this chapter, these issues are considered in 
relation to the findings of the three parts of the PETRA study along with, and in the 
context of, other literature and current clinical practice. 
 
11.1. PETRA cohort study and development of the QUIPP app. 
 
 
11.1.1. Prediction of sPTB 
 
PETRA is the largest prospective cohort, to date, of UK women with symptoms of TPTL 
whose clinical assessment included qfFN plus or minus TVS CL.  Although many 
investigators have previously found associations between a plethora of factors and 
preterm birth, including demographic and lifestyle characteristics, the only factors 
identified in this cohort to be predictive of sPTB at <34 and <37 weeks were the major 
risk factors, such as previous preterm birth or cervical surgery, as shown in Section 
8.4.2.   Creation and validation of the prediction models also found no association with 
demographic or other risk factors, so they were subsequently not included in the risk 
prediction algorithms.  This apparent lack of effect was possibly due to the 
heterogeneity of mechanisms leading to PTB, sample size and low event rates in this 
population.  Therefore, perhaps a larger, more varied cohort would produce different 
results. 






Prediction based on qfFN and CL category, and that the likelihood of sPTB increases 
with rising fFN and shortening CL is no surprise, and is concordant with a large amount 
of literature on the subject (Section 1.4).  To compare and contrast all research 
findings in this area is difficult, partly because investigators use different thresholds of 
fFN concentration and cervical length for what they deem a “positive” test. For 
example, some will use a CL of <15mm and a fFN of 50 ng/ml (Tsoi et al., 2006), while 
others choose CL ≤20 mm and/or fFN of 20 ng/ml (Levine et al., 2018) or even an fFN ≤ 
5 ng/ml (Jwala et al., 2016).  The aim of this project was not to demonstrate the ability 
of fFN or CL in predicting sPTB but it is interesting to compare results with previous 
research carried out in the same hospital and therefore with a similar population.   An 
earlier prospective study with a cohort of 300 symptomatic women, published by our 
group (Abbott et al., 2013), investigated the ability of qfFN to predict sPTB at <34 
weeks and within 2 weeks of testing.  We found the relative risk of sPTB at less than 34 
weeks’ increased in each category when compared with the lowest category (<10 
ng/ml): fFN 10-49 ng/ml, 5.6 (95% CI,1.05–29.57; P<0.01); 50-199 ng/ml, 7.9 (95% CI, 
1.38–45.0; P<0.01); fFN 200-499 ng/ml, 22.8 (95% CI, 3.84–135.5; P<0.01); and fFN 
≥500 ng/ml, 51.3 (95% CI, 12.49–211.2; P<0.01).  These findings are similar in the 
PETRA cohort for the categories: 50-199 ng/ml, 7.4 (95% CI, 2.8-19.5) and fFN 200-499 
ng/ml, 20.5 (95% CI, 8.8-47.8). However, there was not a significant difference for sPTB 
at <34 weeks, (or at <37 weeks or within one or two weeks of testing) between the 
lowest and second lowest category (10-49 ng/ml) with a RR of 2.1 (95% CI, 0.7-6.6).  
Additionally, in the highest category, fFN ≥500 ng/ml, the risk ratio was lower than the 
second highest for sPTB < 34 weeks, 8.9 (95% CI, 1.2-65.9).   Abbott et al. (2013) did 





not report any data on CL measurements because this was not standard practice in 
TPTL assessment in the UK at that time. 
 
It is also useful to compare the PETRA findings with another from our group, (Kuhrt et 
al., 2016a), where we reported the creation and validation of the predictive algorithm 
for symptomatic women used in the first version of the QUIPP app.  This study 
included data on 382 women (190 training set, 192 validation set) with qfFN test 
results.  We reported predictive statistics demonstrating the ability of our prediction 
model to predict sPTB at <30, <34 and <37 weeks, and at within 2 and 4 weeks, using a 
threshold of >10% as a positive result.   
 
In the PETRA study, prediction was investigated for sPTB at <30, <34 and <37 weeks, 
and within 1 and 2 weeks, using a threshold of ≥5% as a positive result, with a 
substantially larger cohort (1173 training set and 576 validation set).  Comparison can 
only be made with the fFN group predictive statistics as CL measurements were not 
available in the earlier study.   Comparable prediction statistics for validation sets of 
Kuhrt and PETRA data are summarised in Appendix 17.6.  PETRA findings demonstrate 
a significant increase in sensitivity, the test’s ability to correctly predict sPTB, at all 
times points.  The specificity, however, is reduced, but not by as much.  These 
differences are likely due to the reduction in risk threshold for a positive test from 10% 
to 5%    Positive predictive values (PPV), the probability that a women with a positive 
test (in this case, a ≥ 5 or 10% risk of sPTB) are lower in the PETRA cohort while the 
negative predictive values (NPV), the probability that a women with a negative test (% 
risk < 5% or 10%) will not have sPTB, is similar to the Kuhrt cohort.  Unlike sensitivity 
and specificity, PPV and NPV are dependent on prevalence, and NPV will always be 





high where the prevalence is low.  In Kuhrt’s study, the prevalence of sPTB was higher 
at all time points, so it is not surprising that the PPV is higher than in the PETRA cohort 
validation set.    
 
The area under the ROC curves (AUC), which demonstrate the predictive ability of the 
QUIPP algorithms at different thresholds, can also be compared with Kuhrt et al.’s 
findings in Appendix 17.6.  In that study, we found AUCs of 0.88, 0.83, 0.77, 0.77 and 
0.78, for prediction of sPTB at <30, <34, <37 week’s gestation and within two and four 
weeks of testing, respectively.  This represented an overall improvement compared to 
an earlier systematic review of fFN for predicting sPTB (Honest et al., 2002).  Honest et 
al.’s review included data from forty studies and 26,876 women, in which ROC curves 
ranging from 0.71 to 0.77 demonstrated the ability of fFN to predict sPTB at < 34 and 
<37 weeks’ respectively.    In the PETRA validation set, AUCs were, therefore, higher 
than previously reported (Honest et al., 2002; Kuhrt et al., 2016a) in all but the < 37 
weeks’ time point: 0.96 (<30 weeks); 0.85 (<34 weeks); 0.77 (<37 weeks); 0.91 (<1 
week) and 0.92 (<2 weeks).    
 
Comparison of the predictive statistics with our earlier work (Kuhrt et al., 2016a) 
demonstrate improved prediction but are based on algorithm developed for qfFN only.  
For the 2nd version of QUIPP algorithms for predicting sPTB using qfFN alone, TVS CL 
alone or a combination of both tests were created and validated.  The ability of the 
new version of the QUIPP app to predict risk of sPTB using risk factors and either, or 
both, tests, increases its utility as the app has the flexibility to be used by clinicians 
where fFN testing is not available, and TVS CL is likely to become more common as 
more clinicians are trained. 





11.1.2. Administration of steroids in PETRA cohort 
 
In the PETRA cohort, whether steroids had been administered or not, was known in 
1024 cases. Of these, over 30% had steroids on at least one occasion.  Considering that 
only 12.1% of women overall had sPTB this appears high.  However, this rate is 
substantially lower than reported in previous similar cohorts where often more than 
50% of women received steroids (Freeman et al., 2015).  In one study over two thirds 
of women with TPTL who delivered after 34 weeks had received an unnecessary course 
(Sanya et al., 2014).    The lower rate in our cohort, compared to earlier studies, might 
suggest that identification of women who really need them is improving, with over 
76% of the women who delivered at term not receiving them. This may be due to an 
increased confidence of clinicians, over time, in the value of fFN as a rule out test.  All 
the hospitals participating in this study used fFN in TPTL assessment as part of 
standard care.   
 
There were few repeated courses, which again could reflect more appropriate 
targeting of this intervention.   It is reassuring to note that, in the small number of 
women delivering within 7 days, the optimal window for steroid administration, 90% 
(18/20) had received them.  The two that did not receive steroids were at 32+3 and 34+6 
weeks’ gestation, so it is possible that in at least one of these cases steroids were 
deliberately withheld as the gestation was over 33+6, and inside a range within which 
NICE (2015) recommends “considering” rather than definitively “offering” them (Figure 
2).   
 
 





11.1.3. Discussion of QUIPP App users study findings in relation to other 
literature. 
 
The literature review on mobile apps for clinical decision support (Chapter 2) 
highlighted the importance of mobile app users being involved in development and 
evaluation, both for informing further developments and maximising the likelihood of 
the tool being used in practice.   Part 3 of the PETRA study investigated clinical users’ 
views of the first version of the QUIPP app with the intention of incorporating ideas for 
improvements and addressing negative issues ahead of the 2nd version development.   
 
In terms of acceptability and ease of use, respondents were generally very positive. 
This was particularly in respect of its simplicity, both in ease of use, and how it 
combined separate factors (i.e. background risk, gestation and test results) into a 
simple percentage figure.  No users reported problems with downloading the app or it 
closing unexpectedly.  No training had been provided but this was not highlighted as a 
problem.  
 
Suggestions for improvements included increasing flexibility by including the option to 
use QUIPP with either or both test results.  In the first version of the app, the user was 
required to enter both qfFN and CL results for the high risk asymptomatic women.  It 
was only possible, however, to enter qfFN for symptomatic women.  This was because 
there were insufficient data on CL from women with TPTL symptoms when the first 
algorithms were created and validated.   
 





Another suggestion for improvement was increasing the specificity of background risk 
factors, and use of preventative interventions, e.g. stipulating the number, and 
gestations, of previous preterm births and whether the women had had a preventative 
intervention, such as cerclage or progesterone.  This was considered when the new 
algorithms were developed, but there were insufficient numbers to detect differences 
between these sub-groups. Future revisions with larger cohorts may allow 
incorporation of these elements. 
 
Multifunctionality was an element apparently prized by the clinicians involved in the 
studies included in the literature review on mobile apps for clinical decision support 
(Chapter 2).  In PETRA, clinicians suggested increasing the functionality of the app by 
including information or links to current clinical guidelines and using the tool to collect 
data on outcomes, which could later be used in future algorithm development.  It was 
not possible to include these suggestions in the 2nd version of QUIPP due to time and 




11.1.4. QUIPP app users’ and women’s views in relation to presentation of risk 
 
 
The variety in the views and preferences of the women participants of this study 
confirmed findings from previous research and literature which reports wide 
differences in risk perception (Brewer et al., 2007; Herxheimer, 2005; Lee et al., 2012).    
It is reassuring that the clinician participants understood the value of individualising 
their approach to communicating risk and of using illustrations to explain it, both of 
which are consistent with best practice evidence and current guidelines (David and 





Akintomide, 2016; Fagerlin et al., 2011; Royal College of Obstetricians and 
Gynaecologists, 2007; Lipkus et al., 1999; Spiegelhalter 2008). 
 
The women in this study did not favour the ratio illustrations and tended to feel more 
negatively, because they perceived the risk to be higher, when the denominator was 
lower, i.e. 1:20 as opposed to 5:100.  This is concordant with Schapira and colleagues 
(2001) who undertook a qualitative study of how women’s perception of breast cancer 
risk varied depending on the way the risk was presented.  They found that icon arrays 
with larger denominators were perceived as representing lower risks.  This contrasts, 
however, with earlier studies which suggest participants perceive risk to be higher 
when the denominator was higher, the so-called “ratio bias” effect (Reyna and 
Brainerd, 2008).   
 
Most of the clinicians and women participants preferred pictorial illustrations of risk, 
particularly the icon array with female symbols, which was the favourite with the 
donut chart being second pictorial preference for the women.  Goodyear-Smith and 
colleagues (2008) also found a preference amongst patients for visual illustrations of 
risk.  They interviewed 100 patients with cardiovascular disease and found that 57% of 
those who expressed a preference of one method over others said they preferred 
graphical presentation of risk.  This was significantly greater than those who chose the 
next popular option which was relative risk (19%, p=<0.001). 
 
All clinicians and most women in the PETRA study also felt comfortable with 
percentages, although some clinicians said they sometimes converted the % risk into a 





number in a hundred and tried to adapt the way they explained it on an individual 
basis.   
 
As a result of the PETRA findings a visual illustration of risk was included in 2nd version 
of the QUIPP app.  Although the icon array was the most popular amongst both the 
women and the clinician QUIPP app users, the image detail did not display well on a 
typically sized mobile phone screen. Additionally, a % risk of less than one is commonly 
calculated (e.g. 0.1%), which means a denominator of 1000 would be necessary.    A 
decision was taken, therefore, to use the women’s next most popular pictorial 
preference, which was the donut chart, and place the percentage, their overall second 
















Figure 29. Screen shots of 2nd version of QUIPP. User indicates risk factors and enters 
gestation and test results on first screen. % risks are revealed on second screen. User 
clicks arrow to reveal visual illustration of risk on third screen. 
 
 
Although an icon array is not included in the 2nd version of QUIPP, the findings have 
changed practice in our preterm surveillance clinic at GSTfT.  A4 sized laminated cards 
with icon arrays illustrating risks of 1 in 100 on one side, and 1 in 1000 on the other, 
are now being utilized when a clinician feels they will help a woman to understand her 




11.2. Women’s experience of TPTL 
 
In this section, the main themes identified in this qualitative study, as well as potential 
areas for improvement in care, one of the research objectives, will be discussed in 









11.2.1. Uncertainty and conflict in threatened preterm labour 
 
The very nature of threatened preterm labour is one of uncertainty. Preterm labour is 
very difficult to diagnose in its early stages, so it is not surprising that women in our 
study experienced a great deal of uncertainty and, at times, conflicting opinions as to 
what may be causing their symptoms.   TPTL symptoms can have many potential 
causes, some requiring urgent treatment, for example urine infections, while others 
need less urgent treatment, e.g. pelvic girdle pain and constipation.  Other causes of 
pain, such as fibroid degeneration, are usually managed with pain relief and 
reassurance. Most of the time TPTL symptoms are transient and resolve on their own, 
but as a diagnostic test for very early preterm labour does not exist, clinicians are likely 
to be uncertain and must consider the possibility of labour, whilst not ruling out other, 
sometimes potentially serious, causes for the symptoms that may be unrelated to the 
pregnancy.       
 
Women too are uncertain as to the causes of their symptoms and participants in this 
study were no exception.  They appeared to undergo a process which included trying 
to make sense of their symptoms before seeking reassurance or medical help, and this 
echoed findings reported in other studies (Patterson et al., 1992; Coster-Shultz and 
Mackey, 1998; Barlow et al., 2007; Weiss et al., 2001).  This process appeared to be 
more prolonged in primiparous women in this study, however, and women with 
previous experience of preterm birth were quicker to seek help and less concerned 
about being seen as over-reacting, which is also reported by the high risk women in 
O’Brien et al.,’s study (2010). 






The uncertainty of clinicians around TPTL can lead to increased anxiety caused by 
conflicting advice and information, and this was reported by several study participants. 
Conflicting advice and information appeared to be an important theme in our study 
and although mentioned by Barlow et al., (2007) does not feature prominently in the 
studies identified in the literature review.   Although evidence on how best to deal 
with uncertainty in clinical practice remains unclear (Politi et al., 2007; David and 
Akintomide, 2016) failing to acknowledge it can cause further problems (Politi, 2015).  
Clinicians may try to minimize uncertainty for the benefit of their patients, but if they 
give the impression of confidence in a diagnosis, particularly without reliable test 
results, the woman whose symptoms persist may hear a different diagnosis from 
another very soon afterwards. 
 
Although a recurring theme, it was noticeable that the high risk women in our study 
tended to get less conflicting advice than the low risk mothers.  This was possibly 
because the hospital where this study took place has a dedicated specialist preterm 
team.  Newly admitted women, including those transferred from other units, will be 
quickly referred to the team and a management plan made.  The hospital staff have 
confidence in this well-established team, and therefore the likelihood of advice and 
information being inconsistent is lower.  It is also possible that clinicians may be more 
inclined to recommend interventions at lower thresholds for high risk women.    
 
The emotional stress of conflicting responsibilities, the need to care for other children 
as well as their unborn baby, was also apparent in the women in our study, and has 





been reported previously.  Those who remained under threat of preterm birth 
appeared to be trying to “hold it together”, and employed a range of coping 
mechanisms as they dealt with the sometimes intense anxiety and the recommended, 
albeit temporary, life changes such as hospitalisation or restriction of activity.  This also 
resonates with findings from earlier studies (Adler and Zarchin, 2002; Mackinnon, 
2006; Höglund and Dykes, 2013).    
 
11.2.2. Anxiety in threatened preterm labour 
 
There is a possibility that the uncertainty and conflict associated with TPTL and its 
resulting anxiety could even increase the risk of preterm birth (Section 1.3). It would 
appear sensible, then, to seek to address the modifiable causes of anxiety in women at 
risk of preterm birth, including those with symptoms of TPTL.   Simple interventions, 
such as using reliable predictive tests (e.g. fFN and CL measurement) could reduce 
uncertainty, at least in those women with reassuring results, who make up the 
majority of women with TPTL symptoms.    
 
Interventions designed to directly address stress and anxiety in women at risk of 
preterm birth have been investigated.   Jallo et al., (2017) examined the use of a 
mobile app which provided women with information and guided imagery and 
compared stress levels (Perceived Stress Scale (PSS), Visual Analog Stress Scale (VASS) 
scores, Coping Self-efficacy (CSES)) in 15 women hospitalised for TPTL.  They found a 
significant difference (p<0.0001) in VASS scores, but not PSS or CSES, which suggests 
that immediate stress, at least, was relieved by the intervention.   In another study 





(Chuang et al., 2012) researchers found that a relaxation training programme 
improved the immediate psychological and physiological stress responses in women 
with TPTL.  They also found that, although numbers were too small to prove effect on 
outcomes (n=129), fewer women in the experimental group gave birth within one 
week of study entry (16% vs 30%), and within two weeks of study entry (7% vs 19%). 
  
Another intervention, an internet-based cognitive behavioural self-management 
training programme (IB-CBSM), was tested in 93 women with TPTL (Scherer et al., 
2016).  The researchers found the control group, who had been given alternative 
exercises, such as Sudoku, riddles and writing stories, experienced the same reduction 
in stress and anxiety as the intervention group.  This suggests that distraction itself 
could be useful, and several women in our study appeared to be using distraction as 
coping mechanism.  Other studies have found distraction to have beneficial effects on 
stress in both preterm labour (van Zuuren, 1998) and other stressful conditions (Priem 
and Solomon, 2009; Ram et al., 2010).   
 
Women who were trying to stay positive and using distraction in coping with their 
anxiety did not always feel the staff understood when they declined offers of 
information and books about what might happen if the baby was born early and 
needed neonatal admission.  This finding echoes those of Gaucher and colleagues 
(2016) who surveyed women about their experience of neonatal specialist consultation 
when they had been hospitalised for TPTL.  Of the 229 women who responded, 90% 
indicated they had had a positive experience, although 39% felt they had received too 
much information.  





11.2.3. Aspects of care and interactions with professionals 
 
The organisation of maternity care and interactions with healthcare professionals can 
have a profound effect of women’s experience of TPTL.   Several women in this study 
spoke about the importance of continuity of carer, and how this could enhance 
relationships and trust, as well as potentially making care more efficient and safer.  
Knowing who, and how, to call, and feeling comfortable doing so, makes speedy access 
to information, another important issue for women in this study, and reassurance 
easier.  Continuity of care models have been shown to be safe and effective in 
reducing interventions, preterm birth and fetal loss (Sandall et al., 2016), although the 
actual mechanisms involved remain unclear.  The women in our study who had quick 
access to specialist advice and continuity of carer appeared to be most likely to have 
confidence in the health professionals. 
 
Most of the women in this study who were considered to be particularly at risk of 
preterm birth, either because of their obstetric history or the severity of their 
symptoms, were known to the specialist preterm team.   They appeared to trust the 
clinicians advising them, who were less likely to display uncertainty, and they spoke 
less of receiving conflicting advice.   Specialist preterm clinics and teams that can 
quickly identify risk and instigate timely interventions are not currently established in 
all maternity services.  However, numbers are increasing (Carter et al., 2018a) and they 
have been identified as a useful mechanism in achieving the UK government’s target to 
reduce the preterm birth rate from 8 to 6% by 2025 (Department of Health, 2017).     
 





Evidence on the effectiveness of specialist preterm services is, however, limited.  A 
systematic review of the effectiveness of specialist preterm clinics in reducing preterm 
birth and its consequences found mixed results (Malouf and Renshaw, 2017).  Findings 
from randomised controlled trials, all of which were carried out before 1990, showed 
no benefit, however later cohort studies reported a reduction in preterm birth.  As 
cohort studies are regarded as low quality evidence the authors recommend caution 
when interpreting the results, but acknowledge that the lack of recent RCT evidence is 
likely to continue due to the difficulties of conducting randomised trials which deny 
women a valued service.  The women attending a specialist preterm clinic in O’Brien et 
al.,’s (2010) qualitative study appreciated the regular reassurance and support they 
obtained at these clinics and reported feeling that other health professionals did not 
always understand their particular worries.  The high risk women in this study 
expressed similar views.  Women known to the specialist preterm team often spoke of 
how they felt comfortable accessing the team for the reassurance they frequently 
required.    
 
Fernandez Turienzo et al., (2016) in their systematic review and meta-analysis of 
models of antenatal care designed to reduce and prevent preterm birth found that 
while “alternative” models of care (i.e. midwife-led continuity of care and specialised 
care) reduce preterm birth, conclusions on the relative benefits of the two models 
could not be drawn.     
 
The findings from this study suggest that these two models share at least two 
elements: 1. quick and easy access to advice from a known and trusted clinician and 2. 





continuity of carers who know the woman and how best to support her in her coping 
mechanisms, whether that be providing more information or helping her to be 
positive, and giving, in most cases, speedy reassurance. As anxiety is highly associated 
with preterm birth risk, perhaps one of the most important factors is the reduction of 
anxiety that comes with quick access and continuity of carer.     
 
 





12. Limitations  
 
A number of limitations must be taken into consideration when reviewing the PETRA 
study findings.  Nearly half of the participants in the cohort study, and all in the 
qualitative study, were recruited from one inner-city teaching hospital with a specialist 
preterm surveillance clinic which is directed by an internationally renowned expert in 
preterm birth.  Care of women with symptoms of TPTL may not be representative of 
care in other hospitals, many of which do not currently offer these specialist services, 
and local guidelines and policies may differ from those elsewhere.  Clinicians working 
in this hospital may also have greater confidence in one of the tests used, i.e. fetal 
fibronectin, because much of the research that validated its use in the UK was carried 
out at this hospital.   
 
Similar to other studies of TPTL, the prevalence of preterm birth was low.  This was 
particularly so in respect of delivery within 7 days, where the numbers were very small 
with only 15 cases in the training set, and 13 in the validation set.  This is an important 
interval for risk prediction as it is the optimal window for administration of steroids.  
Confidence in QUIPP’s ability to accurately predict sPTB <1 week of testing would be 
increased with a larger cohort.  One of the reasons the prevalence was low was 
because the prospective cohort study design meant women had to be consented 
before delivery.  Many women whose TPTL symptoms progressed quickly into 
established labour could have been missed because research staff were unable to 
approach them before they delivered.  Other study designs which allow more 





comprehensive data collection, such as retrospective cohort studies, might capture 
these important cases, but would be vulnerable to selection bias.  
 
Another limitation was the smaller than expected number of cases with both fFN and 
TVS CL.  This was despite efforts to increase the availability of ultrasound vaginal 
probes and the encouragement of staff training.   There was, nevertheless, sufficient 
data available to create and validate predictive algorithms for TVS CL in the 2nd version 
of QUIPP, but these could be further refined with a larger dataset.  For this reason, 
ethical approval for an extension, focusing on recruitment of women with TVS CL, was 
sought and achieved, as outlined in section 5.4.    
 
The women’s experience study was, as is common in qualitative research, small, so the 
findings are not necessarily representative of all women who have experienced TPTL.  
Even in respect of the local population the experience and views of the women who 
agreed to participate may not be the same as those who did not.  Some of the 
participants were known to be high risk for PTB and had been reviewed by members of 
the specialist team and their experience of this and these women’s knowledge of the 
tests may have influenced their experience when they presented with symptoms.  
Additionally, interpretation of the findings will have been influenced by the 
researcher’s experience, as a woman, a mother, a midwife, and a midwife with a long 
experience of caring for women at risk of preterm birth.   
 





13. Implications for practice 
 
13.1. Ongoing improvements in PTB risk prediction 
 
The NICE guideline (NICE, 2015) recommends that, when established labour has been 
ruled out during the clinical assessment of women over 30 weeks’ gestation, TVS CL 
should be offered, followed by fFN testing, only if TVS CL is unavailable or 
unacceptable.   NICE do not recommend using a combination of both tests, based on a 
paucity of evidence to support its value and cost effectiveness.  While some 
investigators have found added value in combining tests, others have not, as discussed 
in section 1.4.4.  In PETRA, the effect of combining CL with qfFN on predictive ability 
was examined.  Results indicated that it did not improve prediction and, in fact, that 
TVS CL alone was inferior in predicting sPTB within 1 or 2 weeks (AUC 0.698 vs 0.875, 
sPTB < 1 week, p=0.02; AUC 0.730 vs 0.889, sPTB < 2 weeks, p=0.02).  This suggests 
that fFN has superior predictive ability, and that, based on these findings, fFN should 
be first choice of test in TPTL over TVS CL.  
 
The PETRA study findings support use of 15mm as a cut-off for the NICE guideline, as 
the majority of women in this study were recruited after 30 weeks and CL category 15-
24 mm appears to have the same rate of sPTB as CL >24 mm (Table 24), with risk ratios 
of only 1.1 (95% CI 0.2-5.6) and 1.8 (95% CI 0.9-3.4) for sPTB <34 and <37 respectively.  
Similarly, analysis of fFN by category in this study confirmed a threshold of 50 ng/ml 
was appropriate as there was no difference in accuracy of prediction between the 0-9 
and 10-49 ng/ml categories. 
 





In the PETRA cohort, 85% of women were treated according to the fFN and CL 
thresholds recommended in the NICE guideline:  87.4% (181/207) of those with an fFN 
of >50 ng/ml or CL of ≤ 15 mm received steroids appropriately, 84.3% (689/817) with 
longer cervix or lower fetal fibronectin did not receive steroids.  However, PETRA study 
recruitment commenced before the NICE guideline was published so it is unclear to 
what extent the guideline influenced practice. 
 
Findings from our Delphi consensus of preterm experts (Carter et al., 2016) suggest 
that NICE’s treat-all strategy for women under <30 weeks without reference to either 
TVS CL or fFN may not be universally accepted.  If fully implemented it is likely to lead 
to a significant increase in unnecessary intervention (Watson et al., 2017b).    
Validation of the predictive algorithms developed in this PhD project for the 2nd 
version of QUIPP show excellent prediction for sPTB <30 weeks as well as within 1 and 
2 weeks (Section 8.7).  The value and safety of QUIPP for decision support in TPTL are 
currently being evaluated in practice in the EQUIPTT study.  The results of that study 
may provide evidence for this recommendation to be reviewed.   
 
The findings from the PETRA study will contribute to the ongoing quest to find more 
accurate methods in predicting preterm birth.  Use of the QUIPP app in practice could 
lead to an increased confidence and better targeting of interventions for both reducing 
preterm birth and its associated morbidities, as well as unnecessary intervention. The 
excellent prediction of sPTB at less than 30 weeks has particular importance and may 
inform a review of the NICE recommendation to treat all women with TPTL under 30 
weeks without even testing with qfFN or TVS CL. Nevertheless, however accurate 





QUIPP is, whether its use influences practice is yet to be determined and results of the 
EQUIPTT study are eagerly anticipated.   
 
13.2. Developments in specialist PTB care provision 
 
Findings from the qualitative study suggest that continuity of carer is a significant issue 
for women at risk of preterm birth and the importance of continuity in preterm birth 
reduction has been acknowledged by the UK Department of Health (Department of 
Health, 2017).  Since publication of “Changing Childbirth” in 1993, continuity of carer 
has been virtually enshrined in UK maternity policy (Expert Maternity Group & 
Cumberlege, 1993; Department of Health, 2004; Department of Health, 2007; NHS 
England, 2016), yet this model of care remains unavailable to most women (Redshaw 
and Henderson, 2015).     There is new impetus, however, since the Better Births 
Maternity Review Report (NHS England, 2016) and the NHS England’s Maternity 
Transformation Programme which is working towards implementing the 
recommendations.  
 
The establishment of national guidance on referral to specialist preterm services, 
currently in development, could lead to a reduction in conflicting advice and 
information for women at risk, as well as the targeting of interventions that reduce 
preterm birth and the risks associated with it.    Additionally, utilizing reliable tests 
such as qfFN and/or TVS CL, which have high negative predictive values, could reduce 
the number of unnecessary interventions, at least in women where risk of delivery is 
low.  Reducing unnecessary hospitalisation, treatments and the in utero transfers 





which result in women being sometimes long distances from their families would 
undoubtedly reduce concomitant anxiety. 
 
Increased awareness of the issues important to women with symptoms of TPTL will 
help to improve their experience and, potentially, pregnancy outcomes.  Where risk 
remains high and reassurance cannot be given, clinicians must take care to 
acknowledge uncertainty, minimize delays and conflicting advice and take time to 
assess the woman’s individual coping strategies.  Providing detailed information may 
be important for some, but this is not necessarily the case for women who are coping 
by distracting themselves and trying to stay positive.    
 
  





14. Recommendations for further research 
 
As previously noted, the PETRA study was extended beyond its original recruitment 
period for continued collection of TVS CL data. This is particularly important because 
NICE recommends this as the test of first choice in TPTL and because more clinicians 
are being trained in practice.  Additionally, there is a need to evaluate the QUIPP app 
in practice and it is hoped that the findings of the ongoing EQUIPTT study will provide 
the necessary answers.   
 
Recently published systematic reviews on the effect of TVS CL and fFN on management 
and outcomes reached the conclusion that use of TVS CL for assessment of women 
with TPTL appears to reduce sPTB while fFN does not (Berghella and Saccone, 2016; 
Berghella et al., 2017).  However, more research is needed in this area because most of 
the studies included in these reviews were carried out before fFN was an established 
and trusted test. Future studies and systematic reviews may come to different 
conclusions.  Findings from PETRA suggest that confidence in fFN testing may have 
increased and better targeting of intervention is already underway.  
 
Research into other biomarkers for predicting sPTB continues.  The ongoing QUIDS 2 
study (ISRCTN trial registry number: ISRCTN41598423) is evaluating two bedside tests, 
Actim Partus and Partosure, alongside side qfFN.  If these two biomarkers prove to be 
as valuable as fetal fibronectin, it may be possible to include them in future 
developments of QUIPP, increasing its flexibility further. 
 





In PETRA, only major obstetric risk factors, such as previous preterm birth or cervical 
surgery influenced, and were therefore included in, the predictive algorithms.  Other 
factors that have previously been associated with sPTB, such as age, ethnicity, history 
of urinary tract and Group B Streptococcal infection did not influence prediction in our 
cohort, but this may have been due to the sample size.  It is important, therefore, that 
data collection is ongoing so that, if effects are noted in larger cohorts, they can be 
included in future refinements of QUIPP.   Other research projects, clinical registries 
and databases, such as the Preterm Clinical Network Database (Carter et al., 2018a), 
have the potential to provide high quality prospectively collected data for this purpose.     
 
Further research into the relationship between anxiety and preterm birth and anxiety 
reducing interventions is needed.  This is a promising area and more needs to be done 
to explore how stress management interventions can be utilised to help women at risk 
of preterm birth.   
 
Research into continuity models for high risk women would also be useful.  One such 
project is ongoing. The POPPIE study (ISRCTN trial registry number: ISRCTN37733900) 
is an RCT investigating potential improvements in experience and outcomes of women 
at risk of preterm birth between women allocated to either specialist preterm 
midwifery team care or standard care.  
 






15. Summary and conclusion 
 
This PhD project sought to develop a risk assessment tool for predicting preterm birth 
in women with symptoms of TPTL.  This, along with establishing an understanding of 
women’s experience and the aspects of care that effected it, would ultimately inform 
future improvements in care.   Findings from all three parts of PETRA were utilized in 
development of the 2nd version of QUIPP.  This new version appears to be superior in 
predicting sPTB in women with symptoms of TPTL when compared with previously 
reported findings on prediction using fFN, TVS CL or the first QUIPP algorithms.   
Whether its use in practice leads to more appropriate management will remain 
unknown until the EQUIPTT study is complete.  As the largest cohort study of women 
with TPTL in the UK to date, it also throws some light on current use of interventions 
intended to reduce sPTB and its associated risks. 
 
The women’s experience study was the first exploring women’s experience of TPTL in a 
UK hospital with a specialist preterm service.  The findings provide insight into the 
experience of both low and high risk women with symptoms of TPTL and further 
supports the need for women of all risk groups to have timely access to advice and 
information, and continuity of care.  These findings have already been published 
(Carter et al., 2018b) and are, therefore, available to interested clinicians and those 
involved in the development of clinical management guidelines.  
 
In conclusion, then, the research questions addressed by this PhD thesis have been 
successfully answered and all the specific objectives have been met; these findings will 
go on to inform future research and clinical practice. 
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17.2. PETRA - Participant Information Sheets (parts 1, 2 and 3)  
 
 
















17.3. PETRA – Consent forms (parts 1, 2 and 3) 
 



















17.4. PETRA  - Interview schedules (parts 2 and 3) 
 
























17.5. QUIPP v.2 formulae.  
 
Symptomatic women (based on log-normal survival model). 
 
NOTE: the app is designed for women having symptoms suggestive of abnormal or 
premature uterine activity, and being tested between 23+0 and 34+6 weeks.  It was 
not designed for triplets or higher multiples. 
 
Method 4: Symptomatic women with both CL and fFN measured (methods 1, 2 and 3 
relate to asymptomatic models): 
 
Symptoms suggestive of abnormal or premature uterine activity: [D1] 
Previous cervical surgery: [D2] 
Previous PPROM: [D3] 
Previous preterm birth ≤36+6: [D4] 
Number of fetuses: [D5] 
Gestation of test: [D7]*7+[D8] 
Weeks: [D7] 
Days: [D8] 
Shortest cervical length (mm): [D9] 
fFN result (ng/ml): [D10] 
Mu: [D11] = 0.00896*CL-0.0007748*fFN-0.1351627 (if twin pregnancy, previous 
cervical surgery, PPROM or preterm birth) + 5.53231915. 
Sigma: [D12] = exp(-1.74601) = .1744687 
S(test): [D13] = 1-(NORMSDIST(loge(gestation of test-Mu)/Sigma) 
S(30): [D14] = 1-(NORMSDIST(loge(30*7-Mu)/Sigma); likewise, S(34): D[15], S(37): 
[D16] 
S(1week): D[17] = 1-( NORMSDIST( loge(gestation of test+1*7-Mu)/Sigma); likewise, S(2 
weeks): D18], S(4 weeks): [D19] 
Probability of delivering before 30 weeks: [D20] =MAX((S(test)-S(30))/S(test), 0) 
Other probabilities are calculated similarly 
[Results are as calculated in anal2_symp_ffn_cl_equiptt_app_ph.txt] 
 
Method 5: Symptomatic women with only CL measured: 
 
Symptoms suggestive of abnormal or premature uterine activity: [D1] 
Previous cervical surgery: [D2] 
Previous PPROM: [D3] 
Previous preterm birth ≤36+6: [D4] 
Number of fetuses: [D5] 
Gestation of test: [D7]*7+[D8] 
Weeks: [D7] 
Days: [D8] 
Shortest cervical length (mm): [D9] 





Mu: [D10] = 2.397495*loge(CL+1)/10 -.1751846 (if twin pregnancy, previous cervical 
surgery, PPROM or preterm birth) + 4.9803773 
Sigma: [D11] = exp (-1.575416) = .2069215 
All other results are calculated as method 4 
[Results are as calculated in anal2_symp_cl_equiptt_app_ph.txt] 
 
Method 6: Symptomatic women with only fFN measured: 
 
Symptoms suggestive of abnormal or premature uterine activity: [D1] 
Previous cervical surgery: [D2] 
Previous PPROM: [D3] 
Previous preterm birth ≤36+6: [D4] 
Number of fetuses: [D5] 
Gestation of test: [D7]*7+[D8] 
Weeks: [D7] 
Days: [D8] 
fFN result (ng/ml): [D9] 
Mu: [D10] = -0.0013155*fFN -0.1911503 (if twin pregnancy, previous cervical surgery, 
PPROM or preterm birth) + 5.936622 
Sigma: [D11] = exp (-1.509526) = .22101474 
All other results are calculated as method 4 




fFN Fetal Fibronectin (ng/mL) 
CL Cervical length (mm) 
loge Log base e; natural log. In Excel written LN(). 
NORMSDIST() Cumulative probability function of the Standard Normal distribution; in 
algebra written as Φ(). NORMSDIST(0) = 0.5, NORMSDIST(1.96) = 0.975. 
Exp() Natural exponent; inverse of natural log. Exp(x) = ex. Exp(log(x)) = log(exp(x)) = x 
for x > 0 
^ Power. a^b = ab. 10^2 = 102 = 100. 
MAX( , ) Maximum. MAX(a,b) = larger of a or b.  It is used only to ensure that a zero 
probability is presented for risk of delivery at dates that have already passed. 






17.6. Comparison of statistics from Kuhrt et al. (2016a) and PETRA study. 
Table 54. Summary of predictive statistics for delivery at < 30, < 34 and < 37 weeks' 
gestation and delivery within 2 weeks from fFN test in validation sets from PETRA and 
Kuhrt et al., (2016). 
  sPTB at less than sPTB within 
Outcome 30 wk 95% CI  34 wk 95% CI  37 wk 95% CI  1 wk 95% CI  2 wk 95% CI  
 
Sensitivity % 




























































Likelihood ratio - positive 





























Likelihood ratio - negative 


























Positive Predictive Value (%) 





























Negative Predictive Value (%) 





























Area under the ROC 





























Table 55. Prevalence rates of sPTB at <30, <34 and <37 weeks' gestation and within 1 
and 2 weeks of delivery in  Kuhrt and PETRA cohorts. 
  sPTB at less than sPTB within 
Outcome 30 wk n 34 wk n 37 wk n 1 wk n 2 wk n 
 
Prevalence % (rate of sPTB) 
Kuhrt et al. (n=192) 5.2% 10 7.3% 14 13.0% 25 
Not 
reported 
 5.2% 10 
PETRA (n=576) 1.7% 10 4.5% 26 11.8% 68 2.3% 13 3.1% 18 
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